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Introduction
Functional motor disorders (FMD) consist of involuntary movements, posturing, 
gait disorder and paresis. They are defined by signs that demonstrate the functional 
nature of the mechanism like variability, influence of attention and distraction and 
incongruity with anatomical boundaries. FMD exists at the interface between 
neurology and psychiatry. Functional motor disorders are part of the broader 
group of functional neurological disorders (FND). FND account for between 15-30% 
of neurology outpatients depending how they are defined and may co-exist with 
neurological disease [1–4]. Having FMD often impacts the lives of patients to a large 
extent Quality of life and impairment have been found to be comparable to disabling 
neurological conditions like Parkinson’s disease [5] and Multiple Sclerosis [6].
At the start of this thesis, the clinical research field of functional neurological 
disorders was rapidly changing. New insights changed the leading theories on the 
mechanism, diagnosis and approach to patients with FMD. This has been pivotal for 
the composition of this thesis, which explores the mechanism, prognosis (natural 
history) and treatment of FMD. Therefore these important developments in the field 
are briefly discussed below, followed by an outline of the thesis.
THE NEW NORMAL
What we call “functional neurological disorder” now, has been in and out of fashion 
within academic circles over the centuries. Interestingly, the symptoms of patients 
with FND in neurology clinics nowadays are highly comparable to historical 
descriptions and photos. For example the presentation of functional limb weakness 
through the 18th to 20th century is strikingly similar to the present with the typical 
dragging gate, the same inconsistencies in the examination, and highly comparable 
precipitating factors [7]. However, the concepts explaining these symptoms and the 
names they were given were subject to change, which means parallels cannot always 
be drawn in a meaningful way. Take Shell shock, a disorder soldiers suffered from in 
the 20th century as a result of the traumatic experience of fighting in the trenches. 
It most likely comprised post-traumatic stress disorder, functional neurological 
symptoms, physical injury, head injury and possibly also malingering [8].
In the 19th century, interest in hysteria (a word originating from ancient Greek and 
referring to mostly women suffering from neurological and/or emotional symptoms) 
came to a head when the prominent physician Charcot, who led L’hospital de 
Salpêtrière in Paris, started studying large numbers of patients. Demonstrations 
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of his patients were attended by many influential physicians who would later become 
the founders of modern day neurology and psychiatry, but they became so popular 
that even non-medical spectators visited the hospital. Charcot focused on clinical 
observation of the symptoms, and explained the disorder to be originating from 
a “dynamic” or “functional” lesion of the central nervous system [9]. Freud, who 
developed an interest in hysteria after his stay with Charcot, developed the conversion 
theory, which hypothesised that repressed traumatic experiences (abuse, and in his 
later work sexual abuse or sexual fantasies) were converted into physical symptoms 
[10]. This theory was not confirmed by experimental studies, but nevertheless had 
a major impact on the general view on functional disorders. Due to several factors 
- amongst them the growing detachment of neurology and psychiatry - attention to 
functional neurological disorders reduced after the first world war, especially within 
neurology [11].
In the last two decades, a small (but currently growing) number of physicians and 
psychologists showed renewed interest in patients with functional neurological 
symptoms. They realised that patients were often left undiagnosed and received 
very limited care, because the underlying cause of their symptoms was seen as ‘non-
organic’ or ‘psychiatric’ (ref Edwards, Stone, Sharpe), although they suffered from 
neurological symptoms. A ‘normal’ approach to the patient, in which the neurologist 
takes a history focused on the symptoms, performs full physical examination and 
provides an explanation of the symptoms and their cause, would overcome a large 
part of the difficulty experienced by both patients [12,13] and physicians [14–17]. 
This insight has led to a paradigm shift whereby neurologists base the diagnosis of 
functional neurological symptoms on positive signs in history and examination and 
ideally take responsibility in organizing treatment. A ‘new normal’ [18–20].
Based on observation and experimental studies, the pathophysiology of FMD has 
been updated as well. This is best understood when the aetiology and the mechanism 
are separated. The aetiology is a model with biological, social and psychological 
factors that either play a role in predisposing, precipitating or perpetuating the 
functional symptoms. In each patient a different composition of factors is assumed 
to be present [20], many factors still remain unknown. The mechanism of FMD is 
best explained in the landmark paper of Edwards et al. [21]. The paper describes a 
Bayesian model based on the principle that the brain is not a sole machine of input 
and programmed response, but a hierarchical system that bases its actions on prior 
beliefs (or expectations) and updates these through sensory input [22–24]. Functional 
disorders are no longer seen as a black box with the ‘cause’ (for example childhood 
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trauma) going in (at any given time in the past) and physical symptoms coming out. 
The new concept is more complex: aetiological factors contribute to a set of prior 
beliefs (for example ‘when I have severe symptoms, this means something important 
must be damaged’) that create vulnerability for developing a functional disorder, once 
confronted with the right trigger (for example severe backpain after a car accident). 
These beliefs or expectations are the basis of programmed responses in the brain. 
There are several (not necessarily mutually exclusive) theories on the formation of 
beliefs and the consequent development of motor symptoms in FMD. There are clues 
that the phenomenon of modelling disorders witnessed in one’s environment could 
play a role (ref). However, such studies are prone for recall bias. Another illustration 
on how specific symptoms are likely to result from beliefs, is that the presentation of 
functional symptoms are partly in line with common belief about the presentation of 
neurological symptoms. And, like in many mental disorders, traumatic experiences 
(for example in childhood) cause a stress reaction that most likely alters expectations 
and with that, an altered programmed response in the brain towards future triggers. 
It is hypothesised, amongst others based on imaging findings [25], that the above 
prior beliefs influence perception of sensory input and motor output by altering the 
mapped representations (top-down) of the body and bodily perceptions (and most 
likely also the outside world).
Attention and sense of agency are key elements within the Bayesian framework, 
which are distorted as a consequence of prior beliefs or vice versa. The element of 
attention is expressed clearly in clinical practice, as symptoms abate temporarily 
when patients are distracted [26,27]. Altered sense of agency has been found in 
several experimental studies. In two different experiments the experience of intention 
before a movement was distorted in patients with FMD [28,29]. Sensory attenuation, 
a measure of motor agency, is impaired in FMD: When performing a force matching 
task, healthy controls overestimate the force required when pressing directly on their 
own finger, but patients do not [30]. Using clinical neurophysiology, abnormal sense 
of voluntariness in FMD was found. Abnormal preparation of intended voluntary 
movements with an often absent Bereitschaftspotential was demonstrated, while 
the functional movement symptoms that are perceived involuntary by the patient 
(in this study jerky movements), were preceded by normal preparation and a 
present Bereitschaftspotential [31]. Imaging studies have implicated the role of 
the temporoparietal junction in this altered sense of agency, amongst others in a 
task comparing functional tremor with simulated tremor in the same individuals 
[32]. More generally results from fMRI studies suggest an association between 
emotional processing and motor planning and/or execution, because they have 
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shown connectivity between the supplementary motor area and the amygdala in 
emotional tasks [33,34] and a simple motor task [25]. Another area found to be 
involved in several imaging studies is the insula, a multi-functional brain region 
involved in emotion regulation and self-awareness amongst others [25,33,35,36].
The treatment approach to patients with FMD has changed accordingly. A stepped care 
model has been proposed [37], in which explanation of the disorder by the neurologist 
is an essential first step. Inconsistencies in the presentation of symptoms, that were 
previously used to point out non-organicity, were now proposed to be helpful in the 
explanation of the disorder to the patient [38]. Further effective treatments have a 
strong emphasis on relearning normal movements, for example using physiotherapy 
[39] or in a multidisciplinary setting [40–43]. In addition, psychological treatment 
can be added that has expanded from predominantly psychodynamic to cognitive 
behavioural or acceptance and commitment oriented therapy.
NEW QUESTIONS
New research findings and altered theories elicit many new research questions. 
In light of these developments, this thesis addresses questions about mechanism, 
prognosis and treatment.
From a mechanistic point of view, defining the clinical picture in a more detailed 
manner could provide new insights. Patients often experience non-motor symptoms 
in addition to the functional motor symptoms. Fatigue, for example, seems very 
prominent in clinical practice. It is of interest to investigate the severity of common 
non-motor symptoms: fatigue, pain, depression and anxiety and their influence on 
health related quality of life, compared to other neurological disorders. And, are 
these non-motor symptoms the same for all different functional motor disorders?
Furthermore, from the proposed mechanism by Edwards et al, the topics of distorted 
self-agency and abnormal attention to the self (or more specifically towards the 
symptoms) need to be further substantiated. Which brain networks are involved 
in the distorted perception of self-agency and how do they relate to abnormal 
attentional processes and perception of body scheme?
A better knowledge on the prognosis (natural history) of the symptoms of FMD and 
the course of quality of life in time are important to answer patients’ questions and 
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to interpret outcomes of clinical trials. Do the symptoms usually resolve (as is a 
commonly held belief by many physicians, although not substantiated)? Does the 
diagnosis often change? Could we find a way to predict an individual’s chance of a 
positive outcome?
Ultimately, the clinical aim is to find better treatments for FMD patients. Especially 
as the prognosis appears to be poor, effective treatments are needed. To start with, 
no trials have been performed to test the hypothesis that explanation is important as 
the first step in treatment. Would that lead to overall better outcomes and perhaps 
more effective further treatments?




In order to better understand FMD, we need a clearer picture of the (variability of) 
clinical syndromes that patients present with. At the same time, experiments should 
be designed to disentangle the underlying mechanism.
Clinical aspects
In this thesis we compare non-motor features, triggers and demographics between 
groups of different functional motor symptoms in chapter 1. Furthermore we explore 
the severity of fatigue - and its influence on quality of life - in FMD compared to 
organic neuromuscular disorders, in chapter 2. For chapter 1 and 2 baseline data 
of the trial described in chapter 10 was used. We compared non-motor features 
between patients with functional and organic myoclonus in chapter 3.
Experimental aspects
Three experiments were performed. First, to further explore the concept of self-
agency, an experiment was performed where incongruence between of motor action 
and sensory response was used to compare patients with functional myoclonus 
or tremor and healthy controls (chapter 4). Secondly, Chapter 5 investigates the 
concepts of self-agency and perception of body scheme using a previously developed 
fMRI paradigm. In this study the same patients as in the above-mentioned agency 
experiment, were scanned during a task comparing self-referenced versus goal 
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directed and self-initiated versus fixed movement. Thirdly, we performed a resting-
state fMRI study to compare brain activity at rest between FMD and healthy 
controls, in the same subset of patients, in chapter 6 a data-driven approach using 
independent component analysis was used, forming networks of brain activity.
Part 2:
Prognosis
Knowledge on the prognosis of functional motor disorders is mainly based on small, 
retrospective studies which show variable but overall poor outcome. In this thesis, a 
systematic review summarizing the literature on the prognosis of functional motor 
disorders is included as chapter 7. We performed a 14 year follow-up study of 
patients with functional paresis, currently the longest systematic follow-up study in 
the literature, the results are displayed in chapter 8. Issues including misdiagnosis, 
mortality, symptom outcome and quality of life are studied and discussed here.
Part 3:
Treatment
Treatment options for patients with FMD are scarce and evidence on effective 
treatments is limited, mainly due to the small number of studies performed in the 
field, and the quality of the available studies. In chapter 9 the literature at the start 
of this thesis is summarised in a review on the treatment of FMD. To enhance the 
first step of treatment - explanation of the disorder by the neurologist - we designed 
a new website with education and self-help. The effect of this website on self-rated 
general health and a number of secondary outcomes, was studied in a randomised 
controlled trial in patients with FMD and the results are reported in chapter 10.
In the general discussion the findings are interpreted and implications for the future 
are described.
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In ancient times, hysteria was used for symptoms comparable to (but not limited 
to) functional neurological disorders, but this term is abandoned for obvious 
reasons. Psychosomatic, psychogenic, somatization and conversion disorder all imply 
a dominantly psychological etiology or the conversion of psychological distress into 
physical symptoms. Studies show higher rates of psychological comorbidity, and 
some useful treatments are psychological. However psychological factors in the 
etiology are now seen as risk factors that can contribute to the development of a 
functional motor disorder, but not the sole cause. Non-organic (e.g. non-epileptic) 
and medically unexplained label the problem by what it is not. This is not helpful for 
patients. Also, these terms imply a strict separation between functional disorders 
and other neurological disorders, while many conditions in neurology have a 
largely unknown etiology. The term functional neurological disorder emphasizes a 
disorder of function without assuming aetiology. It also has been found to be more 
acceptable to patients [13], where other terms are perceived as being offensive. In 
this thesis therefore we will use functional neurological disorder (FND), and when 
referring to motor symptoms functional motor disorder (FMD) or in some chapters 
motor FND, conform DSM-5.
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Introduction: Functional motor disorders are often delineated according to 
the dominant motor symptom. In a large cohort, we aimed to find if there were 
differences in demographics, mode of onset, pain, fatigue, depression and anxiety 
and levels of physical functioning, quality of life and social adjustment between 
patients with different dominant motor symptoms.
Methods: Baseline data from the Self-Help and Education on the Internet for 
Functional Motor Disorders Trial was used. Patients were divided into dominant 
motor symptom groups based on the diagnosis of the referring neurologist. Data on 
the above topics were collected by means of an online questionnaire and compared 
between groups using parametric and nonparametric statistics.
Results: In 160 patients a dominant motor symptom could be determined, 31 had 
tremor, 45 myoclonus, 23 dystonia, 30 paresis, 31 gait disorder. No statistical 
differences between groups were detected for demographics, mode of onset and 
severity of pain, fatigue, depression and anxiety. Physical functioning was worse in 
the gait disorder group (median 20, IQR 25) compared to tremor (50 (55), p=0.002) 
and myoclonus (50 (52), p=0.001). Work and social adjustment was less impaired 
in the myoclonus group (median 20, IQR 18) compared to gait disorder (median 30, 
IQR18, p<0.001) and paresis (28, IQR 10, p=0.001). Self-report showed large overlap 
in motor symptoms.
Conclusion: No differences were detected between groups of functional motor 
symptoms, regarding demographics, mode of onset, depression, anxiety, pain and 
fatigue. The large overlap in symptoms contributes to the hypothesis of shared 
underlying mechanisms of functional motor disorders.
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INTRODUCTION
Functional motor disorders (FMD) consist of involuntary movements, posturing, gait 
disorder and paresis, that are internally inconsistent or incongruent with patterns of 
pathophysiological disease [1]. In organic movement disorders, detailed phenotyping 
of the motor symptoms is important to determine a phenomenological classification 
and to make an etiological diagnosis. This is increasingly expanded with motor 
phenotype specific associated non-motor features, like anxiety, depression, pain and 
fatigue and demographic differences [2–4]. It is unclear if these same associations 
exist in FMD.
FMDs are often delineated according to the dominant movement disorder 
such as tremor, dystonia or paresis. All FMD are assumed to share the same 
pathophysiological mechanism, but a shared mechanism cannot explain why one 
patient would suffer from paresis and another from tremor. It has been suggested 
based on clinical experience that specific FMDs are associated with for example 
gender, age at onset or pain. A small study in which functional paresis was compared 
to functional movement disorders has found relatively non-specific differences, 
like male predominance, lower psychiatric hospitalisation and higher incidence of 
head trauma in functional paresis [5]. When comparing patients with non-epileptic 
attacks to FMD, differences in risk factors, etiological background and psychological 
comorbidity were found [6] [7]. A review paper comparing non-epileptic attacks 
and FMD however, concluded that similarities exceed the differences in terms 
of demographics and associated psychological and physical symptoms [8]. From 
individual studies focussing on single FMD non-motor symptoms like depression, 
anxiety, fatigue and pain seem to be comparably high [9–13]. However, a direct 
comparison between groups has not been performed.
Here, we aimed to find if there were differences between different FMDs, by 
comparing demographics, mode of onset, non-motor symptoms pain, fatigue, 
depression and anxiety and levels of physical functioning, quality of life and social 
adjustment and self-rated additional motor symptoms between patients with 
different dominant motor symptoms, as categorised by the referring neurologist.
1
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All patients were included as part of a randomised Self-Help and Education on the 
Internet for Functional Motor Disorders Trial (SHIFT) (clinicaltrials.gov: NCT02589886). 
This was a two-group parallel superiority non-blinded randomised controlled trial 
in which patients were randomised to receive an education and self-help website or 
usual care. Patients were referred from 31 neurology centres across the Netherlands.
Between October 2015 and July 2017, patients considered eligible by the referring 
neurologist were contacted and informed by email or post. Inclusion in the SHIFT 
study required a functional motor disorder diagnosed by a neurologist, associated 
distress or impairment in social, occupational or other important areas of 
functioning, regular access to the internet, and Dutch language proficiency. Patients 
were excluded if they were unable to provide informed consent due to cognitive 
problems and if they were under 18 years of age. All included patients provided 
written informed consent. Patients with co-morbid neurological disease were not 
excluded from the study, but were told that this intervention was aimed at their 
functional motor symptoms.
Data for the current study came from the baseline questionnaires for this trial 
gathered before randomization took place. We previously published an article 
on the high prevalence of fatigue, from this same baseline data [14]. Data for the 
SHIFT study was collected in accordance with the ethical and legal guidelines of the 
University Medical Center Groningen (Medical Ethical Committee reference number: 
METc 2015/141, M14.150920).
Determination of the dominant motor symptom
Categorisation of patients into groups of the dominant motor symptom was based 
on the neurologist rating of the motor symptoms. The dominant motor symptom for 
each patient was determined based on the diagnosis of the referring neurologist, 
either provided directly on request, or via their clinic letter. When the neurologist 
was unable to identify one dominant motor symptom but rather thought two or more 
symptoms were equally severe (and/or impairing) or when referring information 
could not be obtained (neurologists could not be contacted/referring letters were 
not available/patients did not consent to obtain this information), the dominant motor 
symptom was labeled ‘ unknown’ and these patients were left out of the group 
comparisons.
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Demographics and onset of symptoms.
Patients filled out questionnaires online including their age and sex. A multiple 
choice question was used asking in how much time the motor symptoms had arisen, 
with the following options: within seconds to minutes, minutes to 6 hours, more than 
6 hours, symptoms were present at awakening or after an operation. Furthermore, 
patients were asked if migraine, a panic attack, general anesthesia, illness due to an 
infection, medication side effects, sleep paralysis, a pain, fatigue, or injury preceded 
onset of the first motor symptom(s), or if symptoms were first noticed by a health 
care professional.
Pain, Fatigue, Depression and Anxiety
With regard to non-motor features, we assessed pain using the pain subscale of the 
RAND36 (the health-related quality of life questionnaire which is almost identical to 
the Short-Form 36 questionnaire, (maximum score is 100 which stands for low pain) 
[15], fatigue using the subdomain fatigue severity of the Checklist Individual Strength 
(CIS, 8-56) [16], depressive symptoms using the Patient Health Questionnaire 9 
(PHQ-9; 0-27) [17]and anxiety measured using the Generalized Anxiety Disorder 
Questionnaire (GAD-7; 0-14) [18].
Physical Functioning, Quality of Life, Occupational and Social Functioning
Physical functioning was measured with the corresponding subscale of the RAND36 
(0-100, with 100 reflecting optimal functioning). Quality of life was measured with a 
single question from the WHO-QoL questionnaire: “How would you rate your quality 
of life on a 5-point Likert scale” [19]. Work and social adjustment were assessed 
using the Work and Social Adjustment Scale (score range 0-40, with 0 reflecting 
best adjustment) [20]. Patients were also asked to report their working status and 
whether they received benefits for health-related reasons by means of several 
multiple-choice questions.
Patient-rated motor symptoms
We asked patients to indicate the presence and severity of the functional motor 
symptoms they experience using a variety of descriptors, specifically tremor (tremor/
trembling/shivering), myoclonus (myoclonus/jerky movements), dystonia (dystonia/
abnormal posturing), paresis (paresis/weakness/loss of strength) and gait disorder. 
All patients rated each of these five functional motor symptoms. They were were 
asked to rate the severity of each symptom on a 7-point Likert scale (0= not present 








For group comparisons, ANOVA was used for normally distributed data and Kruskall 
Wallis tests for non-normally distributed and ordinal data. Chi squared tests were 
used to compare categorical variables. When statistical differences between groups 
were found with a p-value < 0.05, Mann-Whitney U tests were used for pairwise 
comparisons between groups. SPSS by IBM version 23 was used to perform 
statistical analyses. Correction for multiple comparisons according to Bonferroni 
was performed and resulted in a threshold p-value of 0.003.
To assess differences in prevalence of additional motor symptoms between dominant 
motor symptom groups, Chi squared tests were used. Correlations were made using 
Spearman’s rho non-parametric analyses.
The patient-rated severity of the main motor symptom was compared to patient-rated 
severity of the other motor symptoms by a Friedman test.
RESULTS
Of the 186 patients that were included in the SHIFT study, 31 had tremor, 45 
myoclonus, 23 dystonia, 30 paresis, 31 gait disorder, 3 facial dystonia as the 
dominant motor symptom recorded by the neurologist and for 23 cases, classification 
according to their dominant motor symptom was not possible because the referring 
neurologists could not be contacted (n=19) or he/she considered two or more motor 
symptoms to be comparably prominent (n=4). Cases with facial dystonia (n=3) were 
not included in the between group analyses, given their low prevalence.
Demographics and motor symptom characteristics
Mean age of the overall cohort (n=186) was 48 years (SD 15); females formed a 
large majority (71%). The median duration of symptoms was 24 months (IQR 6-69). 
Symptom onset was acute (within minutes) in 40% (n=74) of cases. There were no 
significant differences between groups in terms of age, sex, symptom duration, onset 
duration or mode of onset. Reported mode and clinical features at onset were equally 
distributed in all five dominant motor symptom groups with no statistical differences 
between groups. In the total group the commonest factors at onset were pain (n=46, 
26%), noticed by a health care professional (n=18, 10%), injury (n=15,8%) and general 
anesthesia (n=14, 8%) (Table 2).
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Pain, Fatigue, Depression and Anxiety
Scores were high for pain and fatigue in the entire cohort (Table 1); pain median 46 
(IQR 22-80) and fatigue median 44 (IQR 25-44). The median scores of depressive and 
anxiety symptoms were respectively 8 (IQR 4-13) out of a maximum score of 27 on 
the PHQ9 and 5 (IQR 0-9) of 14 on the GAD7. There were no statistically significant 
differences in the levels of pain, depression and anxiety between the dominant motor 
symptom groups. Differences in fatigue scores between groups did not remain 
significant after correction for multiple comparisons.
Physical Functioning, Quality of Life, Occupational and Social Functioning
Physical functioning (median 40 (IQR 20-65, score maximum 100)) and quality of 
life scores (median 3 out of 5 (IQR 2-4) were low in a majority of patients. The work 
and social adjustment score represents high impairment (26, (IQR 16-32), score 
maximum 40) and 56% (n=104) of patients were (temporarily or permanently) not 
in work and received benefits. Scores on physical functioning and work and social 
adjustment were different between groups. Pairwise comparisons showed that the 
gait disorder group had significantly worse physical functioning (median 20, IQR 
15-40) than the tremor (50 (25-80), p=0.002) and myoclonus (50 (25-78), p=0.001) 
groups. The work and social adjustment scale was significantly more impaired in 
the gait disorder and paresis group compared to myoclonus (gait disorder: median 
30 (IQR 26-34), versus myoclonus 20 (9-27), p<0.001, paresis 28 (24-34) versus 
myoclonus, p=0.001). There were no statistically significant differences between 
groups in quality of life scores, or in percentages of patients in work or receiving 
benefits for health-related reasons.
Patient-rated motor symptom severity
The severity of the dominant motor symptom on a scale from 0-7 (0 corresponding to 
total absence of the symptom, 7 corresponding to most severe) in each group was: 
Tremor median 4 (IQR3-5) (61% of patients had marked (5), severe (6) or very severe 
(7) symptoms), Myoclonus median 3 (IQR 2-4) (44% marked-very severe), dystonia 
median 3 (IQR 2-6) (43% marked-very severe), paresis median 3 (IQR 1-4) (47% 
marked-very severe), Gait disorder median 4 (IQR 3-5) (61% marked-very severe). 
The dominant motor symptom (as indicated by the neurologist) was self-rated as the 
most severe motor symptom in all groups (Friedman test for every group p<0.001) 
when compared to other motor symptoms that patients reported. Only in the dystonia 
group, paresis severity (median 3, IQR 0-5) was reported as high as dystonia severity 
(median 3, IQR 2-6) (Chi2 = 14, Friedman test p=0.008).
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There was a high prevalence of self-rated additional functional motor symptoms in 
all dominant motor symptom groups (77% (n=35) in the myoclonus group to 100% 
in the dystonia group, 87% (n=161) overall, Chi2 7.0, p=0.134) , when counting all 
symptoms with a severity of 2 (‘mildly bothered’) or higher. Table 1 shows these 
additional patient-rated motor symptoms per dominant motor group. Overall, the 
median number of motor symptoms, including the dominant motor symptom, was 
2 (IQR 2-4), with no statistically significant differences between dominant motor 
symptom groups (Chi2 4.4, p=0.357).
DISCUSSION
In this study, we did not find differences in demographics, mode of onset, non-
motor features, levels of physical disability or quality of life between patients with 
different types of functional motor symptoms. We found equally high rates of fatigue, 
pain, depression and anxiety in all dominant motor groups. We had expected that 
some symptoms, particular functional dystonia, might be associated with more pain 
[21,22]. However, patients with functional paresis or gait disorder as a dominant 
motor symptom had more severe impairment of physical functioning. Self-reported 
overlap in motor symptoms was high in all groups.
Tremor and myoclonus were overrepresented in our data compared to general 
neurology clinics [23,24], probably due a large number of referrals from movement 
disorders clinics rather than general neurology clinics in our data. In line with 
studies in this field, patients were mainly female, had a long symptom duration and 
were on average middle-aged. In 8% of our cohort, patients suffered some form 
of injury before symptom onset. This is lower than previously reported (10-37%), 
and would contradict the theory that the type of trigger might determine the motor 
phenotype in FMD. However, it is not clear to what extent the questionnaire used in 
this study can accurately assess triggering events as compared to the previously 
used interviews [25–27]. The speed of symptom onset was within minutes in 40% and 
within 6 hours in 49%, in line with findings in the literature, in which 54% of patients 
with movement disorders [25] and 49% of patients with paresis [26] had an acute 
onset. Acute onset in organic tremor, myoclonus and dystonia is rare and therefore 
could be a supportive diagnostic sign.
We did not find correlations between non-motor features fatigue, pain, depression 
and anxiety and groups of dominant motor symptoms. The high pain and fatigue 
1
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scores in all groups underline the growing realisation that non-motor symptoms 
are relevant in both functional and organic movement disorders and should be 
recognised when treatment strategies are chosen [14]. The lack of differences 
between groups stresses the importance of addressing non-motor features in all 
FMD patients. There are varying reports of psychopathology in functional motor 
symptoms. In the largest study into functional paresis (n=107) scores on pain 
and fatigue (median 33 (IQR 22) and 30 (35) of the SF36 scale respectively) and 
psychopathology (any current affective 61%, generalised anxiety in 21% of cases) 
were high [13]. It is possible that the frequency of depression and anxiety is higher 
than it appears in the data. Patients with FMD have been found to report lower rates 
in questionnaires than when questioned directly , because of stigma of mental illness 
and/or because of alexithymia [13,28]. We did not confirm small studies in which 
psychopathology seems less frequent in functional tremor and myoclonus [12,29].
Physical functioning and work and social activities were highly impaired in most 
patients and worse in paresis and gait disorders who are more likely to have 
persistent symptoms and problems walking than for example patients with tremor 
or myoclonus which is intermittent and doesn’t affect ambulation. For the entire 
cohort, data relating to physical functioning, not being in work due to ill health and 
scores on the work and social adjustment scale, were comparable to the data in the 
literature [13,30,31].
This large overlap between patient-reported symptoms is an important finding. The 
current literature shows variable overlap in motor symptoms ranging from only 8% 
to 72% of patients with paresis reporting an additional motor symptom [9,13,32], 
and up to 79% of patients with a functional movement disorder that had another 
motor symptom [33]. The high rate in our study could be explained by the fact that 
we explicitly asked for severity of all motor symptoms within our questionnaire. 
Self-report could have led to an overestimation, compared to findings in neurological 
examination (at one timepoint), although for a disorder in which subjective report 
is arguably the key feature of the disorder [34], it is a valid method of assessment. 
Also, there was concordance between patients and neurologists when indicating 
the dominant motor symptom, which lends some weight to our exploratory analysis 
of motor symptom overlap.
There are several possible explanations for the lack of differences between 
groups. Similar rates of non-motor features, comparable demographics and the 
fact that we did not find an association between typical patterns of mode of onset 
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and motor phenotypes, might indicate a (at least partly) shared pathophysiological 
mechanism between the different motor symptoms. The large overlap between 
groups in terms of self-rated additional motor symptoms adds to that argument. 
Authors have highlighted the similarities between the broader group of functional 
syndromes, like sex ratios, comorbid emotional disorders and etiological factors and 
a comparable response to similar treatments across studies [35], which would be 
supported by the findings in our sample. Another explanation could be the potential 
difficulty physicians face when phenotyping functional motor disorders, because 
they are by definition clinically incongruent with recognized neurological disease. 
Myoclonus and tremor appear most linked, as we noticed that these terms were 
often used interchangeably in the history, examination and conclusion sections in the 
referral letters. However, the concordance between patients and neurologists when 
indicating the dominant motor symptom, affirms the existence of distinct dominant 
motor phenotypes.
Our data do not indicate specific treatment targets for the non-motor features in 
different motor symptom groups. Thus far, treatment that has been found effective 
for FMD is either symptom focused, like in physiotherapy [32], or a combination 
of elements generic to shared disability and symptoms (e.g. rehabilitation advice), 
symptom specific elements and/or individual elements (e.g. in psychotherapy) 
[36–38]. It therefore seems optimal to combine specific symptom-tailored with a 
recognition of the likelihood of shared comorbidities. Measuring outcome in FMD 
is subject of debate. Our data show that motor symptoms are not distinctive for 
non-motor profiles or general outcome. Therefore they support the notion that with 
respect to FMD, it may not be necessary to focus excessively on motor symptom 
phenomenology to categorise and measure outcome in FMD. This approach has also 
been adopted by the ‘Simplified Functional Movement Disorders Scale’ for example 
[39].
Our study has several limitations. Differences between groups might have 
been missed due to the relatively small size of the groups or due to co-morbid 
neurological disease that might have been present in some cases. The results might 
be partly skewed by recall bias or due to the fact that we cannot be sure the online 
questionnaires were always filled out by the patients themselves. As discussed 
above, self-report has disadvantages. Especially the fact that motor symptom 
severity in this study was rated by patients themselves should be taken into account 
when interpreting the data.
1
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In this study we did not find clinically relevant differences between groups of 
functional motor symptoms, regarding demographics, triggers and non-motor 
features such as depression, anxiety, pain and fatigue. Also, patients rated a large 
number of additional motor symptoms, apart from the dominant motor symptom as 
reported by the neurologist. This suggests a large overlap in phenotype and possibly 
underlying mechanisms of functional motor symptoms. High pain and fatigue scores 
in all groups underline the growing evidence that non-motor symptoms are relevant 
in both functional and organic movement disorders and should be recognised when 
planning treatment strategies.
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While fatigue is found to be an impairing symptom in functional motor disorders (FMD) 
in clinical practice, scientific evidence is lacking. We investigated fatigue severity 
and subtypes in FMD compared to organic neurological disease. Furthermore the 
role of fatigue within FMD and its impact on quality of life and self-rated health were 
investigated.
Data from 181 patients participating in the Self-Help on the Internet for Functional 
motor disorders, randomised Trial was included. Data from 217 neurological controls 
with neuromuscular disorders (NMD) originated from a historical cohort. Fatigue 
was measured using the Checklist Individual Strength (CIS). Motor symptom severity, 
depression and anxiety were correlated to fatigue. For multivariable regression 
analyses, physical functioning and pain were additionally taken into account.
Severe fatigue was respectively present in 78% and 53% of FMD and NMD patients 
(p<0.001). FMD patients scored higher than NMD patients on all fatigue subdomains 
(P<0.001). In the FMD group, fatigue subdomains were correlated to depression, 
anxiety and partly to motor symptom severity. Quality of life was negatively 
associated with fatigue (OR 0.93 (0.90-0.96), p<0.001) and depression (OR 0.87 (0.81-
0.93), p<0.001), but not self-rated motor symptom severity. Self-rated health was 
negatively associated with fatigue (OR 0.92 (0.88-0.96), p<0.001) and pain (OR 0.98 
(0.97-0.99), p<0.001).
Fatigue was found to be a prevalent problem in FMD, more so than in organic 
neurological disease. It significantly affected quality of life and self-rated health, 
while other factors like motor symptom severity did not. Fatigue should be taken 
into account in clinical practice and treatment trials.
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Functional motor disorders (FMD) are motor disorders that cannot be explained on 
the basis of known organic neurological disease, and can be significantly altered 
by distraction or non-physiological manoeuvres [1]. Fatigue is often reported by 
patients with FMD in clinical practice. However, there are only few studies reporting 
high levels of fatigue in functional neurological symptoms in general [2] and FMD 
specifically [3,4]. Fatigue is a multidimensional concept and has a complex role in 
neurological disorders. One way to operationalize fatigue is to study self-reported 
severity of subdomains of fatigue, including tiredness, concentration problems, 
reduced motivation, and reduced activity. In other neurological disorders, like 
neuromuscular disorders these subdomains have been investigated [5,6], but not 
in FMD.
Determinants of fatigue in FMD are unknown. In neurological disorders like 
Parkinson’s disease [7] and muscular dystrophy [8], fatigue severity was significantly 
influenced by depression and motor symptom severity. In FMD fatigue could be 
presumed to be secondary to the functional motor symptom burden, related to 
comorbid anxiety or depression, or could primarily be part of the phenotype.
In organic neurological disorders fatigue is one of the major factors influencing 
quality of life [9,10]. This might also be the case for FMD, in which quality of life is 
known to be as severely impaired as in Parkinson’s disease [11]. Thus, understanding 
how fatigue influences quality of life and self-rated health in patients with FMD, could 
offer a more focused target for interventions.
We aimed to study the prevalence and severity of fatigue and its subdomains in 
FMD compared to organic neurological disorders. To determine if fatigue in FMD 
could be explained by motor symptom severity, depression or anxiety, correlations 
between these factors and fatigue subdomains have been studied. Furthermore, 
we aimed to investigate the degree to which fatigue predicts quality of life and self-
rated health in patients with FMD, independent of severity of the motor symptoms, 
physical functioning, pain, depression, and anxiety.
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All FMD patients included in this study participated in the ongoing Self-Help and 
Education on the Internet for Functional Motor Disorders Trial (SHIFT). This trial aims 
to determine the effect of an online education and self-help intervention. For this study 
baseline data was used, which was obtained before allocation to an intervention type. 
Participants were referred from secondary and tertiary neurology clinics all over the 
Netherlands. Inclusion criteria were: age older than 18 years; a diagnosis of a functional 
motor disorder (including functional movement disorders and functional weakness) 
made by a neurologist; the functional motor symptom(s) cause(s) distress or impairment 
in social, occupational or other important areas of functioning, regular access to the 
internet and ability to read the Dutch language. All patients provided informed consent 
and were asked to fill out online questionnaires. The SHIFT study was performed in 
accordance with the the ethical and legal guidelines of the University Medical Center 
Groningen (Medical Ethical Committee reference number: METc 2015/141, M14.150920).
The control group consisted of patients with neuromuscular disorders (NMD), which 
served as an organic neurological counterpart with motor symptoms. This data 
had been collected previously [5]. Patients were recruited from the Neuromuscular 
Centre of the Institute of Neurology, Radboud University Nijmegen Medical Center 
outpatient clinic. Neuromuscular disorders consisted of facioscapulohumeral 
muscular dystrophy (FSHD), adult-onset myotonic dystrophy (MD), and hereditary 
motor and sensory neuropathy type I (HMSN-I).
Fatigue subdomains were compared between FMD and NMD. To determine if 
fatigue in FMD can be explained by motor symptom severity, depression or anxiety, 
correlations between these measures and fatigue subdomains were made. 
Furthermore, we performed multivariable regression analyses with quality of life and 
self-rated health as outcome measures and fatigue, severity of the motor symptoms, 
physical functioning, pain, depression, and anxiety as predictors, to investigate the 
impact of fatigue on these outcomes.
Measures
The Checklist Individual Strength (CIS) was used to measure fatigue in both groups. 
It assesses four different subdomains. The fatigue severity subdomain consists of 8 
questions concerning tiredness and physical condition and has a score range from 
8 to 56. Severe fatigue is defined as a score of 35 or higher on this subdomain. The 
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concentration subdomain consists of five questions on concentration (score range 
5-35); the motivation subdomain has four questions asking patients about motivation 
and planning (score range 4-28). The physical activity subdomain consists of three 
questions (score range 3-21). The CIS has been validated in patients with chronic 
fatigue syndrome [12] and healthy control subjects [13]. The scale was previously 
found to have a Cronbach’s alpha of 0.95, with a high test-retest reliability (Spearman 
rank correlation: 0.86) and moderate correlations with other fatigue scales, such as 
the vitality subscale of the SF36 [14].
Quality of life was measured with a single question from the WHO-QoL questionnaire: 
“How would you rate your quality of life on a 5-point Likert scale”[15]. Self-rated 
health was measured on a 7-point Likert scale, the Clinical Global Inventory (CGI), 
with the question ”How would you rate your health in general”. Based on previous 
studies in patients with non-epileptic attacks or FMD, the following covariates were 
selected: depression [16], anxiety [17], pain [18], physical functioning and motor 
symptom severity. Severity of all present functional motor symptoms combined was 
measured using a 7-point Likert scale for self-rated severity (1=no motor symptoms, 
7=very severe motor symptoms). Physical function and pain were assessed using the 
respective subdomains of the RAND36 health-related quality of life questionnaire 
which is a Dutch translation of the Short-form 36 questionnaire. These subdomains 
range from zero to 100 with zero reflecting bad quality of life and functioning and 100 
optimal functioning. The Patient Health Questionnaire 9 (PHQ-9) sum score was used 
to assess depressive symptoms (scores 0-27), and the generalized anxiety disorders 
questionnaire 7 (GAD7) for anxiety (scores 0-14).
Statistical analyses
All data was analyzed in SPSS software, version 23. Patients were excluded from all 
analyses when data of the Checklist Individual Strength was missing. For between 
group analyses, unpaired students t-test were used for normally distributed data, 
and Mann-Whitney U or Chi-squared tests for non-normally distributed or ordinal 
data. Correlations between fatigue, motor symptom severity, depression and anxiety 
were calculated using Spearman’s rho.
For the association between fatigue and both quality of life and self-rated health, 
multivariable ordinal logistic regression models were used. Motor symptom severity, 
physical functioning, pain, depression and anxiety were included as covariates in 
the multivariable models. To avoid multicollinearity between subdomains and with 
depression and physical functioning, of all fatigue subdomains, only the subdomain 
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fatigue severity was included. Models were tested for multicollinearity. Data was 
directly entered into the multivariable models without univariable pretesting of 
candidate predictors, to avoid over-fitting [19]. If the multivariable ordinal logistic 
regression analysis would provide to many empty cells (cells with zero frequencies), 
which is expected when including continuous and ordinal variables, additional testing 
using dichotomized outcomes (Quality of life: Very poor and poor versus neutral, good 
and very good, Self-rated health: Very poor, poor and moderately poor versus neutral, 
good, very good, excellent) will be performed, to confirm reliability of the findings. 
Correction for multiple comparisons according to Bonferroni was performed.
RESULTS
In total, 181 FMD patients out of 186 who participated in the SHIFT study, filled out 
the CIS and were included in the analyses. Of these patients, 71% were female, with 
a mean age of 48 (SD 15) years at time of inclusion. FMD consisted of hyperkinetic 
symptoms (myoclonus, dystonia, tremor), paresis and gait disorder. Many patients 
had more than one motor symptom. Self-rated severity of the motor symptom(s) 
patients experienced was very mild in 5%, mild in 3%, moderate in 9%, marked in 27%, 
severe in 27% and 17% reported very severe symptoms.The control group consisted 
of 217 patients with a NMD, of whom 48% were female, with a mean age of 41 (SD 
10) years. In the control group, 30% of patients had facioscapulohumeral muscular 
dystrophy (FSHD), 36% (adult-onset) myotonic dystrophy (MD) and 34% had hereditary 
motor and sensory neuropathy (HMSN). Data is displayed in table 1. Correction for 









Mean age (SD) 48 years (15) 42 years (10) t 4,6 396 P<0.001
Percentage females 71% 48% χ2 21,3 1 P<0.001
Fatigue (CIS) median score (IQR)
Severity 44 (17) 35 (18) U 11574 - P<0.001
Severe fatigue 
(Severity scores ≥35)
78% 53% χ2 26,7 1 P<0.001
Motivation 15 (10) 11 (8) U 14160 - P<0.001
Concentration 21 (15) 12 (13) U 11266 - P<0.001
Physical activity 14 (9) 9 (8) U 11155 - P<0.001
Table 1. Patient characteristics and fatigue scores. For CIS-fatigue scores: higher scores 
mean more fatigue. SD = Standard Deviation, IQR = interquartile range.
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Fatigue in FMD compared to NMD
FMD patients scored significantly higher on all fatigue subdomains compared to 
the NMD control group (see table 1 and fig 1). Severe fatigue (a score of 35 or more 
on the fatigue severity subdomain) was present in 78% of FMD patients compared 
to 53% of NMD patients (p<0.001). The FMD group was significantly older and had a 
higher percentage of females than the NMD group. However, differences between the 
groups persisted after linear regression with as outcome log transformed CIS scores 
and predictor disorder group while adjusting for age and sex (p-values remained < 
0.001).
Figure 1. CIS fatigue subdomains between groups. Subdomain scores are expressed as 
percentage of the maximum score of the subdomain, with the minimum scores converted to 
zero. High scores represent a high level of fatigue. Median and interquartile range of these 
percentages are given for both groups.
Correlations between fatigue subdomains and depression, anxiety 
and motor symptom severity in FMD
To determine if depression, anxiety or motor symptom severity could be (partly) 
explanatory for fatigue in FMD, they were correlated to all fatigue subdomains. 
Correlations are displayed in table 2. Depression and anxiety were correlated with 
all fatigue subdomains. Severity of the functional motor symptom was correlated 
to fatigue severity (Spearman’s rho 0.35, p<0.001) and physical activity (rho 0.29, p 
<0.001), but not to concentration (rho 0.19, p=0.010), and motivation (rho 0.11, p=0.125). 
The associations between depression and all subdomains of the CIS remained 
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significant when removing the one fatigue related question from the PHQ9, however, 
Spearman’s coefficients reduced somewhat for all subdomains.
Motor symptom severity 
(7-point Likert scale)
Depression (PHQ9) Anxiety (GAD7)
Fatigue (CIS) Spearman’s 
rho
P value Spearman’s 
rho





0.35 p<0.001 0.63 p<0.001 0.35 p<0.001
Concentration 0.11 p=0.010 0.66 p<0.001 0.43 p<0.001
Motivation 0.19 p=0.125 0.48 p<0.001 0.34 p<0.001
Physical 
activity
0.29 p<0.001 0.56 p<0.001 0.30 p<0.001
Table 2. Spearman’s correlations between fatigue subdomains and motor symptom severity, 
depression and anxiety.
Relationship between fatigue and quality of life and self-rated 
health in FMD
To investigate the influence fatigue has on quality of life and self-rated health, two 
multivariable ordinal logistic regression analyses were performed (Table 3). Both 
models were tested for multicollinearity, which was ruled out.
Regarding quality of life, the analysis revealed an increase of depressive symptoms 
(on the PHQ9 which ranges from zero to 27) was associated with a decrease in the 
odds of higher quality of life, with an odds ratio of 0.87 (0.81-0.93), Wald χ2 =15.57 and 
p<0.001. Fatigue severity, motor symptom severity, physical functioning, pain, and 
anxiety symptoms were not significantly associated with quality of life. To adjust for 
overlap between fatigue and depression (which were found to be strongly correlated, 
see the above), a post-hoc multivariable ordinal logistic regression was performed 
in which the depression score was replaced by the residuals of depression, obtained 
after regression with fatigue severity. The residuals of depression remained 
unchanged (odds ratio, 0.87 (0.81-0.93), Wald χ2= 15.57 p<0.001), while fatigue 
severity also became a significant predictor. An increase of fatigue (on the CIS fatigue 
severity scale, with a score range of 8-56), was associated with an decrease of the 
odds of higher quality of life, with an odds ratio of 0.93 (0.90-0.96), Wald χ2= 19.77, 
p<0.001. R-squared values for the model remained the same after this procedure.
The analysis on the outcome self-rated health revealed that fatigue severity and 
pain were significantly associated. An increase in fatigue was associated with a 
decrease in the odds of high self-rated health, with an odds ratio of 0.92 (0.88-
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0.96), Wald χ2= 18.70, p<0.001. An increase in pain (scored on the RAND 36, which 
ranges from zero to 100) was associated with a decrease in the odds of high self-
rated health, with an odds ratio of 0.98 (0.97-0.99) Wald χ2= 17.38, p<0.001. Motor 
symptom severity, physical functioning, depressive symptoms and anxiety symptoms 
were not significantly associated with self-rated health. The post hoc multivariable 
ordinal regression using the same residuals of depression, did not change this model 
substantially.
As both models yielded a large percentage of cells with zero frequencies, we 
performed additional binary logistic regression models with dichotomized quality 






















44 (17) 0.98 
(0.94-1.01)






6 (1) 1.0 
(0.80-1.23)





40 (45) 1.01 
(1.00-1.03)
3.37 0.067 1.01 
(0.99-1.02)
1.06 0.304
Pain (RAND 36) 46 (57) 1.00 
(0.99-1.01)
0.00 0.988 1.02 
(1.01-1.03)
17.38 <0.001
Depression (PHQ9) 7 (9) 0.87 
(0.81-0.93)
15.57 <0.001 0.96 
(0.89-1.03)
1.37 0.242
Anxiety (GAD7) 5 (9) 0.99 
(0.92-1.07)
0.03 0.869 1.02 
(0.94-1.09)
0.28 0.596
Table 3. Multivariable associations between predictors and Quality of life, self-rated health 
in FMD (n=180). Explained variance (R2 ) according to Cox and Schnell provided per model. 
High scores of quality of life and self-rated health represent high wellbeing/high functioning.
DISCUSSION
This study showed that 78% of FMD patients are severely fatigued, as compared 
to 53% of NMD patients. Fatigue subdomains motivation, concentration, and 
physical activity were all more severely affected in FMD compared to NMD. All 
fatigue subdomains were associated with depression and to a lesser degree with 
anxiety scores, while only the subdomains fatigue severity and physical activity 
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were associated with motor symptom severity. However, fatigue was significantly 
associated with self-rated health and with quality of life in patients with FMD, 
independent of motor symptom(s) severity, physical functioning, pain, depression, 
and anxiety.
The very high level of fatigue in FMD that was found, is remarkable. The fact that 
we found even higher levels of fatigue when compared to the neurological control 
group in this large cohort of patients underlines the scope of this problem in FMD. 
Our results are in line with findings from interventional studies in which fatigue was 
measured as a secondary outcome [4,20]. Compared to recently published norm data 
(n=1923), which showed 17% of healthy controls had severe fatigue when a cut-off 
of 35 was used [14], both FMD (78%) and NMD (53%) were more severely fatigued. 
However, our data do not indicate fatigue could be used diagnostically, because 
fatigue is high in both neurological groups and the dispersion is large in patients 
and healthy subjects.
We found that fatigue was clinically relevant for FMD patients, as it influences 
quality of life and self-rated health negatively. This is in line with findings in organic 
neurological disease [9,10,21]. In our data, quality of life was associated with 
depression and fatigue, while self-rated health was related to pain and fatigue. This 
might indicate patients perceive quality of life to be more strongly related to a mental 
state of wellbeing, while their health status would be linked to physical symptoms. 
The rather counterintuitive finding that motor symptom severity did not contribute to 
quality of life or self-rated health is not unique for FMD. The same was found in other 
neurological disorders, like cervical dystonia and early Parkinson’s Disease [22,23].
The suggestion that fatigue in FMD could be totally explained by the burden of 
functional motor symptoms or an expression of affect was not supported by our 
data. Motor symptoms were only correlated to some of the fatigue subdomains. 
Depression was correlated to fatigue, however depression scores were remarkably 
lower than anticipated from the literature [24], while fatigue scores were much 
higher. That leaves us with the question if fatigue could be a core feature and part 
of the phenotype of FMD.
An important shared element of fatigue and FMD is that tasks require more effort 
than they normally would. In fatigue, it has been hypothesised that a mismatch 
of expectations and sensory feedback results in this altered perception of effort. 
Impairment of sensory attenuation would be a key element of this mechanism 
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[25]. Sensory attenuation is the phenomenon in healthy subjects, of a reduction of 
perceived intensity of sensation when a movement is self-generated (opposed to 
externally generated) and has interestingly also been found to be impaired in FMD 
[26]. Altered perception of voluntary and involuntary movements originating from a 
mismatch in expectations and feedback, are considered part of the explanation of 
the mechanism behind FMD [27], which aligns nicely with the above hypothesis to 
explain fatigue. Enhanced attention towards motor execution is considered another 
element within this framework. Abnormally enhanced attention towards execution 
and processing of movement and cognition, could be one of the factors causing 
perceived enhanced effort, both in motor symptoms and fatigue in FMD.
Although this is the largest study into fatigue in FMD including a control group, 
the following limitations should be taken into account. There is conceptual overlap 
between fatigue and depression and anxiety, which is also reflected in our measures. 
We have tried to minimize this by using the CIS fatigue severity subdomain for the 
multivariable analyses, since this subdomain does not include questions on mood 
or anhedonia. In addition, we have performed correlation analyses of the depression 
scale while excluding the fatigue question, which did not fundamentally change any of 
our conclusions. Also, the choice of any organic control group for FMD is debatable. 
NMD share characteristics like motor impairment and the association with fatigue 
with FMD, but do not display the same heterogeneity in symptomatology as FMD. 
Lastly, there are no standardised methods for measuring outcome of the severity 
of functional motor symptoms, which is hindered by the heterogeneous nature of 
FMD (the high variability in the number of symptoms, percentage of the day that 
symptoms occur and (number of) body parts affected). We chose for one combined 
self-rated Likert scale, as this was seen to reflect severity overall per patient in the 
most meaningful way, and provided the possibility to compare this severity between 
patients. The obvious downside of this approach is a loss of fine-grained information 
and the risk of limited variability of the data that comes with the use of a Likert scale.
In conclusion, a large number of patients with FMD experience severe fatigue, also 
compared to patients with organic neurological disorder. Fatigue is an important 
factor in FMD and is significantly associated with reduced quality of life and lower 
self-rated health in these patients, irrespective of the severity of the functional 
motor symptoms or the presence of comorbid pain or mood symptoms. The role 
of fatigue in FMD should therefore be recognized in clinical practice. Intervention 
studies in Multiple Sclerosis show improvement of fatigue after resistance training 
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and mindfulness [28–30]. Our results suggest FMD patients might benefit from 
interventions focussed on fatigue as well.
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Functional movement disorders are accompanied by a high occurrence of 
psychopathology and cause serious impairments in quality of life. However, little is 
known about this in patients with functional jerks and no comparison has been made 
between patients with functional jerks and organic myoclonus. This case control 
study compares the occurrence of depression, anxiety and quality of life (HR-QoL) 
in patients with functional jerks and cortical myoclonus.
Patients with functional jerks and cortical myoclonus, consecutively recruited, 
were compared on self-rated anxiety (Beck Anxiety Inventory), depression (Beck 
Depression Inventory), health-related quality of life (RAND-36), and myoclonus 
severity (UMRS and CGI-S rating scales).
Sixteen patients with functional jerks and 23 with cortical myoclonus were evaluated. 
There was no significant difference in depression (44% vs. 43%) or anxiety (44% 
vs. 47%) scores between groups. The HR-QoL was similarly impaired except that 
functional jerks patients reported significantly more pain (p < 0.05). Only in the 
functional jerks group myoclonus severity correlated with depression and anxiety.
Depression and anxiety scores are high and do not discriminate between functional 
jerks and cortical myoclonus. Quality of life was equally impaired in both sub-groups, 
but pain was significantly worse in patients with functional jerks.
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INTRODUCTION
Functional movement disorders (FMD) are disabling involuntary movements, 
which can be defined by incongruence with known neurological pathology and the 
influence manoeuvres like distraction and suggestion. One of the manifestations of 
FMD is functional jerks (myoclonus) (FJ), which has a prevalence amongst FMD of 
approximately 15% [1].
FJ is characterized by an acute onset of jerks with a slow or variable burst duration, 
an inconsistent distribution, and reduction with distraction [2]. Clinical discrimination 
between FJ and organic myoclonus can be very difficult, even for world class experts 
[3]. In these cases, electrophysiological testing aids in the diagnosis of FJ, especially 
with the finding of a pre-movement or Bereitschaftspotential with back-averaging. 
Accurate and early diagnosing of FJ is important as prompt treatment improves 
patient’s outcome [4]. There is no evidence on specific therapy for FJ, but patient 
education and specialized physiotherapy are considered increasingly important in 
the treatment of FMD [5].
Symptoms of depression and anxiety are more common in FMD than in healthy 
controls, with 37,1%-61% lifetime depression and 20% - 21% generalised anxiety 
disorder in two key publications [6]. Although psychopathology has been found to be 
high in FMD [7], this is not unique for FMD as organic movement disorders are also 
often accompanied by psychopathology [8-10]. Studies comparing FMD with organic 
neurological disorders found either more affective disorders and anxiety in FMD, 
or equal prevalences [6]. Furthermore, previous studies reported a similar level of 
impairment of the quality of life and daily functioning, for example when comparing 
FMD with Parkinson’s Disease [7,11]. In multiple movement disorders there is an 
ongoing discussion whether psychiatric co-morbidity are primary and part of the 
phenotype or a secondary consequence of the motor disorder [8,12].
Little is known about the psychiatric co-morbidity in patients with FJ, and, to date, 
there has been no systematic comparison with an appropriate control group. In our 
study we explored the depression and anxiety rate, and whether these psychiatric 
symptoms and the perceived health related quality of life could discriminate between 
FJ and cortical myoclonus (CM). Based on the literature, our hypothesis is that 
patients with FJ experience more symptoms of depression, anxiety, and have a 
greater impairment of their quality of life.
3
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Adult patients with FJ and CM were consecutively recruited from both the outpatient 
clinic and the ward of the Neurology department of our tertiary referral centre 
between May 2014 and June 2016. Patients were excluded if they were aged less than 
16, or were judged to have significant cognitive impairment interfering with ability to 
complete measures. In all patients a comprehensive history was taken, including age 
at onset, co-existing neurological symptoms, and non-neurological co-morbidity. All 
subjects previously participated in a study about the value of electrophysiological 
testing in determination of the myoclonus subtype (article under review).
The Ethical Board of the University Medical Center Groningen (UMCG) approved the 
study (Number M14.157933).
Motor assessment
All patients underwent a medical history, protocolled videotaped clinical examination 
and electrophysiological testing. The diagnosis CM or FJ was made by a movement 
disorder specialist (MT) based on clinical characteristics. Co-existing neurological 
symptoms including additional movement disorders were recorded.
Severity of myoclonus was scored by two independent experts using the modified 
versions of the Unified Myoclonus Rating Scale (UMRS) [13] and the 7 point Global 
Clinical Impression – Severity (GCI-S) scale [14]. The average score of the two 
experts was used.
Psychiatric and quality of life assessment
Participants were asked to fill out a questionnaire consisting of the Beck anxiety 
Inventory (BAI) [15], and the Beck depression inventory (BDI) [16]. For the BDI, we 
used a cut-off score of 10 or higher to distinguish depressive from non-depressive 
patients, the range for mild depression was 10-19, moderate 19-29 and severe 
30-63 [16]. For the BAI the same scores were used to divide symptoms into no, mild, 
moderate and severe anxiety [17]. Three items on the BAI concerning trembling or 
shaking of several body parts were excluded from analysis, without adjustment of 
the marking of the BAI, as these questions are inherent to the movement disorders 
studied. The RAND 36 questionnaire, a Dutch validated version of the SF36 was used 
for measuring quality of life [18].
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Statistical analysis
Chi-square tests were used for categorical variables and Mann-Whitney U tests for 
ordinal and continuous not-normally distributed data in SPSS 23. When differences 
between groups were found, odds ratios were calculated using binominal logistic 
regression analysis, to provide predictive value of the factor for being in one of the 
groups. Inter-rater reliability for video motor scoring was assessed using the intra-
class correlation coefficient (ICC) (Two way mixed, consistency, average measures). 
Correlations between physical functioning (RAND-36 subscale), depression (BDI), 
anxiety (BAI) and symptom severity (CGI), were calculated using Spearman’s 
correlation in both groups. No violations were noted of the completed statistical 




Forty-seven adult patients, including 27 with CM and 20 FJ were recruited. Three 
CM cases were excluded from the study due to cognitive problems and five cases 
(4FJ and 1CM) had not completed the questionnaires. In total 39 patients; 16 FJ (69% 
female, median age at examination 32 years) and 23 CM patients (52% female, median 
age at examination 30 years) participated in the study. The severity of myoclonus 
on the UMRS was significantly higher for FJ (FJ:16.5, CM: 5.7) without a significant 
difference in CGI-S (FJ:4, CM:3) with a good ICC between raters (ICC UMRS = 0.98 
(95% CI: 0.95-0.99) / ICC GCI-S = 0.82 (95% CI: 0.67- 0.91)). Co-existing neurological 
symptoms were detected in five of the 20 FJ and in nine of the 27 CM patients (Table 
1). In the CM group, in 15/23 cases an aetiological diagnosis was made; five had an 
acquired cause, 10 cases were thought to have a genetic origin of which a causative 
gene mutation was found in seven cases (see Supplementary Table 1).
The demographic features are shown in Table 1.
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CM (n=23) FJ (n=16)
Female N (%) 12 (52%) 11 (69%)
Age at examination, median (IQR) 30 (32) 32 (38)
Age at onset of myoclonus, median (IQR) 17 (39) 25 (36)
Total UMRS, median (IQR) 5,7 (15) 16,5 (14)*
Total GCI-S, median (IQR) 3 (4) 4 (4)
Medical history
epilepsy 5 0
cognitive problems 4 0





other functional symptoms 0 4
Median RAND-36 scores (IQR)
Physical functioning 60 (56) 75 (63)
Social functioning 63 (38) 63 (59)
Role limitation physical 50( 100) 12,5 (94)
Role limitation emotional 100 (100) 100 (50)
Mental health 76 (32) 78 (20)
Vitality 50 (30) 50 (30)
Pain 80 (33) 49 (52)*
General health perception 40 (15) 50 (35)
Expected health change 50 (25) 50 (50)
Median BDI,
range (cut-off scores)
9 (0 - 25) 7 (0 - 43)
No depression (0-9) 13 9
Mild depression (10-18) 7 4
Moderate depression (19-29) 3 1
Severe depression (30-63) 0 2
Median BAI
Range (cut-off scores)
7 (0 - 26) 7 (3 - 28)
No anxiety (0-9) 12 9
Mild anxiety (10-18) 7 4
Moderate anxiety (19-29) 4 3
Severe anxiety (30-63) 0 0
Table 1. Demographic features, psychiatric co-morbidity and quality of life in functional 
jerks versus cortical myoclonus patients. CM = cortical myoclonus, FJ=functional jerky 
movements.
Occurrence of depression, anxiety, and health related quality of life
As is shown in Table 1, in the FJ group, 7/16 (44%) met criteria for a mild to severe 
depression and in the CM group this was 10/23 (43%). The median depression score 
on the BDI was not significantly different between the FJ and CM groups (FJ: 7 (0-
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43), CM: 9 (0-25), p=0.72). Seven of 16 (44%) FJ patients and 11/23 (48%) CM patients 
met criteria for mild to severe anxiety. The median BAI score was not significantly 
different for FJ (6 (0-28)) compared to CM patients (7 (0-26)).
On all subdomains of HR-QoL FJ and CM patients were equally impaired, except for 
the subdomain of pain. FJ patients reported significantly more pain (FJ vs CM median 
49 (IQR 52) vs median 80 (IQR 33), p < 0.05). Details about HR-QoL subdomains and 
severity of depression and anxiety can be found in Table 1.
As is shown in Table 2, myoclonus severity was correlated to both depression and 
anxiety in the FJ group, but not in the CM group. Pain was correlated to physical 
functioning in CM but not in FJ.










































Table 2: Correlations between myoclonus severity, psychiatric co-morbidity and HR-
QoL. BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory, CGI-S: Global Clinical 
Impression – Severity, CM: cortical myoclonus, FJ: functional jerks.
Statistically significant correlations using Spearman’s Rho (p<0.05) are highlighted 
in bold.
DISCUSSION
In this prospective study, we showed functional jerks and cortical myoclonus patients 
had equally high depression and anxiety scores and a similar impaired health related 
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The occurrence of mild to severe depression and anxiety in both FJ and CM found in 
our cohort is high compared to the normal population. In FJ, this confirms earlier 
findings in several types of functional neurological disorders [7]. Psychiatric co-
morbidity in a heterogeneous group of CM has not been studied before, but our 
results are comparable with the rates of anxiety and depression reported in CM 
patients diagnosed with Familial Cortical Myoclonic Tremor and Epilepsy and 
Juvenile Myoclonus Epilepsy [19,20]. These findings might implicate that cortical 
myoclonus syndromes in general are associated with psychiatric co-morbidity. In 
myoclonus dystonia (M-D) psychiatric comorbidity has consistently been described 
[10]. However, as M-D has a subcortical anatomical origin rather than cortical, a 
direct comparison with CM cannot be made. All in all, the similar levels of depression 
and anxiety in FJ and CM underline current views that these symptoms are not 
diagnostically relevant for FJ. The findings do, however, emphasize the importance 
for treatment of looking for anxiety and depression in both patient groups [5].
Health related quality of life was similarly impaired in FJ and CM patients, as was 
hypothesized based on the literature [7,11]. Pain was the only HRQoL subdomain 
significantly higher in the FJ group (median 49 (IQR 52) vs median 80 (IQR 33), p< 
0.05). Pain has been reported to be high in other subtypes of FMD, mainly functional 
(fixed) dystonia [21]. The relation between FJ and pain has not been studied before. 
Our finding implies that pain might be a promising diagnostic tool to discriminate FJ 
from other jerky movements, but this requires further studies in a larger prospective 
cohort.
Myoclonus severity was found to correlate with anxiety and depression scores in 
FJ but not CM. This might suggest that in the FJ group, there is a bidirectional 
relationship between anxiety/depression and myoclonus. Previous studies have 
shown that chronic pain negatively influences mood and quality of life [22]. However, 
in our cohort pain did not explain the relationship between anxiety/depression 
and myoclonus, as pain was not correlated to myoclonus severity. The lack of a 
relationship between anxiety/depression and myoclonus in CM suggest that these 
symptoms could be part of the CM phenotype or could be caused by other factors 
not taken into account in this study. To be able to determine whether the psychiatric 
symptoms have a primary or secondary cause, larger, preferably longitudinal, 
studies are required.
This study has limitations. As applies to all rare disorders, we had to study a small 
sample from a tertiary clinic, which improves diagnostic accuracy but might impair 
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generalizability. Furthermore, using the BAI might have caused an overestimation 
of anxiety in both groups, as it largely measures the experience of physical 
complaints, which are partly influenced by having myoclonus. In order to minimize 
this overestimation, we have excluded questions directly related to jerky movements, 
while retaining the cut-off value.
In conclusion, this study showed high depression and anxiety scores and a 
comparable impairment of the quality of life in patients with FJ and CM, with 
significantly more pain in the FJ group. It is important for clinicians to be aware 
of the high appearance of depression and anxiety in myoclonic disorders as these 
symptoms often require treatment. Unfortunately, the presence of depression and 
anxiety cannot be used as a diagnostic tool for FJ, however, pain might be a significant 
marker of differentiation between organic myoclonus and functional jerks.
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We investigated whether self-reported sense of agency is reduced in patients with 
functional movement disorders (FMD) compared to healthy controls.
Nineteen FMD patients and nineteen healthy volunteers matched on age, gender 
and educational level participated. A computer-designed task based on the principle 
of creating sensory incongruence was used to modulate sense of agency. In this 
experiment subjects were asked if their action (pressing a button) caused a reaction 
(auditory tone) which would follow at a variable time delay (0-1100 ms).
We demonstrated impaired self-reported sense of agency in both patients and 
volunteers (p = .002) with increasing sensory incongruence during the experiment. 
No differences however were detected between groups (p = .655).
Self-reported Sense of agency using an action-reaction paradigm, modulated by a 
time delay creating sensory incongruence, was normal in patients with FMD.
We discuss how choices in the experimental design, may explain a lack of difference 
between cases and controls. Moreover, our findings offer a view on the complex and 
apparent multileveled nature of sense of agency. We conclude that the link between 
Sense of agency and its experimental markers as well as its role in FMD need to be 
further researched.
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INTRODUCTION
It has been hypothesized that abnormal experience of (motor) action, or a reduced sense 
of agency, is a potential hallmark of FMD (Edwards et al., 2013). Disturbances in sense 
of agency– i.e. the sense of oneself as the agent of one’s own (motor) actions – could 
explain why FMD patients report lack of control for movements that physiologically 
appear as voluntary (Hallet, 2010; vd Salm et al., 2012; Parees et al., 2014).
Sense of agency allows for distinction between ‘self’ and ‘other’, thereby representing 
an essential component of human volition and movement (Gallagher, 2000; David 
et al., 2008). Several theoretical models (reviewed by David et al., 2008) have been 
developed on sense of agency, among which the ‘comparator model’ is one of the 
most influential. It describes how Sense of agency arises from the comparison 
of sensorimotor plans (“efference copies”) and predictions prior to movement, to 
post-motor sensory feedback. In case of a match between predicted movement 
and sensory feedback after the movement, sense of agency is present; in case of a 
mismatch, agency will be attributed to an external source or the motor action will be 
interpreted as ‘failed’ or ‘not one’s own’ (Blakemore et al., 2002; Synofzik et al., 2008). 
Studies in FMD patients have shown altered activity in the temporo-parietal junction, 
which has been posed to be the neuro-anatomical substrate of these comparative 
processes, i.e. sense of agency (e.g. Farrer and Frith, 2002, Voon et al., 2010).
Few studies in FMD assessed sense of agency in an experimental fashion thus far. 
Kranick et al. (2009) found reduced intentional (action-effect) binding in FMD. This is the 
effect by which healthy people report the timing of a motor action and its sensory effect; 
they occur nearer in time when these events are considered cause-and-effect (Haggard, 
2002). Since this perceptual distortion is only observed for voluntary movement - 
i.e. movement for which one experiences agency, intentional binding is thought to 
represent a marker of Sense of agency (reviewed by Moore & Obhi, 2012). Similarly, 
sensory attenuation, the phenomenon in which the intention of sensory sensations is 
reduced when a movement is self-generated, is considered as another indicator of 
sense of agency. Parees et al. (2014) and Macerollo et al. (2015) demonstrated loss 
of sensory attenuation in FMD patients and linked this to impaired Sense of agency.
In the current study, we hypothesized to reveal reduced sense of agency in patients 
with FMD through the principle incongruence between motor action and sensory 
feedback. This can be experimentally assessed by creating temporal delay between a 
motor action and its sensory outcome (David et al., 2008). We conducted a computer 
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task similar to an experiment carried out by Sato & Yasuda (2005), who demonstrated 
that temporal delay reduced sense of agency in healthy people. Sensory incongruence 
was found to alter Sense of agency in several groups of patients as well, for example 
in schizophrenia (e.g. Maeda et al., 2012).
METHODS
Participants
FMD patients were included from the Neurology department of the University Medical 
Center Groningen and the Academic Medical Center (the Netherlands). All patients 
with a FMD (e.g. tremor, myoclonus, dystonia), who had a minimal symptom duration of 
one year or more, who were aged 18 years or older and had the ability to give informed 
consent were invited to participate. The diagnosis was made by a movement disorders 
specialist, conform the current standards based on positive signs in the disease history 
and neurologic examination. Healthy volunteers, recruited by advertisement in the 
hospital and university, were matched based on age, gender and educational level; the 
latter was determined using the Dutch scoring system of Verhage (1964). Volunteers with 
(a history of) neurological symptoms of any nature were excluded from participation. 
Written informed consent was obtained from all participants. This study was approved 
by the Medical Ethical committee of the University of Amsterdam, as part of a larger 
study to the effect of Botulinum Toxin injections for functional movement disorders.
Agency Experiment
We adapted a paradigm from Sato & Yasuda (2005). In this experiment incongruence 
between motor action and sensory feedback is used as a model to measure (reduced) 
sense of agency. The incongruence that was introduced, was a temporal delay 
between button press and a tone response. Below a detailed description of the 
experiment is provided in flowchart 1. In short, patients were asked to rate whether 
or not they felt to have been the cause of a response sound after a self-timed button 
press. The crucial part of the experiment was a variable delay between these two 
(button press and response sound), which was unknown to the patient. Before the 
experiment started, there was a training phase, in which patients learned what the 
normal action-response time was.
Analysis
For statistical analysis, we used IBM SPSS Statistics version 22.0.0. The number of 
times a participant answered ‘yes’ (judging the tone as self-produced) resulted in 
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a mean reported sense of agency. For every participant, we calculated cumulative 
scores on the twelve different delay conditions (0 – 1100 milliseconds) throughout 
each of the six subsets; i.e. in case a participant responded by ‘yes’ three out of six 
times on the delay condition “500 milliseconds”, mean reported sense of agency of 
the participant on this condition would be 0.5 (50%). Missing values were imputed 
using mean scores of the entire group (patients and controls) on the particular 
variable. A two-way repeated measures analysis of variance (ANOVA), with within-
groups factor “temporal delay” and between-subject factor “group” (patient/control) 
was used to determine the effect of temporal delay on reported sense of agency 
along with potential differences between patients and controls in the extent of this 
effect. Statistical significance of p < .05 was assumed significant.
Flowchart 1: events and instructions of the agency experiment
RESULTS
Participants
19 patients with FMD and 19 healthy volunteers participated. The phenomenology of 
motor symptoms in the FMD patient group included myoclonus (n=8, 42%), tremor 
(n=6, 32%), dystonia (n=4, 21%) and gait disorder (n=2, 11%). Matching succeeded well, 
based on age (45.8 ± 15.6 and 45.3 ± 16.0 for patients and volunteers respectively), 
gender (8 males and 11 females in both groups) and educational level (5.7 ± 1.1. and 
6.2 ± 0.9 respectively).
Agency Experiment Results
Analysis of results revealed that overall, temporal delay significantly lowered 
reported sense of agency, F (11, 26) = 4.021, p = .002. However, this effect did not differ 
significantly between FMD patients and healthy volunteers, F (11, 26) = 0.782, p = .655. 
Neither did any of the delay durations separately reveal significant differences 
between patients and controls. Results are presented in figure 1.
4
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A learning effect was observed through repeated measures ANOVA with the 
cumulative scores of patients and controls on each of the six subsets (each consisting 
of the twelve different delay conditions),F (5, 32) = 4.215, p = .005, see figure 2.
Although patients had a lower mean sense of agency rating than controls on all but 
the first of the subsets (1-6) of conditions (0-1100 ms), a MANOVA test revealed that 
this was not significant on any of the subsets F (1, 36) ≤ 0.045, p ≥.142.
Fig. 1. Mean sense of agency rating in each delay condition.
Results of the mean reported Sense of agency by patients versus volunteers per 
delay condition (0-1100 ms). Reported Sense of agency is based on the number of in 
total 144 trials (divided into six subsets) in which a patient responded by ‘yes’ (judging 
the tone as self-produced), per delay duration, as displayed on the x-axis (no delay 
to 1100 milliseconds delay).
Fig. 2. Mean sense of agency rating over time.
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Results of the evolution of responses in time are displayed in patients and controls, 
with on the x-axis the trial subset from 1 to 6. Sense of agency ratings are expressed 
on a scale of 0 (agency attribution to computer) to 1 (agency attribution to self), based 
on the number of times a patient reported the stimulus to be self-generated.
DISCUSSION
We demonstrated that creating a time delay between motor action, i.e. a voluntary 
movement, and a sensory outcome, i.e. an auditory tone, causing sensory 
incongruence, lowers self-reported sense of agency in patients with FMD as well 
as healthy subjects, thereby replicating previous work (e.g. Farrer and Frith, 2002; 
Sato and Yasuda, 2005; Maeda et al., 2012; Delorme et al., 2016). Impaired Sense of 
agency is thought to to play a key role in the pathophysiology of FMD (Kranick et al., 
2013; Edwards et al., 2011; Edwards et al., 2013; Voon et al., 2010). Opposed to what 
we hypothesized, sense of agency assessed in this experiment was not lower in FMD 
compared to healthy controls.
Our negative findings might reflect that sense of agency is not merely a product 
of sensory congruence in a comparative process; instead, sense of agency might 
be more adequately described as a multileveled phenomenon, composed of low-
level (sensorimotor), as well as high-level (cognitive), ‘reflective’ experiences of 
agency (David et al., 2008; Synofzik et al., 2007). Furthermore, the optimal-cue-
integration theory sense of agency states that multiple internal and external cues, 
together with prior beliefs and expectations, are weighted based on their different 
reliabilities, eventually leading to a sense of agency (reviewed by Moore & Fletcher, 
2012). Perhaps, the specific cue of sensory congruence in the formation of sense of 
agency is unaffected in FMD, whereas cue-integration is still disturbed leading to 
reduced sense of agency. Moreover, the fact that previous authors found reduced 
sense of agency in FMD when measured through indirect markers (such as action-
effect binding and sensory attenuation), whereas we did not through explicit self-
report, supports the notion of different processes involved in indirect and explicit 
sense of agency, which has been described elsewhere (Moore & Obhi, 2012).
Finally, sense of agency is most clearly affected in FMD in relation to the motor 
symptoms themselves, which are perceived involuntary. Although previous studies 
have found altered sense of agency in FMD in tasks comprising general motor control 
(not related to the symptoms), our negative findings might be explained by the fact 
4
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that motor symptoms are associated with reduced sense of agency, but voluntary 
motor might not be.
Besides uncertainty regarding the use of explicitly reported sense of agency, 
there are several limitations in our study that may have contributed to the lack of 
differences. In general, the small sample size and heterogeneity of FMD phenotypes 
make this study explorative in nature and hamper bold conclusions. Furthermore, 
including temporal delay conditions up to 1100 milliseconds may have caused 
blurring of an effect around the threshold of 150-300 milliseconds, when healthy 
people can normally recognize temporal delay and estimations of agency may be 
most uncertain (Blakemore and Frith, 2003). However, the group comparison per 
delay duration did not reveal differences around this threshold either. Finally, every 
experiment is an approximation of reality. Perhaps our experiment merely shows 
the capacity of subjects to recognize delay, which might not translate into a sense of 
agency. There were no significant differences between patients and controls reaction 
times.
In conclusion, our results suggest that explicitly reported sense of agency, in an 
experiment using sensory incongruence, is not affected in FMD. This idea fits into 
a theoretical framework emphasizing the multileveled nature of sense of agency. 
It seems likely that different experimental designs refer to different levels of sense 
of agency. However, we believe our study offers reflections on the complexity of 
(studying) sense of agency as well as the unanswered questions regarding FMD 
pathophysiology, and warrants further research.
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In functional motor disorders, altered perception of the body and sense of agency 
are key aspects of the underlying mechanism.
To identify FMD-related changes in cerebral activation with fMRI in regions implicated 
in self-perception and sense of agency, self-referenced versus goal directed and 
both free and fixed action selection are assessed in patients with FMD, compared 
to healthy controls.
16 FMD patients and 16 matched healthy controls (HC) underwent fMRI-scanning 
during a motor task with alternating blocks selecting fingers (self-referenced) versus 
buttons (goal-directed) and free (internal) versus fixed (external) cues. Differences 
were analyzed using statistic parametric mapping (SPM). Regions of interest were 
correlated with symptom severity (spearman’s rho) and studied for connectivity using 
psycho-physiological interactions.
We confirmed findings in HC of predominantly prefrontal and parietal activations in 
free versus fixed conditions, the opposite contrast showed the extrastriate visual 
cortex and activation along the dorsal intraparietal sulcus. In finger versus button 
selection, activations of the occipital and anterior parietal cortices, including the 
postcentral sulcus were found. In FMD compared to HC we found reduced activation 
of the left primary motor cortex in the conjunction of all motor conditions (p<0.05 
FWE-corrected). The left insula of patients showed reduced activation during free 
finger selection compared with both fixed finger and with free button selections 
(p<0.001 uncorr), which correlated to symptom severity (Rho 0.463 (p=0.035)). In 
fixed versus free selection reduced activation of the left premotor and right parietal 
operculum and along the left intraparietal sulcus were key findings in patients 
compared to controls. Finger versus button selection showed additionally reduced 
activation of the right anterior cingulate and the postcentral gyrus (p<0.001, uncorr). 
Increased connectivity between the primary motor cortex and occipitotemporal 
cortex and reduced connectivity between the left insula and left postcentral gyrus, 
and between the parietal operculum and hippocampus in FMD was found (p<0.05 
FWE-corrected).
We further specified previously reported associations of the insula with reduced 
sense of agency and altered perception of body scheme in FMD. Reduced sense of 
agency was further underlined by our findings of reduced activations of premotor 
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and parietal cortices, most apparent in fixed (externally cued) compared to free 
action selection. Finally, reduced activation of the primary motor cortex corroborates 
impaired explicit motor control in FMD.
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The pathophysiology of functional movement disorders (FMD) is gaining more 
and more interest and increasingly influences treatment strategies. The leading 
explanation of FMD is a Bayesian model in which biopsychosocial factors that exist 
in varying combinations in each patient form expectations and beliefs (I), that interact 
with alterations of agency (II) and attention to the self (III) [1].
Sense of agency is the perception that you are the cause of an action [2]. Consequently, 
a distorted sense of agency in FMD could explain the discrepancy between patients’ 
experience that their symptoms are involuntary, while measurements of these 
movements indicate normal preparation of movement. For example by the presence 
of a Bereitschaftspotential in functional myoclonus [3]. Findings of a reduced 
intentional-binding effect [4] and less sensory attenuation [5], both seen as measures 
of sense of agency, fit with that notion.
Functional brain imaging has enabled identification of neural substrates of sense of 
agency such as the parietal cortex (specifically anterolateral and lateral temporo-
parietal areas), the frontal and prefrontal cortex, the insula and postero-midline 
structures like the precuneus and posterior cingulate cortex [6, 7]. In FMD, Nahab 
et al. [8] explicitly studied sense of agency recently, and found that loss of movement 
control was associated with less response of the right anterior insula and right 
temporoparietal junction (TPJ) in a virtual reality paradigm.
Perception of the body and of bodily sensations, the second pillar of the mechanism 
of FMD is strongly linked to perception of agency. In this respect, patients have 
been described to over-attend their symptoms [9], while altered perception of body 
ownership has been demonstrated in motor FMD [10]. Also, patients with functional 
dystonia may experience an abnormal position of their affected body part [11].
Using functional imaging, Maurer et al made the link between sense of agency and 
attention to the self in FMD [12]. Using TPJ as a prespecified seed in resting state 
MRI, decreased functional connectivity was found between the right TPJ and the right 
sensorimotor cortex, cerebellar vermis, bilateral supplementary motor area (SMA), 
and right insula in FMD compared to healthy controls. The authors interpreted this 
as a combination of disturbed feed-forward motor control and distorted sensory 
perception, resulting in reduced sense of agency. Furthermore, a meta-analysis on 
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imaging in FMD showed that the insula, dorsolateral prefrontal and frontal brain 
areas were most consistently affected in FMD [13].
Given the stronger association of free choice responses with sense of agency, 
compared to fixed instructions [14], the study of Voon et al [15] is of particular interest, 
because their fMRI study provided further insight in such link by demonstrating 
reduced functional connectivity of the left SMA with bilateral dorsolateral prefrontal 
cortices in FMD in free versus fixed button selection. However, the effect of 
representation of body scheme in FMD was not studied. An extended fMRI paradigm 
from our group performed in healthy subjects did address both (i) representation of 
body scheme, by comparing self-referenced (finger) versus goal-directed (button) 
selection, and (ii) free versus fixed action selection [16]. This study showed prominent 
prefrontal activations in free versus fixed selection, with differential contributions of 
the dorsal prefrontal and anterior cingulate cortex in self-referenced compared to 
goal-directed selection. In both free selection conditions the inferior parietal cortex 
was bilaterally activated. This added support to novel concepts that free choice is not 
only associated with prefrontal regions, but also involves the parietal cortex [17–19].
In the present study we employed the Beudel paradigm [16] to investigate both self-
referenced versus goal directed movement and free (internally) selected versus fixed 
(externally) instructed tasks in patients with FMD, compared to healthy controls. We 
hypothesized to find particularly FMD-related decreases in activation in prefrontal 
and parietal brain regions when making self-generated (free) compared to externally 
cued (fixed) selections. Furthermore, we expected reductions in (pre)frontal, parietal 
and insula activations during self-referenced (finger) movement compared to goal 
directed movement towards a button.
METHODS
Study design
Participants were included from the movement disorder clinics of the University 
Medical Center Groningen (UMCG) and the Amsterdam University Medical Center 
(AUMC). For this study, all participants were seen twice at the UMCG. During the 
first meeting, participants received instructions, were interviewed and performed 
a computer version of the fMRI paradigm outside the scanner. Patients were asked 
for the severity of the functional tremor/myclonus on a 7-point Likert scale and 
psychiatric co-morbidity using the BDI (Beck Depression Inventory) and BAI (Beck 
5
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Anxiety Inventory). The actual fMRI paradigm was performed approximately one 
week later.
Participants
Sixteen out of 17 scanned patients with a functional myoclonus or functional tremor 
(mean age 43 (SD 14) 50% male (n=8)) and 16 matched healthy control subjects (mean 
age 42 (SD 14),) were included. One patient was excluded due to hearing problems. 
The diagnosis of a functional myoclonus or tremor was made by an expert neurologist 
in movement disorders, based on clinical findings and clinical neurophysiological 
measurements to support the diagnosis. Only right-handed patients older than 17 
were included. All subjects provided written informed consent. Exclusion criteria 
were incompatibility with MRI-scanning and not being able to perform the task. 
Educational level was university of applied sciences (Dutch: HBO) or higher in 50% 
of patients and 75% of controls. None of the healthy controls suffered from anxiety 
or depression, in the patient group depression scores on the Beck depression 
inventory were 8.4 on average (SD 7.9), corresponding to absent depression, while 
anxiety on the Beck anxiety inventory was 17.5 on average (SD 13.2), corresponding 
to mild anxiety (BDI and BAI range 0 – 63). In the patient group, symptom severity 
on the clinical global impression (CGI), rated by consensus of the investigator and 
the patient, was median 4 (IQR 2).
Task Paradigm
We used the paradigm previously published by Beudel et al. [16]. In this auditory 
instructed block-design, there were four different motor conditions and one rest 
condition. These were alternated, in order to test both internally and externally 
generated cues of which finger to use and which button to press. Figure 1 illustrates 
the paradigm. It worked as follows: there were four buttons and patients were 
instructed to use fingers 2,3,4,5. They received auditory instructions before each 
block indicating which condition followed, and during each condition. In the first two 
conditions, subjects had to use the same button (Bu), while the choice of which finger 
to use was either chosen by the patient (Fi_Free) or externally imposed (Fi_Fixed). 
In the third and fourth condition, the same finger was used (digit 2) and the choice 
of which button to use was either chosen by the patient (Bu_Free) or externally 
imposed (Bu-Fixed). The fifth condition (Rest), served as a control condition. Apart 
from the auditory instructions before each block, patients received auditory cues 
before each button press. In the free conditions (1 and 3) and the rest condition (5), 
these were meaningless numbers 6,7,8 and 9. In the fixed conditions, these numbers 
represented which finger to use, 2,3,4 or 5 (condition 2), or which button to press 
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1,2,3 or 4 (condition 4). See figure 1 for graphical depiction of the task conditions. 
Response choices and reaction times were logged.
Figure 1. Conditions of the block paradigm. Blocks were alternated, each block contained 
8 stimuli and blocks were repeated 16 times in total.
Each condition contained 8 stimuli, and was repeated 16 times, resulting in 128 
stimuli per condition, divided over 2 runs of 18 minutes in duration. The order of 
these conditions was organized such a way that each condition was preceded as often 
by each other condition, using pseudo-randomization by means of a magic square. 
The paradigm was designed and run in Presentation software (Neuro Behavioural 
Systems, Inc. Albany CA).
fMRI recording and set-up
The scans were recorded with a 3 Tesla MRI scanner (Philips Medical Systems, 
Best, the Netherlands), with a 32-channel SENSE head coil. An axial T1-weighted 
3D turbo field echo (T1TFE) sequence image was made for anatomical reference: 
TR 9 ms; TE 3.5 ms; number of echoes 1; flip angle 8°; matrix size = 256 x 256; 
FOV: 232 x 170 x 256 mm; voxel size 1 x 1 x 1 mm; acquisition time: 4 minutes 18 
seconds. Functional imaging was acquired with a gradient-echo T2* blood oxygen 
level-dependent contrast technique, with a TR (time repetition) of 2000 msec and a 
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TE (time echo) of 28 msec. 37 slices and 550 volumes per run were acquired. Images 
were tilted in the anterior commissure-posterior commissure plane, flip angle 70°. 
Patients were instructed to lay as still as possible. For auditory instructions, MR-
compatible electrodynamic headphones were used (MR Confon GmbH, Magdeburg, 
Germany). Subjects were able to see their right hand via a double mirror, and with 




Response times were compared between groups using t-test, using the means of 
single subjects for each condition per run. Response time was measured from the 
beginning of the stimulus to the recorded response.
fMRI analysis
We used statistic parametric mapping software for fMRI data analysis (SPM12, 
Wellcome Department, University College London, London, UK). Preprocessing 
consisted of realignment to the mean image and co-registration to T1-weighted 
anatomical image of the participants. Normalization was done using the EPI Montreal 
Neurological Institute (MNI) template provided in SPM12 and spatial smoothing with 
an 8 mm full-width at half maximum Gaussian kernel.
First level analysis was performed in which all 4 experimental conditions were 
contrasted to the rest condition at subject level using 1-sample t-tests. Framewise 
displacement was calculated from the motion parameters and added to the model.
At second level a flexible factorial design was used for results at group level. 
Contrast between conditions were made one-on-one (for example free finger versus 
fixed finger selection) and combined (for example all free (both finger free and button 
free) versus all fixed (both finger fixed and button fixed) conditions). In this respect 
the combination of Fi_Free and Bu_Free is referred to as ‘all free’, Fi_Fixed and 
Bu_Fixed is ‘all fixed’, Fi_Free and Fi_Fixed is ‘all fingers’, Bu_Free and Bu_Fixed 
is ‘all buttons’. A combination of all conditions compared to rest is referred to as 
‘all motor’.
Initially these contrast were made in the healthy control group only, to replicate our 
previous study. Then, contrasts at subject level were compared between groups 
(both Patients > Controls, and Controls> patients).
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In this second level design, conditions were assumed to be dependent, while subjects 
were considered independent. The resulting set of maps for the different contrasts 
were thresholded: Clusters of increased activation within the cortex were considered 
statistically significant at p < 0.001; threshold (k) of 20 voxels (uncorrected), following 
Woo et al [20].
Post hoc, four crucial activated regions were selected for further investigation, 
originating from the second level contrasts . These were selected based on 
hypothesis, focusing mainly on parietal and frontal regions derived from our previous 
study [16], supplemented with regions that are known to be involved in FMD from 
meta-analysis [13]. These regions, annotated as ‘regions of interest (ROI)’, were used 
for connectivity analyses and correlations with symptom severity.
Connectivity analyses were performed using generalized PPI (psychophysiological 
interactions). For this PPI analysis, an Automated toolbox for a generalized form of 
psychophysiological interactions (GPPI), was used [21].
Symptom severity, as measured on the CGI, was correlated to the beta values 
extracted from the ROIs, using Spearman’s rho (one-tailed).
RESULTS
Supplementary figure 1. Response times for every condition in patients and controls. No 
significant differences between groups were found.
5
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Patients showed consistently slower reaction times, which were not specific for one 
of the conditions and did not significantly differ between groups (see supplementary 
Fig.1 for details). The pattern of reaction times between conditions is highly 
comparable to our previous paper [16].
fMRI results
1. Contrasts of conditions within the healthy control group
The contrast of all free compared to all fixed conditions in healthy controls, showed 
predominantly bilateral involvement of antero-superior prefrontal and bilateral 
parietal activations, of which the latter particularly resulted from the comparison 
of free finger versus fixed finger selection. The reverse contrast of fixed vs free 
conditions showed involvement of the extrastriate visual cortex and activation along 
the dorsal intraparietal sulcus. In healthy controls, all finger (both free and fixed) 
conditions versus all button selection (free and fixed), showed activations of the 
occipital and anterior parietal cortices, including the postcentral sulcus. The reverse 
contrast, all button versus all finger selection, did not result in significant differences 
of cortical activations. Figure 2 summarizes these findings. The results were highly 
comparable to the results found in our previous paper [16].
Figure2. Contrasts of conditions within healthy controls. A: All free vs all Fixed conditions 
show activations in the prefrontal cortex bilaterally, B: All fixed over all free conditions show 
activation of the occipital lobes bilaterally and in the interparietal sulcus. C: All fingers over 
all buttons showing activations in the occipital and parietal lobe, including the postcentral 
sulcus. The fourth contrast, all buttons over all fingers did not result in significant cortical 
activations. D: p<0.001 uncorrected, A+C: p<0.05 FWE-corrected.
2. Contrasts of conditions in FMD compared to healthy controls
2A) All motor conditions versus rest
The conjunction of all motor conditions compared to the rest condition revealed that 
patients had significantly reduced activity of the left primary motor cortex (M1) and 
left premotor cortex (P<0.05 FWE corrected). See Table 1 and Fig.3A. Contrasting the 
four motor conditions separately to rest, showed a small area of reduced activation 
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in patients in the same part of the primary motor cortex (M1). No other differences in 
activations were found in this contrast, nor in the opposite contrast (patient-related 
increases over controls).
2B) Contrasts between motor conditions
In general, patients showed task specific regional decreases of activation in a 
coherent distribution of distinct parietal regions, when compared to controls. In 
addition, regional changes were seen which are specified below. All findings are 
summarized in figure 3 and table 1.
Free selection versus Fixed instruction
In all free over all fixed conditions patients had less activation in the left angular 
gyrus, i.e. the infero-posterior parietal cortex (p<0.001 uncorr.) compared to controls.
Fixed instruction versus Free selection
In the contrast of fixed over free finger selection (Fi_fixed>Fi_Free), there was a 
larger difference in FMD patients compared to controls in the left insula (Fig.3C).
Contrasting fixed button versus free button selection, there was less activation in 
patients than in controls in the right parietal operculum, i.e. the infero-anterior 
parietal cortex (Fig.3D), and additional small foci in the left temporal cortex and the 
right auditory cortex (p<0.001 uncorrected) (see table 1).
In the comparison between fixed finger and free finger selection, there was reduced 
activation in the left premotor area (p<0.001 uncorr.) ((Fig.3B) in patients compared 
to controls.
The conjunction of all fixed conditions compared to all free conditions, the same 
patient-related reduction of activation, compared to controls, was found in the right 
parietal operculum and left premotor area. Furthermore, superior parietal activation 
along the intraparietal sulcus (Fig.3E) was found to be reduced in patients compared 
to controls.
Finger selection versus Button selection
In the contrast of free finger selection compared to free button selection, there was 
a significant difference in the left insula. In patients there was higher activation in 
button than finger selection, in controls there was a higher activation in finger than 
button selection (Fig.3C). The right anterior cingulate cortex showed a pattern in 
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which patients had less activation in the finger free condition compared to the button 
free condition, while controls showed the opposite pattern (Fi_Free>Bu_Free).
When fixed finger selection was compared to fixed button selection, the right 
postcentral gyrus (Fig.3F) and the left somatosensory cortex were less activated 
in patients then controls. In patients, the right dorsal extrastriate visual cortex 
(dorsal cuneus) revealed lower activations in fixed fingers than fixed buttons, while 
in controls the opposite pattern (fixed fingers > fixed buttons) occurred.
Contrasting all finger over all button selection tasks, the somatosensory cortex on 
the right side, the right dorsal extrastriate visual cortex (dorsal cuneus) and the 
postcentral gyrus revealed less activation in patients than in healthy controls, all 
of which were found in the above described fixed finger over fixed button contrast 
as well.
Button selection versus Finger selection
There were no significant changes in activation found in the contrast of buttons over 
fingers between groups.
Two foci of activation that were observed in the cingulate gyrus and anterior 
prefrontal cortex were disregarded, because the difference between groups was 
entirely explained by one strongly deviating value in the control group.
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Fig 3. Contrasts of motor conditions between groups. Left: Activation clusters from con-
trasts between conditions between groups. Right: Beta value of the given cluster in each con-
dition contrasted to the rest condition, per group. A. M1 contrast all motor>rest, pt<co. B. Left 
premotor cortex, contrasts: all_motor pt<co and fi_fixed>fi_free and all_fixed>all_free. C. Left 
insula, contrast fi_free>bu_free and fi_free>fi_fixed pt<co. D./E./F. Parietal cortex, respective-
ly: D. Right parietal operculum, Bu_Fixed>Bu_Free , Patients<Controls and all_fixed>all_free; 
E. Left interparietal gyrus from the contrast All fixed>All_free, Patients<Controls; F. Right 
postcentral gyrus, Fi_fixed>Bu_Fixed and All fingers>all buttons, patients<controls.
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3. Post hoc correlations
Based on the above described activations and the hypothesized involvement of 
distinct cortical regions, 4 regions of interest (ROIs) were selected for post hoc 
analysis: 1: The left primary motor cortex (M1), 2: left premotor cortex, 3: the left 
insula 4: the right parietal operculum (See table 1).
Correlations with symptom severity
We found a significant correlation of symptom severity with reduced activation of 
the insula in the free finger vs free button contrast, Rho 0.463 (p=0.035) and with 
the activation of the left premotor area in the fixed finger versus free finger contrast, 
Rho 0.481 (p=0.030) in patients.
There were no significant correlations between symptom severity and the activations 
found in the primary motor cortex (p=0.282), and the parietal operculum (p=0.124) 
and the left insula (p=0.426) in the corresponding contrasts.
Connectivity analysis (PPI)
There was enhanced connectivity in patients over controls of the primary motor 
cortex with the ventral occipitotemporal cortex (BA37) in the contrast of free finger 
over fixed finger conditions. The left insula showed reduced connectivity in patients 
with the superior parietal cortex, extending onto the gyrus postcentralis (- 34 
-38 46 = BA 40), the left premotor cortex (- 46 0 30 = BA 6) and along the lateral 
part of the parieto-occipital sulcus (32 -78 42 = BA 7). There was no difference 
in connectivity between the left premotor cortex and the rest of the brain. There 
was reduced connectivity in patients between the right parietal operculum and the 
bilateral perirhinal cortex/hippocampus in all fixed compared to all free conditions. 
PPI results are depicted in figure 4.
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Figure 4. PPI analysis. 1. Enhanced connectivity in patients in Fi_free>Fi_fixed with the oc-
cipitotemporal cortex (30 -40 -12, BA37) 2. No significant differences between groups, 3. 
Reduced connectivity in patients in Fi_free>Fi_fixed with left postcentral gyrus (- 34 -38 46, 
BA 40) 4. Reduced connectivity in patients in All_fixed>All_free with the bilateral perirhinal 
cortex/hippocampus (22 -18 -20, BA35). All: P<0.05, FWE-corrected.
DISCUSSION
In this fMRI study of FMD patients and healthy controls, we employed a paradigm 
comparing selections between either fingers (self-referenced) and buttons (goal-
directed), that were either freely chosen (internally cued) or made by fixed instructions 
(externally cued). In healthy control subjects, the pattern of task-specific fronto-
parietal activations replicated previous results [16], with parietal activations along the 
intraparietal sulcus extending into the post-central sulcus that were dominant in the 
fixed selection tasks, while activation along the post-central sulcus was particularly 
related with all finger tasks. This reflected involvement of basic sensorimotor 
transformations, based on respectively visual and somatosensory information. 
Parietal activation related to the free selection conditions was particularly seen on 
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the lateral convexity of the inferior parietal lobe. In FMD patients, reduced activation 
of premotor and parietal cortices included the left parietal operculum and decreases 
along the interparietal sulcus in fixed versus free selections, while reduced post-
central gyrus and right anterior cingulate activations particularly occurred in self-
referenced movement, compared to the goal-directed tasks. An unpredicted main 
finding was the reduced left primary motor cortex activation in all motor tasks in 
FMD. Reduced activation of the insula in the contrast of free self-referenced action 
compared to both fixed self-referenced and free goal-directed action selection in 
patients, more than in controls, provided novel insight in functional impairment of 
this region that has often been described in FMD.
The observed FMD-related changes in the fronto-parietal circuitry are consistent 
with and add to theories on its involvement in motor initiation and voluntary action 
[2, 22]. In this respect, the coherence between motor intention and mechanisms 
underlying sensorimotor transformations, that have been found to be particularly 
maintained by specific parietal regions [23], appears to be affected in FMD. Regarding 
motor initiation, a contribution of the left angular gyrus has been inferred from 
switching between motor programs, while the onset of a simple movement element 
particularly activated the anterior parietal cortex [24]. Consistent with such left 
hemisphere dominance is the proposed role of the left inferior parietal cortex in 
motor attention [25]. Moreover, consistent with the concept of ‘internal attention’ 
serving motor control, is a left-lateralized parietal involvement in body scheme 
input to goal-direct movement which can be segregated from the right parietal 
contribution of an external space representation [26].
Explicit motor control
The overall lower activity of the primary motor cortex and left premotor area in all 
motor conditions in patients compared to controls might be explained by a difficulty 
in performing automatic simple motor tasks. Experimental studies have shown a 
failure of explicit motor control, in which easiest tasks are the most affected in FMD 
[27, 28] while patients experience most difficult performance with easy, predictable 
tasks in clinical practice. The slower reaction times in all conditions fit with that 
explanation. The enhanced connectivity between the primary motor cortex and 
the ventral occipitotemporal cortex, involved in object recognition, might reflect 
increased effort of the FMD patients in the simple motor tasks in which an external 
button is the target to be pushed in all four conditions in patients with FMD.
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Sense of agency and body scheme
Arguably, the free finger selection condition implies involvement of both sense of 
agency (free choice) and body scheme (self-referenced selection), more so than the 
other conditions in our paradigm. The contrast of the free finger condition with either 
free button selection or fixed finger selection, yielded reduced left insula activation 
in FMD patients, which meant that the difference between tasks was stronger in 
patients than in controls. This relation between free finger selection and the insula 
thus supports our hypothesis of altered sense of agency and body scheme in FMD. 
The significant correlation between severity of motor symptoms as measured on 
the CGI with the insula in one of these contrasts underscores this conclusion, while 
reduced connectivity of the left postcentral gyrus (somatosensory cortex) and left 
insula further underlines its relation with an altered perception of body scheme. 
The insula has indeed been associated with both sensory processing, including 
the integration of body scheme, and sense of agency [29] and is involved in many 
neuropsychiatric disorders [30]. It also serves as a network hub that coordinates 
information across multiple cognitive domains and processes that also include 
visceral perception and regulation of the autonomic nervous system [31]. Previous 
studies in FMD have often found altered activity of the insula, both in task-paradigms 
mostly studying pure motor tasks [32, 33], sense of agency [8] or the interaction 
between locomotion and emotion [34], and in resting state fMRI [12], including resting 
state fMRI in non-epileptic attacks [35]. Also, reduced left anterior insular volume 
was found using voxel-based morphometry in patients with FMD, when stratified 
for physical health impairment [36]. However, the exact location of differences in 
the insula varies between studies, as well as the direction of activation compared 
to healthy controls.
In line with its contribution to sensorimotor transformations, the parietal cortex plays 
a pivotal role in maintaining a body scheme representation and mediating willed 
action [7, 37]. Involvement of the parietal cortex, and subsequently the premotor 
cortex, was found in the contrast between fixed and free action selection. The 
finding of FMD-related decreases in activation of the left premotor and right parietal 
operculum in fixed compared to free selections, could be supportive of the hypothesis 
of reduced sense of agency. Indeed, these regions are involved in functions including 
visuospatial cognition, imagery of movement and motor preparation, amongst others 
[25]. The left premotor cortex is specifically associated with selecting movements 
and is stronger implicated in externally than internally cued action [22], while the 
opposite holds for the SMA [38]. In this way, the absence of altered activity in the 
SMA, which was found by Voon et al. [15], may fit the stronger alteration in the 
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premotor cortex, together with that in the parietal operculum, while it does still 
underline their conclusion of “potential impairment of prefrontal top-down regulation 
of motor control to guide action selection”. We did not find functional changes in 
limbic structures.
Some of our results might be interpreted in the light of altered attentional processes, 
processes that are strongly implicated in reduced sense of agency and altered 
perception of body scheme. Reduced activation along the posterior part of the 
intraparietal sulcus (precuneus) in patients when performing the fixed, compared 
to free conditions, might point at e.g. shifting spatial attention [39] and localizing 
processes within the internal representation of the body state/ body part [40]. This 
might be part of a causal mechanism underlying functional impairment in FMD, or 
could indicate difficulty in allocating attention adequately, inflicted by distraction due 
to the motor problem. Involvement of the anterior cingulate cortex might similarly be 
placed in this context. Interestingly it was found reduced in FMD in the fingers over 
buttons contrast, linking perception of body scheme to decision making.
Apart from the relation between sense of agency and parietal and frontal cortical 
regions as well as the insula, sense of agency may be seen as deliberate self-
attribution of an external event, which is associated with posterior midline 
structures, mainly the precuneus (i.e. the postero-medial superior cortex) and 
posterior cingulate cortex [6]. Consistent with such a concept, fixed selection tasks 
would induce enhanced attention to external cues, with consequent incorporation of 
such information to match the internal state of the recruited body scheme. This could 
explain that the observed differences between fixed and free selection seemed to be 
mainly the result of a relative reduction of activation in the fixed conditions in FMD 
compared to controls. Even though we had hypothesized to find group differences 
particularly due to changes in free selection, ie the opposite effect in the same 
comparison, this unpredicted finding fits with the notion of altered self-attribution 
associated with abnormal attention towards externally cued movement. In our 
parallel resting state fMRI study (in the same subjects) using independent component 
analysis, we found alterations in the low frequency spectra of a component existing 
of those midline structures associated with self-attribution, namely the (pre)cuneus 
and a segment of the posterior cingulate cortex (Marapin et al, submitted). The 
findings in the current study of reduced activity along the intraparietal sulcus, 
bordering the precuneus, and reduced activity in the right dorsal extrastriate visual 
cortex in patients neatly complement the resting-state observation. In other words, 
the functional overlap of these posterior (midline) regions in resting state and 
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task-evoked imaging highlights a dynamical aspect of a widely distributed network 
involved in sense of agency and self-attribution within FMD.
The reduced connectivity between the right parietal operculum and the bilateral 
perirhinal cortex/hippocampus in patients during all fixed conditions, compared to all 
free, would be consistent with the above proposed concept of self-attributed external 
events, if one assumes that the specific information in fixed selection introduces 
potential difficulty in linking such specified information to fitting finger responses.
LIMITATIONS
A number of limitations of the present study need to be considered. We had a 
relatively small sample size of 16 patients and 16 controls. We chose to display all 
findings with a threshold of p<0.001 uncorrected, which we considered justifiable 
with our sample size. Also, the reproduction of earlier findings in this new sample 
and the significant correlation with symptom severity are supportive that our findings 
are not false-positive.
FMD is a difficult group to study. There is large heterogeneity, in terms of other 
physical and psychiatric symptoms, intensity and frequency of the movement 
disorder and a presumed multifactorial etiology. Due to this heterogeneity, it is less 
likely to find differences between groups. We chose to improve homogeneity by only 
selecting patients with tremor and myoclonus. Within our sample, depression and 
anxiety scores were low (comparable to the general population), and therefore our 
findings could not be attributed to differences between groups on that count.
Within movement disorders, patients’ movement during scanning is a general 
concern. Although we observed patients were lying (perhaps surprisingly) still during 
the task, we also used frame-wise displacement values within our second level 
model to correct for movement.
Patients had lower mean reaction times in all conditions. Because we used a block 
design in which all brain activity within this set time-frame is used, this does not 
influence the fMRI contrasts. Because this was true for all conditions, it did not 
influence outcomes of contrasts between conditions.
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Generally, experimental setups only partly resemble reality. We aimed to capture 
‘free selection’ (or ‘free will’) by comparing free choice of a finger or button 
compared to a instructed finger of button, while timing was specified. However, that 
is a rather narrow definition of free will. As Haggard [2] pointed out, it is paradoxical 
to instruct someone to be voluntary. Also, people experienced difficulty with linking 
the indicated numbers to the different fingers, while this was less difficult in the 
button condition. Although this was partly overcome by introducing training sessions 
and did not likely influence differences between groups, it could interfere with the 
within group comparisons.
CONCLUSION
In this study we identified brain regions implicated in sense of agency and perception 
of body scheme, of which task-related activations was reduced in FMD. Our data 
reinforced the association of the insula with both reduced sense of agency and 
altered perception of body scheme in FMD. Furthermore, reduced activations of 
premotor and parietal cortices in fixed compared to free action selection further 
underline the role of a reduced sense of agency, most apparent in response to 
externally defined tasks. Finally, reduced activation of the primary motor cortex 
corroborates impaired explicit motor control in FMD.
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Objective: To explore changes in resting-state networks in patients with hyperkinetic 
functional movement disorders (hFMD).
Methods: Resting-state fMRI data from seventeen patients with hFMD and seventeen 
age-, sex-, and education matched healthy controls was investigated. Independent 
component analysis was used to examine the central executive network (CEN), 
salience network (SN), and default mode network (DMN). Frequency distribution of 
network signal fluctuations, intra- and internetwork functional connectivity were 
investigated. Symptom severity was measured using the Clinical Global Impression-
Severity scale.
Results: Compared with healthy controls, patients with hFMD had significantly 
decreased power of lower-range (0.01-0.10 Hz) frequency fluctuations in a precuneus 
and posterior cingulate cortex (PCC) component of the DMN (FDR-corrected P<0.05). 
No significant group differences were found for intra- and internetwork functional 
connectivity. In patients with hFMD, symptom severity was not significantly correlated 
with network measures.
Conclusions: The precuneus and PCC contribute to attention shifting, while the 
precuneus is further known to be involved in parietal circuitry underlying sense of 
agency. The hFMD-related functional alterations that we demonstrated in these 
regions therefore provide support for the concept that particularly attentional 
dysregulation is a fundamental disturbance in these patients.
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INTRODUCTION
Functional movement disorders (FMD) represent one of the more common disorders 
seen in neurological clinics (Stone et al., 2010). Despite its tangible impact, the 
pathophysiological basis of FMD remains poorly understood.
Recently, Edwards et al. (2012) proposed a Bayesian model which posits that 
functional symptoms are the result of pathological prior experiences that are 
modulated by alterations of sense of agency and attention dysregulation. These 
altered mechanisms are pertinent in patients with FMD as they experience a lack of 
control over their movements and often direct too much attention towards their body 
(Hallett, 2010; Pennebaker, 1982). Previous functional neuroimaging studies in FMD 
support these hypotheses as decreased activation and altered functional connectivity 
in areas of the right temporoparietal junction (TPJ) and increased activity in the 
ventromedial prefrontal cortex (vmPFC) were detected (Aybek et al., 2014; de Lange, 
Roelofs, & Toni, 2007; Maurer et al., 2016; Voon et al., 2010). The TPJ is associated 
with sense of agency (Decety & Lamm, 2007; Nahab et al., 2011; Ruby & Decety, 
2001), while the increased activity found in the vmPFC could reflect heightened self-
monitoring in patients with FMD as this region is part of the default mode network 
(DMN), which is responsible for self-referential processes (Raichle, 2015; Xu, Yuan, 
& Lei, 2016). Therefore, examining the functioning of brain networks associated with 
attention and sense of agency in FMD patients can provide valuable insight into the 
mechanisms underlying FMD.
Resting-state fMRI (rs-fMRI) provides the opportunity to study brain activations in 
patients while at rest (Biswal, Yetkin, Haughton, & Hyde, 1995). Several rs-fMRI 
studies have consistently reported the existence of resting-state networks, such as 
the DMN, a set of brain regions preferentially active when subjects are not engaged 
in goal-directed behaviors (Damoiseaux et al., 2006; Raichle et al., 2001; Yeo et al., 
2011). While most rs-fMRI studies focus on investigating functional connectivity, 
one can also explore the frequency distribution of blood-oxygen-level dependent 
(BOLD) signal fluctuations, i.e. assessing distinct frequency bands of such distributed 
signal fluctuations. A commonly used analysis method includes exploring the power 
of the lower-range frequency fluctuations (0.01-0.10 Hz), which has been shown to 
reflect synchronized spontaneous neural activity throughout the brain (Zuo et al., 
2010). Investigating this dimension of resting-state functioning is also important, as 
differences in functioning may not only pertain to patterns of connectivity but also 
to regional brain activity.
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The aim of this study was to explore changes in regional brain activity and functional 
connectivity within and between networks involved in attention regulation and 
sense of agency. Therefore, we aimed to study the central executive network(s) 
(CEN) – consisting of the frontoparietal network (FPN) and dorsal attention network 
(DAN) –salience network (SN), and DMN in a homogenous population of FMD 
patients, namely jerky-like (hyperkinetic) functional movement disorders. We used 
independent component analysis (ICA) to identify resting-state brain networks. 
This data-driven approach doesn’t require an a priori manual selection of regions 
of interest, but instead finds networks that consist of areas that are functionally 
independent. We investigated between-group differences in the degree of coherent 
activity in these networks by analyzing the frequency distribution of network signal 
fluctuations and in intra- and internetwork functional connectivity. We subsequently 
assessed whether within-group differences in the frequency distribution of network 
signal fluctuations and in functional connectivity correlate with symptom severity. To 
the best of our knowledge, while previous rs-fMRI studies have been done in patients 
with FMD, no rs-fMRI study has investigated regional brain activity in patients with 
FMD using the frequency distribution of network signal fluctuations.
METHODS
Participants
Seventeen patients with a clinical diagnosis of hFMD (myoclonus or tremor) were 
recruited from the movement disorder clinics of the University Medical Center 
Groningen and the Academic Medical Center, Amsterdam, the Netherlands (Dreissen 
et al., 2019) . The diagnosis of functional myoclonus or tremor was confirmed by 
two movement disorder experts (M.T. & J.H.T.M.K.) according to the current DSM-5 
criteria using positive findings in the history and neurological examination. Seventeen 
age-, sex-, and education-matched healthy controls (HC) were recruited via poster 
ads in the community and the internet.
Exclusion criteria were as follows: age < 18 years; comorbid neurological disorder;; 
contraindications for MRI-scanning; patients with disruptive jerky movements of 
the head; and patients using antipsychotic drugs. Of all FMD patients, only one 
patient was using benzodiazepines at the time and was asked to discontinue their 
medication one day prior to the scan. Patients were included in a broader study, in 
which they performed multiple fMRI task paradigms in addition to the rs-fMRI scan 
and received treatment with botulinum toxin. These results will be analyzed and 
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reported separately. Patients were scanned between January 2014 and November 
2016. All participants in the study provided written informed consent. The study 
was approved by the medical ethics committee of the Academic Medical Center, 
Amsterdam, the Netherlands.
Clinical evaluation
Patients with hFMD self-rated symptom severity using the clinical global impression 
severity (CGI-S) scale, a 7-point Likert-item ranging from 1 to 7 (1 = normal, I have 
no complaints, 7 = severe). Patients also completed the Beck Depression Inventory 
(BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) and Beck Anxiety Inventory 
(BAI; Beck, Epstein, Brown, & Steer, 1988).
MR Imaging acquisition
Functional and structural imaging data were acquired with a 3.0 Tesla MRI scanner 
(Philips Medical Systems, Best, the Netherlands) using a 32-channel SENSE head 
coil. Participants lay head-first supine in the scanner. An axial T1-weighted 3D turbo 
field echo (T1TFE) sequence image was acquired for anatomical reference: TR 9 ms; 
TE 3.5 ms; number of echoes 1; flip angle 8°; matrix size = 256 x 256; FOV: 232 x 170 
x 256 mm; voxel size 1 x 1 x 1 mm; acquisition time: 4 minutes 18 seconds.
With respect to functional imaging, two-hundred twenty-five T2-weighted fast field 
single echo with echo planar imaging (FEEPI) sequence volumes were acquired, each 
with 39 slices aligned in the anterior commissure-posterior commissure plane and 
recorded in descending order: repetition time (TR) 2,000 ms; echo time (TE) 30 ms; 
flip angle 70°; matrix size = 64 x 62; field of view 224 x 137 x 224 mm; voxel size 3.5 
mm x 3.5 mm x 3.5 mm; acquisition time: 7 minutes and 30 seconds. One run was 
collected per participant. All imaging data was acquired in one session. During the 
rs-fMRI scan, patients were instructed to remain as still as possible, to keep their 
eyes open and look in front of them, to remain awake and to think of nothing.
Data preprocessing
We performed rs-fMRI data preprocessing and data analysis following the analytical 
pipeline shown in Figure 1. Statistical Parametric Mapping (SPM12, version 7219) 
software was used for fMRI image preprocessing in MATLAB version R2013a. After 
discarding the first five timepoints of rs-fMRI data for magnetization stabilization, 
functional images were then realigned to the mean functional image. Six head motion 
parameters (3 translation and 3 rotation) were calculated during this step and later 
included in MANCOVA models to control for motion effects. Following co-registration 
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of the individual T1-weighted image to functional images, images were normalized 
to the EPI Montreal Neurological Institute template provided in SPM12 software 
(Calhoun et al., 2017). Finally, the resultant images underwent spatial smoothing 
with an 8 mm full width at half maximum Gaussian kernel. Images were inspected to 
ensure proper co-registration and normalization. These images were subsequently 
used as an input for group ICA.
Data analysis
Preprocessed rs-fMRI data were decomposed into spatially independent components 
using spatial ICA in the Group ICA of fMRI Toolbox (GIFT, version 3.0b; http://mialab.
mrn.org/software/gift/; (Calhoun, Adali, Pearlson, & Pekar, 2001). Spatial ICA entails 
a data-driven approach which identifies temporally coherent networks by estimating 
maximally independent spatial sources, referred to as spatial maps, from their 
linearly mixed fMRI signals, referred to as time courses, and decomposes these 
into separate components (Allen et al., 2011). Note that “networks” and “components” 
refer to the same concept in this report. The mean number of independent 
components was estimated as 24 using the Minimum Description Length criteria 
(Li et al., 2007). Two-step principal component analysis (PCA) was applied to the 
group data for dimensionality reduction: 1st step: 38 principal components; 2nd step: 
25 principal components. After PCA, group ICA was performed using the FastICA 
algorithm. The statistical reliability of independent components was assessed using 
the
ICASSO method that validates the independent components via clustering the results 
of multiple ICA runs (Himberg, Hyvarinen, & Esposito, 2004); using this method, the 
component estimation was repeated 20 times.
After group ICA, the Group information guided ICA (GIG-ICA) algorithm (Du et al., 
2016; Du & Fan, 2013) in GIFT was performed to generate produce subject-specific 
images, enabling a comparison of both the time course and the spatial maps to 
evaluate between-group differences. The GIG-ICA algorithm is a non-data-reduction 
approach that uses template components (in our case the aggregate component 
maps from group ICA analysis) as reference to estimate sources of interest for each 
subject. Subject-specific independent components are computed via a multi-objective 
function optimization based on the individual-subject data and each remaining non-
artifact group-level independent component using a deflation manner. Finally, values 
of each subject’s component image and time course were converted to z-scores. 
The GIG-ICA method has been shown to achieve better performance than back-
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reconstruction (GICA1 and GICA3) and dual regression in aspects of 1) independence 
of subject specific ICs, 2) accuracy of estimated ICs and time courses (TCs), and 
3) spatial correspondence of ICs across subjects (Du & Fan, 2013; Salman et al., 
2019). Furthermore, GIG-ICA can remove artifact-related group-level independent 
components before estimating individual components (Du et al., 2016), therefore only 
yielding subject-specific meaningful networks.
A validated visual inspection and template matching method was used by authors 
R.M., J.G., and J.M. to independently and manually select components/networks 
(Kelly et al., 2010). Components showing spatial overlap with known vascular, 
ventricular and motion artifacts were excluded. Components corresponding with 
the DMN, EN and the SN were identified and selected for further analyses.
Network measures
We investigated three ICA-derived outcome measures with respect to network 
functioning: (1) frequency distribution of network signal fluctuations, denoting the 
within-network degree of coherent activity; (2) intranetwork functional connectivity, 
related to the connectivity and degree of coactivation within a network; and (3) 
internetwork functional connectivity, denoting between-network connectivity. 
Subject-specific time courses were detrended and despiked using 3dDespike, then 
filtered using a fifth-order Butterworth low-pass filter with a high frequency cutoff of 
0.15 Hz. Furthermore, the six motion parameters calculated during the realignment 
step were regressed out of the time courses to reduce motion-induced spin history 
artifacts from the data.
Frequency distribution of network signal fluctuations was estimated on the detrended 
subject-specific time courses using the multi-taper approach implemented in 
Chronux. In this paper, fluctuations of frequencies <0.10 Hz and >0.10 Hz will be 
referred to as lower-range and upper-range frequency fluctuations, respectively. 
Intranetwork functional connectivity was evaluated using the networks’ spatial 
z-maps. Internetwork functional connectivity was estimated as the Pearson’s 
correlation coefficient between pairs of time courses (Jafri, Pearlson, Stevens, & 
Calhoun, 2008).
Group analyses
A between-group MANCOVA model was used to test for differences in the 
frequency distribution of network signal fluctuations and network functional 
connectivity between patients with hFMD and HC, with inclusion of mean framewise 
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displacement as a covariate. Framewise displacement is calculated as the sum of 
the absolute values of the derivatives of the six realignment parameters generated 
in the preprocessing step (Power, Barnes, Snyder, Schlagger, & Petersen, 2012). 
Although ICA in and of itself already separates several sources of artefacts, GIG-
ICA is especially robust against motion artefacts (Du & Fan, 2013; Murphy, Birn, 
& Bandettini, 2013). We also regressed out translational and rotational motion 
parameters and included framewise displacement as a covariate in our statistical 
models, to correct for any remaining head motion effects (Power et al., 2012). We 
applied normalizing log-transformations to the continuous variable framewise 
displacement to improve data symmetry and to reduce disproportionate influence 
of outliers on the data.
Within-group MANCOVA models were used to test for differences in the frequency 
distribution of BOLD signals and network functional connectivity between sum 
scores of CGI-S. Again, log transformed mean framewise displacement was included 
as a covariate to correct for head motion. The CGI-S scores were not transformed 
as log-transformation did not improve the data symmetry. Statistical threshold was 
set at P = 0.05 after correction for multiple comparisons using false discovery rate 
(FDR; Genovese, Lazar, & Nichols, 2002).
Schematic of the pipeline used in rs-fMRI data preprocessing and data analysis for the inves-
tigation of the frequency distribution of BOLD signal fluctuations and functional connectivity. 
BOLD = blood-oxygen-level dependent; EPI = echoplanar imaging; FMD = functional move-
ment disorders; FWHM = full width at half maximum; HC = healthy controls; MANCOVA = mul-
tivariate analysis of covariance; rs-fMRI = resting-state fMRI.
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RESULTS
Patient characteristics
Data from 17 patients with hFMD and 17 age-, sex- and education-matched HC 
were included in the analysis. Patient demographic and clinical characteristics 
are summarized in Table 1. There were no differences in age, sex and education 
level between the patient and control groups (P>0.05). The average score of the 
BDI in patients was 8.2 (SD 7.9), which corresponds to no depression (0-9 out of 63), 
while the average score for the BAI was 17.2 (SD 13.3), which corresponds to mild 
anxiety (10-18 out of 63). These psychometric scores are reported with the purpose 
to demonstrate that there was no clinically significant depression or anxiety in the 






Age, mean (SD), years 43.6 (14.4) 43.2 (14.5) 0.93
Sex, females/males 9/8 9/8 1.00
Education level, less than higher 
professional education
11 7 0.17
CGI-S Score (0-7), mean (SD) 4.8 (1.1) NA
Table 1 Patient characteristics Abbreviations: hFMD = hyperkinetic functional movement 
disorders; CGI-S = clinical global impression-severity scale; NA = not applicable; data are 
presented as the mean ± SD unless specified otherwise.
Resting-state networks
Group ICA was performed using rs-fMRI data from 34 participants and extracted 24 
components. Of these 24 components, eight were selected for further analysis. Spatial 
maps of the selected resting-state networks are shown in Figure 2. Four components 
corresponded with parts of the default mode network (DMN1: precuneus, posterior 
cingulate cortex (PCC); DMN2: medial prefrontal cortex (mPFC); DMN3: precuneus; 
DMN4: mPFC, PCC and inferior parietal cortex), three components corresponded 
with the executive network (left and right frontoparietal network; dorsal attention 
network); one component corresponded with the salience network.
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Figure 2. Resting-state networks of interest. Spatial maps of the 8 resting-state networks of 
interest, where components corresponding to the same network are grouped together. Spatial 
maps are plotted as t-statistics and are displayed at the three most informative slices in the 
sagittal, coronal and transverse plane. Left side of the figure corresponds with the left side 
of the brain and vice versa. DAN = dorsal attention network; DMN = default mode network; 
FPN = frontoparietal network; L = left; R = right.
Frequency distribution of network signal fluctuations analysis
Compared with HC, patients with hFMD exhibited significantly decreased power 
of lower-range frequency fluctuations in the precuneus and PCC network (DMN 
1; Figure 3; FDR-corrected P<0.05). The rest of the components did not show 
significant differences. The frequency distribution of network signal fluctuations 
in the precuneus and PCC component in patients with hFMD and HC were plotted 
for comparison purposes (Figure 4). Frequency distribution of network signal 
fluctuations was not significantly related to CGI-S scores in patients after FDR-
correction for multiple comparisons.
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A
B
Figure 3. Results of the frequency distribution of network signal fluctuations compari-
son in patients with hFMD and HC. Figures demonstrate the between-group differences in 
frequency distribution of network signal fluctuations in patients with hyperkinetic functional 
movement disorders (hFMD) compared with healthy controls (HC). (A) Patients with hFMD 
exhibit a significantly decreased power of lower-range frequency fluctuations (frequency bins 
0.068, 0.070, 0.072, 0.074 & 0.076 Hz) in the precuneus and posterior cingulate cortex network 
(PCC;FDR-corrected P<0.05). (B) Average effect size for each significant frequency. Effects 
are considered significant if PFDR <0.05.
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Figure 4. Frequency distribution of network signal fluctuations in the precuneus and PCC 
component in patients with hFMD and HC. Figure illustrates the differences in frequency 
distributions of network signal fluctuations in the precuneus and posterior cingulate cortex 
(PCC) component between patients with hyperkinetic functional movement disorders (hFMD) 
and healthy controls (HC). Arrows have been included to indicate which frequencies of fluctu-
ations are significantly different: frequency bins 0.068, 0.070, 0.072, 0.074 & 0.076 Hz.
Intranetwork functional connectivity analysis
There were no significant differences in intranetwork functional connectivity in 
resting-state networks between patients with hFMD and HC after FDR-correction 
for multiple comparisons. Intranetwork functional connectivity was not significantly 
related to CGI-S scores in patients after FDR-correction for multiple comparisons.
Internetwork functional connectivity analysis
No significant differences were found in internetwork functional connectivity in 
resting-state networks between patients with hFMD and HC after FDR-correction 
for multiple comparisons. Internetwork functional connectivity was not significantly 
related to CGI-S scores in patients after FDR-correction for multiple comparisons.
DISCUSSION
Currently, the pathophysiological underpinnings of functional movement disorders 
remain largely unknown. In this study, we aimed to gain further insight in neuronal 
mechanism underlying FMD by performing a data-driven resting-state fMRI analysis. 
We found altered regional brain activity in the precuneus and posterior cingulate 
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cortex (PCC) network in hFMD patients. The precuneus and PCC are known to be 
involved in attention shifting, while the precuneus is further known to participate in 
parietal circuitry underlying sense of agency (Cavanna & Trimble, 2006; Farrer & 
Frith, 2002; Nahab et al., 2011). Therefore, this finding is consistent with the current 
Bayesian model of FMD as proposed by Edwards et al. (2012). On the other hand, 
we did not detect any other differences in functional connectivity between groups. 
Furthermore, symptom severity was not significantly correlated with network 
measures in patients with hFMD.
Our findings demonstrate decreased power in lower-range frequency fluctuations 
in the precuneus and posterior cingulate cortex network in patients with hFMD. 
The precuneus and posterior cingulate cortex networks are considered to be core 
subcomponents of the default mode network and are associated with attention 
shifting (Le, Pardo, & Hu, 1998). Altered attentional processing is an important 
element in the presumed mechanism of hFMD. We know from observation and the 
experimental set-up of Pareés et al., 2011) that patients’ focused attention drives 
the abnormal motor behavior, and that diverted attention reduces symptoms. The 
finding of altered activity of the precuneus and posterior cingulate cortex in hFMD 
is consistent with findings previously described in the literature in patients with 
FMD. In 2016, Maurer et al. (2016) found altered functional connectivity between 
the right temporoparietal junction and the right precuneus in patients with FMD. 
Furthermore, in a task-based fMRI study by Espay et al. (2017) functional dystonia 
subjects showed areas of decreased activation in the bilateral precuneus. Finally, in 
a go/no-go task fMRI study with patients with conversion paralysis, the vmPFC (part 
of the DMN), the posterior cingulate cortex and the precuneus cortex have been found 
to be hyperactive (Cojan, Waber, Carruzzo, & Vuilleumier, 2009). These task-based 
analyses confirm the hypothesis that the precuneus is involved in altered attention 
shifting and motor initiation in FMD. While it should be noted that the functional 
role of lower-range frequency fluctuations may be novel and relatively unexplored, 
multiple studies have nevertheless corroborated their importance (Zuo et al., 2010), 
being vitally involved in the coordination and neuronal organization of brain activity 
between regions that frequently work in concert (Fox & Raichle, 2007).
We are confident about our findings for the following reasons. First, we implemented 
a data-driven approach in our study, which eliminates a priori bias in interpreting 
our findings. Additionally, our results remained significant after being corrected for 
multiple comparisons using the FDR. Furthermore, we addressed motion artefacts by 
implementing the ICA method (Murphy et al., 2013), via motion parameter regression, 
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and including framewise displacement as a covariate in all our regression models 
(Power et al, 2012). Importantly, we also implemented the GIG-ICA method, which 
has been shown to yield better performance than existing techniques with respect to 
independence, spatial correspondence, spatial and temporal accuracy, and motion 
artifact removal (Du et al., 2016; Du & Fan, 2013). However, while we conclude that 
our findings may well reflect attention dysregulation, the brain regions found are 
also associated with other functions, such as episodic memory retrieval (Cavanna 
& Trimble, 2006). As we did not perform task-based fMRI, we cannot conclude for 
certain that the alterations found in the precuneus and PCC are directly responsible 
for the attention dysregulation in FMD, although we consider that most likely given the 
existing knowledge on FMD in the literature. In this study we found four components 
which we considered to be part of the DMN, while other studies using the ICA method 
have reported a different composition of components. For that reason, we argue 
that attributing too much significance towards the function of networks as a whole, 
as opposed to individual brain regions, should be dissuaded when interpreting the 
results.
A significant part of the analyses in our study did not show differences between 
groups. In this respect it is important to note that our methodology differs significantly 
from, for example, the study by Maurer et al. (2016) as they used a seed-based 
approach, while we opted for a data-driven approach using ICA. Additionally, the 
studies in conversion paralysis and functional dystonia were both task-based fMRI 
(Cojan et al., 2009; Espay et al., 2017), while we conducted a resting-state based 
fMRI study. These differences in methodological approaches could explain the lack 
of changes found in our study with regards to internetwork functional connectivity. 
Another explanation for the lack of differences between groups in our task-free 
paradigm could be ascribed to the fact that alterations in brain activity in patients 
with hFMD might be subtle and specific. This could partly be due to the heterogeneity 
that is inherent to functional movement disorders in terms of etiological predisposing 
factors, onset, duration of symptoms and severity of symptoms. The disparity found 
between studies could be attributed to this same heterogeneity. On the other hand, it 
is interesting to consider that this is the first rs-fMRI study which analyzed regional 
brain activity in patients with hFMD, showing alterations in regional brain activity in 
the absence of impaired functional connectivity. Similarly, McHugo, Rogers, Talati, 
Woodward, and Heckers (2015) found altered regional brain activity in patients with 
schizophrenia, whilst the functional connectivity was found to be normal. This could 
reflect aberrant activity in isolated brain regions and not functional connectivity 
per se. One may also hypothesize that conventional rs-fMRI analyses focused on 
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static functional connectivity may fail to identify changes in such interconnections 
as these functional connections need not be stable over time. This is illustrated 
e.g. by dynamic rs-fMRI analysis which highlights the dynamic character of state 
fluctuations (Calhoun, Miller, Pearlson, & Adalı, 2014; van der Horn et al., 2019).
We recognize that our study has a few limitations. First, there was a small sample 
size (34 participants in total). However, many studies in patients with FMD consist of 
a sample size smaller than 30 patients. We anticipated the negative effects of a small 
sample size by limiting our analysis to components that were part of prespecified 
networks (DMN, EN and SN) to reduce the chance of getting false positive results. 
However, as a result of that decision we could miss some key findings in networks 
we did not investigate. Furthermore, our study only included functional myoclonus 
and tremor, in order to achieve a homogeneous cohort, however, this means that the 
results are not generalizable to the general spectrum of FMD and are therefore only 
applicable for this population. Additionally, the lack of a well-validated clinical rating 
scale for FMD means that we should be cautious when interpreting the association 
between symptom severity and changes found in this study. Finally, while measures 
such as duration of symptoms and age of onset were not included as this was beyond 
the scope of our study, these remain relevant factors to consider when investigating 
brain functioning in patients with FMD.
While FMD were previously thought to be psychogenic in nature, such a dualistic 
take on the disorder is now considered unconstructive. In the current study we 
demonstrated alterations in the precuneus and posterior cingulate cortex, key 
areas associated with attention shifting which drive abnormal motor behavior in 
patients with hFMD. Furthermore, the precuneus is also known to participate in 
parietal circuitry underlying sense of agency. These findings support the concept 
that particularly attentional dysregulation concerning intended movement and over-
attention to its actual execution is a fundamental disturbance in these patients. The 
lack of differences in internetwork connectivity between groups could be attributed 
to heterogeneity within hFMD. These findings might contribute to new perspectives 
and avenues for future studies and to the growing conceptualization of FMD.
6
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The prognosis of functional (psychogenic) neurological disorders is important 
in being able to help answer patient’s and carer’s questions, determine whether 
treatment is worthwhile, and to find out which factors predict outcome. We reviewed 
data on prognosis of functional neurological disorders from two systematic reviews 
on functional motor disorders and dissociative (non-epileptic) seizures as well as 
additional studies on functional visual and sensory symptoms.
Methodological problems, include heterogeneity in studied samples and outcome 
measures, diagnostic suspicion and referral bias, small size and retrospective design 
of available studies, possible treatments during follow-up and literature review bias.
With these caveats, the prognosis of functional neurological disorders does appear to 
be generally unfavourable. In a large part of the studies, functional motor symptoms 
and psychogenic non-epileptic attacks remain the same or are worse in the majority 
of patients at follow-up. Measures of quality of life and working status were often 
poor at follow-up. Frequency of misdiagnosis at follow up was as low as other 
neurological and psychiatric disorders.
 Long duration of symptoms was the most distinct negative predictor. Early diagnosis 
and young age seem to predict good outcome. Emotional disorders and personality 
disorders were inconsistent predictors. Litigation and state benefits were found to be 
negative predictors in some studies, but others found they did not influence outcome.
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INTRODUCTION
The prognosis of any disorder is important in being able to help answer patient’s 
and carer’s common questions about the future, determine whether treatment is 
worthwhile, and to find out which factors determine poor and good outcome.
Views about prognosis of functional neurological symptoms expressed in the 
literature are quite markedly variable. Historically the neurologists’ view has often 
swithered towards over optimism, mostly based on the conviction that symptoms that 
occur without any assignable pathology, should disappear as quickly as they arise. 
This view has sometimes been confused with an overall treatment approach of some 
neurologists involving a feeling that they must reassure the patient that they will get 
better, with the view that doing so will help that outcome to occur.
However, in clinical practice and especially in tertiary centres, neurologists 
encounter many patients that suffer from chronic, disabling symptoms, resistant 
to many forms of treatment. Over optimistic views of physicians who treat these 
patients can discourage both patient and physician in the long run, when symptoms 
do not resolve. On the other hand too little optimism in a disorder that may be 
dependent in part on abnormal focused attention and ‘habit’ may lead to an outcome 
that is worse than it otherwise might be.
In this chapter, we discuss the prognosis of functional neurological symptoms in 
adults and children starting with methodological issues, then discussing the data 
by symptom type, as well as prognostic factors, misdiagnosis and symptom cross-
over. We have drawn on data from two systematic reviews, one on motor disorders 
co-written by the authors of this chapter (Gelauff et al., 2014), and another on non-
epileptic seizures (Durrant, Rickards and Cavanna, 2011). We supplemented this with 
a further literature search to update these reviews and describe studies of other 
functional neurological symptoms, especially those older studies where symptoms 
were grouped together.
We present data of studies with at least eight patients in follow-up, that report on 








There are a number of difficulties in determining overall outcome of functional 
neurological symptoms, some of which are listed below:
1. Heterogeneity. Arguably the only thing that patient with functional neurological 
disorders really have in common with each other is their symptoms. Some 
patients have symptoms for a few hours, others for their whole life. Some have 
complex psychological and physical comorbidity, some present with a single 
transient symptom. Patients often want to know ‘How long will I have this 
for?’. The studies we have can only hint at the answer to that question. Clinical 
experience also teaches us that some patients who on paper may have several 
poor prognostic factors can do surprisingly well, sometimes in relation to non-
medical life events such as divorce or a change of job. Patients who theoretically 
are in the best prognostic group may do surprisingly badly.
2. Diagnostic Suspicion Bias. Patients with comorbidities, especially psychological 
ones, that may predict poor outcome are perhaps more likely to be given a 
diagnosis of a functional disorder in the first place, thus altering long term 
outcome.
3. Secondary and Tertiary Care Referral Bias. It would be hard to carry out a truly 
population based study of Functional Neurological Disorders since they usually 
require diagnosis in secondary care. Patients may be sampled in neurology 
services, specialist neurology clinics, videotelemetry lists, psychiatry services 
or tertiary centres draining the most complex patients from a wide area. Many 
studies described in this chapter were performed in tertiary centres, while a 
patients that present at an emergency department or at the GP with functional 
symptoms of short duration probably have a better outlook.
4. Study size and design. Many studies are relatively small and potentially prone 
to the play of chance. Retrospective studies dominate the literature. These 
are problematic as they are more likely to be non-consecutive and so less 
representative. Individual studies measure different prognostic factors. 
Statistical analysis for prognostic factors can sometimes seem more like ‘data 
mining’ and may depend on the biases of the authors of the study.
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5. Follow up rates. Follow up rates in studies range between 50% and 100% with 
most studies sitting at around 70%. There is an obvious bias here although 
whether this favours patients with a better outcome or those with a worse 
outcome is uncertain
6. Assessing natural history vs treatment studies. Most of the studies in this chapter 
describe ‘natural history’. However, many of these patients have had treatment 
which may have confounded the outcome.
7. Measuring Outcome. Prognostic and treatment studies and anecdotal experience 
suggest that patients’ wellbeing is not always correlated with improvement of 
symptoms. Either patients’ symptoms have resolved, but quality of life hasn’t 
improved, or vice versa. A study of 147 patients with non-epileptic seizures 
casts doubt on whether measuring seizure frequency for example, is the most 
meaningful outcome measure by showing that equal proportions of patients 
were receiving state related benefit in the 29% who had seizure remission 
at four years compared to those who still had seizures (Reuber et al., 2005). 
Outcome may objectively appear better but from the patients perspective be 
no different. In a study of multidisciplinary inpatient treatment, the objectively 
rated HoNos was the most sensitive to change over time whereas subjectively 
rated measures performed less well(Demartini et al., 2014), perhaps because 
patients have an inherent difficulty in rating themselves accurately (Ricciardi 
et al., 2015).
8. Literature review bias. Most of the data in this chapter comes from a systematic 
review. Nonetheless there are potentially issues with missing studies especially 
from non-english sources, and from studies using different terminology. It 
should be noted that studies that were used in this chapter are heterogeneous 
in their study approach and numbers of included patients are small, so strong 
conclusions cannot be drawn.
SYMPTOM OUTCOME
With all of the caveats and potential confounders listed above, the prognosis of 
functional neurological disorders does appear to be generally unfavourable. 
Tables 1-3 show data from prognostic studies grouped by symptom type. In a 
large number of studies symptoms remain the “same or worse” in the majority of 
7
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patients. Producing a meaningful ‘bottom line’ figure is not really possible due to the 
above mentioned heterogeneity, including in follow-up duration, follow-up rate and 
outcome measures. In addition most study designs are retrospective and numbers 
are generally small.
In recent years research has evolved to categorised studies according to symptom 
type (e.g. non-epileptic seizures, functional movement disorder) in contrast with 
earlier studies that looked at ‘conversion disorder’ or ‘hysteria’ as a whole. We 
therefore discuss prognosis by symptom type but also present data from older 
studies of all functional neurological disorders.
Motor symptoms
We have previously systematically reviewed the prognosis of functional motor 
symptoms, consisting of movement disorders, paresis and gait disorders(Gelauff 
et al., 2014). This review covered studies between 1940-2013. We found 24 studies in 
total (n=2069 patients, two of these studies with overlapping data excluded) where 
there was follow up data of at least 6 months and there were more than 8 patients 
reported (Table 1). The functional motor symptoms studied were tremor (n=5 
studies), dystonia (n=3 studies), weakness (n=5 studies), parkinsonism (n=1 study ) 
and mixed motor (n=11 studies).
The overall prognosis of motor symptoms appeared unfavourable from the studies in 
this review. The mean duration of follow-up was 7.4 years. An analysis of all studies 
weighted according to the size of the study found an overall figure of 40% of patients 
with the same or worse outcome at follow up, with only 20% of patients with complete 
remission. In four studies with 135 patients 66% to 100% of patients had the same 
or worse symptoms at follow-up. In 14 studies with 533 patients, 33% to 66% of 
patients had the same or worse symptoms at follow-up and in only five studies with 
464 patients, 33% or less of patients had symptoms same or worse at follow-up.
The review showed there is variability in outcome between different functional motor 
symptoms, but no clear relationship between outcome and symptom type was found. 
Studies in functional dystonia showed worst prognosis; 73% and 78% of patients had 
the same or worse symptoms. (Schrag et al., 2004; Ibrahim et al., 2009). Functional 
tremor also has a relatively poor prognosis, with 44-90% of patients the same or 
worse at follow-up (Ljungberg, 1957; Deuschl et al., 1998; Kim, Pakiam and Lang, 
1999; Jankovic, Vuong and Thomas, 2006; McKeon et al., 2009), The outcome of 
weakness/paralysis seemed to be more favourable. These differences might be 
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explained by selection bias: many studies of movement disorders (like tremor and 
dystonia) were performed in tertiary specialised clinics, while limb weakness is more 
often seen in general neurology clinics. However, Ljungberg, in a single author study 
which methodologically is still one of the best, even if its 1950s diagnostic certainty 
is potentially problematic, compared different symptoms within one large (n=381) 
prospective study. He also found that tremor had the poorest outcome, compared 
to gait disorder and weakness at 5 years follow-up (Ljungberg, 1957). On the other 
hand, two other studies (n=69 in follow-up) found no correlation between motor 
symptom type and outcome(Williams, Ford and Fahn, 1995; Feinstein et al., 2001) .
Two additional articles of functional axial myoclonus and paroxysmal movement 
disorder were published after the systematic review with 93 patients in follow-up 
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Table 1. Study characteristics of follow-up studies in functional motor symptoms. * and ** partly 
overlapping studies. N= number of patients at follow-up, F-u = follow-up. Follow-up duration in years (y), 
months (m) or days (d). Follow-up rate in percentages. Age: mean age, measured at onset of symptoms (o), 
baseline of the study (b) or unknown (-). Symptom duration in years, either measured at baseline of the study 
or reported as the time between onset en diagnosis ‘time to diagnosis’ (ttd). Percentage of females in the 
Article characteristics Symptom outcome Functioning












Worse Same Improved Complete 
remission
Disability Work
McKeon et al. 2009 Tremor 33 3.2y 53 50 o 0.1-15 b 70 64 36 40% severe, 24% moderate,
36% mild
-
Jankovic et al. 2006* Tremor 127 3.4y 60 44 b 4,6 b 73 43 57 0 - -
Kim et al. 1999 Tremor 10 1.5y 14 41 b 4,1 b 66 30 60 10 0 - -
Deuschl et al. 1998 Tremor 16 0.5-8y 64 42 b 2,5 ttd 80 25 38 0 37 If symptoms remained: 75% mod 
and 25% severely impaired
44% retired
Carter 1949 Tremor 8 4-6y 80 - - - 0 50 0 50 - -
Ibrahim et al. 2009** Fixed dystonia 35 7.6 y 73 43 b 11,8 b 83 31 46 23 0 -
Schrag et al. 2004** Fixed dystonia 69 3.3y 67 30 b 5 b 83 73 19 8 all on allowance
Lang 1995 Dystonia 8 ? 4 35,5 o 3,8 ttd 72 0 37 38 25
Erro et al. 2014 Axial myoclonus 76 2,2 y 10 40 b 5,9 b 51 17 45 16 22 - -
Lang et al. 1995 Parkinsonism 14 ? 100 43 o - 50 0 79 7 14 7% moderate, 57% heavy, 36% 
fully disabled
79% unable to work, 14% early 
retired, 7% unemployed
Ganos et al. 2013 Mixed Mov Dis 17 2,3 y 65 39 o - 73 18 82 - -
Munhoz et al. 2011 Mixed Mov Dis 58 0.5 y 70 39 o - 88 40 22 38 - -
Ertan et al. 2009 Mixed Mov Dis 26 15d-2y 53 7-70 o 4,4 b 70 - - 46 - - -
Thomas et al. 2006* Mixed Mov Dis 122 3.4y 24 43 b 4,7 b 73 22 21 57 0 33% employed, 30% on 
disability, 4% unemployed
Feinstein et al. 2001 Mixed Mov Dis 42 3.2y 48 45 b - 62 33 24 33 10 - 17% at work, 76% unemployed
Williams et al. 1995 Mixed Mov Dis 21 1.8y 88 36,5 o 4,9 ttd 79 14 57 29 27% disabled 27% at work
S A Factor et al. 1995 Mixed Mov Dis 20 0-6 y 71 51 - 2,8 ttd 60 50 0 50 - -
Stone et al. 2003 Weakness 42 12.5y 70 36 b - 81 69 31 38% limited in moderate activities 30% disability leave
Binzer & Kullgren 1998 Weakness 30 3.5y 86 39 o 0,2 b 60 10 27 63 - 57% at work
Knutsson & Martensson 
1985
Weakness 25 0.5-9y 100 19-47 - 1 day – 5 y 76 0 56 44 - -
Brown & Pisetsky 1954 Weakness 10 1-6y 91 26 b - 10 10 20 20 50
Carter 1949 Weakness 22 4-6y 96 - - - 4 14 4 78
Crimlisk et al. 1998 Mixed Motor 64 5-7y 88 37 b 1,5 ttd 48 38 14 20 28 - 33% at work, 47% health 
related retirement
Mace & Trimble 1996 Mixed Motor 31 9.8y ?  ? - 78 44 56
Couprie et al. 1995 Mixed Motor 56 4,5y 93 36 b - 64 43 16 41 34%from small restrictions in 
lifestyle to severely impaired 
independence, 7% total 
dependence
Gatfield & Guze 1962 Mixed Motor 24 2,5-10y 65 14-67 b 83 62 - 38
Ljungberg 1957 Mixed Motor 381 11.9y ? 28,5 o - 65 0 20 80 65% at work, 14% health 
related pension
Total nr of patients in f-u: 1387 Weighted mean complete remission rate: 20 %
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Article characteristics Symptom outcome Functioning












Worse Same Improved Complete 
remission
Disability Work
McKeon et al. 2009 Tremor 33 3.2y 53 50 o 0.1-15 b 70 64 36 40% severe, 24% moderate,
36% mild
-
Jankovic et al. 2006* Tremor 127 3.4y 60 44 b 4,6 b 73 43 57 0 - -
Kim et al. 1999 Tremor 10 1.5y 14 41 b 4,1 b 66 30 60 10 0 - -
Deuschl et al. 1998 Tremor 16 0.5-8y 64 42 b 2,5 ttd 80 25 38 0 37 If symptoms remained: 75% mod 
and 25% severely impaired
44% retired
Carter 1949 Tremor 8 4-6y 80 - - - 0 50 0 50 - -
Ibrahim et al. 2009** Fixed dystonia 35 7.6 y 73 43 b 11,8 b 83 31 46 23 0 -
Schrag et al. 2004** Fixed dystonia 69 3.3y 67 30 b 5 b 83 73 19 8 all on allowance
Lang 1995 Dystonia 8 ? 4 35,5 o 3,8 ttd 72 0 37 38 25
Erro et al. 2014 Axial myoclonus 76 2,2 y 10 40 b 5,9 b 51 17 45 16 22 - -
Lang et al. 1995 Parkinsonism 14 ? 100 43 o - 50 0 79 7 14 7% moderate, 57% heavy, 36% 
fully disabled
79% unable to work, 14% early 
retired, 7% unemployed
Ganos et al. 2013 Mixed Mov Dis 17 2,3 y 65 39 o - 73 18 82 - -
Munhoz et al. 2011 Mixed Mov Dis 58 0.5 y 70 39 o - 88 40 22 38 - -
Ertan et al. 2009 Mixed Mov Dis 26 15d-2y 53 7-70 o 4,4 b 70 - - 46 - - -
Thomas et al. 2006* Mixed Mov Dis 122 3.4y 24 43 b 4,7 b 73 22 21 57 0 33% employed, 30% on 
disability, 4% unemployed
Feinstein et al. 2001 Mixed Mov Dis 42 3.2y 48 45 b - 62 33 24 33 10 - 17% at work, 76% unemployed
Williams et al. 1995 Mixed Mov Dis 21 1.8y 88 36,5 o 4,9 ttd 79 14 57 29 27% disabled 27% at work
S A Factor et al. 1995 Mixed Mov Dis 20 0-6 y 71 51 - 2,8 ttd 60 50 0 50 - -
Stone et al. 2003 Weakness 42 12.5y 70 36 b - 81 69 31 38% limited in moderate activities 30% disability leave
Binzer & Kullgren 1998 Weakness 30 3.5y 86 39 o 0,2 b 60 10 27 63 - 57% at work
Knutsson & Martensson 
1985
Weakness 25 0.5-9y 100 19-47 - 1 day – 5 y 76 0 56 44 - -
Brown & Pisetsky 1954 Weakness 10 1-6y 91 26 b - 10 10 20 20 50
Carter 1949 Weakness 22 4-6y 96 - - - 4 14 4 78
Crimlisk et al. 1998 Mixed Motor 64 5-7y 88 37 b 1,5 ttd 48 38 14 20 28 - 33% at work, 47% health 
related retirement
Mace & Trimble 1996 Mixed Motor 31 9.8y ?  ? - 78 44 56
Couprie et al. 1995 Mixed Motor 56 4,5y 93 36 b - 64 43 16 41 34%from small restrictions in 
lifestyle to severely impaired 
independence, 7% total 
dependence
Gatfield & Guze 1962 Mixed Motor 24 2,5-10y 65 14-67 b 83 62 - 38
Ljungberg 1957 Mixed Motor 381 11.9y ? 28,5 o - 65 0 20 80 65% at work, 14% health 
related pension
Total nr of patients in f-u: 1387 Weighted mean complete remission rate: 20 %
study, mainly from the baseline population (not at follow-up). Symptom outcome in percentage of patients 
with improved, same, worse or remitted symptoms at follow-up. Only studies that reported specifically on 
complete remission were used to calculate the mean weighted complete remission rate. Table partly adopted 
from the JNNP article: Gelauff et al. 2014.
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Table 2. Study characteristics of follow-up studies in non-epileptic attacks. N= number of 
patients at follow-up, F-u = follow-up. Follow-up duration in years (y), months (m) or days (d). 
Follow-up rate in percentages. Age: mean age, measured at onset of symptoms (o), diagnosis 
(D), baseline of the study (b) or unknown (-). Symptom duration in years, either measured 
at baseline of the study (b) or reported as the time between onset and diagnosis ‘time to 
Non-epileptic attacks
Article characteristics Symptom outcome Disability/Functioning




















Disability (%) Work (%)
Sadan et al. 2015 51 4,6 y 70 27 o 7,8 ttd 71 39 - -
Duncan et al.2014 188 8,7 y 72 30,5 o 6,7 ttd 75,5 31,9% attendance with 
seizures
- - 22.8% of 114 patients in 
employment
Chen et al. 2012 47 6-9 m 71 - - - 62 38 - -
Duncan et al. 2011 47 6 m 87 30 o 1,7 ttd 82 36 13 51 - -
Jones et al. 2010 57 4,1 year 26 39 D 6,7 ttd 61 16 35 42 7
McKenzie et al. 2010 187 6- 12 m 72 38 B 7 ttd 76 62 38 Good 11,5%, 
intermediate 
47,5%, poor 36%
23,5% employed (10% at 
baseline)
An et al. 2010 52 15.7 81 21 o 0.5 ttd 50 - 46 54 - -
Arain et al. 2007 48 3 m 29 30 o 9 ttd 63 65 35 - 50% employed at f-u
Bodde et al. 2007 22 4-7y 96 30 D 7,2 ttd 86 - 36 32 32 - -
O’Sullivan et al. 2007 38 21 m 76 34 o 1,7-3,8 ttd 61 84 16 - -
Carton et al. 2003 78 0,5-7 y 93 23 o 10 ttd 77 11 13 48 28 - --
Reuber et al. 2003 164 4,1 y 50 27 o 7,7 ttd 79 71 29 56,4% dependent 40,5% employment or school, 
12,4% unemployed, 41.4% 
retired on health grounds, 
4,8% retired on age grounds
Selwa et al. 2000 57 19 - 4 y 67 40 - ? 74 4 56 40 - -
Silva et al. 2001 17 0,5 -3 y 100 25 o 9 ttd 70 77 23 - -
Ettinger et al. 1999 43 6-9 m 78 34 o - 91 9 16 56 19 - -




Kanner et al. 1999 45 14 m 100 30 b 1,7 b 69 - 71 29 - -
Riaz et al. 1998 15 14 m 60 16 o 17,2 ttd 80 13 7 53 27 - -
Ramani et al. 1996 21 4,7 y 62 - - 5 14 81 Improved in 24%
Lancman et al. 1993 63 60 m 86 32 o - 84 75 25 - -
Buchanan & Snars 1993 
acute/chronic group
50 2,5y / 
3,4 y
100 18 / 28 - 72 42 58 - -
Walczak et al. 1995 51 16 m 71 36 D - 84 0 0 65 35 Improved 20 %
Kristensen & Alving 1992 22 5,8 y 79 28 D 9 ttd 86 - (2 patients died) 45 - -
Meierkord et al. 1991 70 1-14 y 64 7 – 71 o 1-20 ttd 78 60 40 - -
Lempert & Schmidt 1990 40 24 m 80 38 B - 64 - 42,5 22,5 35 good 3 pts, fair 
15, poor 18, very 
poor 5
28% at work, 42 % out of 
work
Total nr of patients in f-u: 1058
Weighted mean complete remission rate: 33%
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Non-epileptic attacks
Article characteristics Symptom outcome Disability/Functioning




















Disability (%) Work (%)
Sadan et al. 2015 51 4,6 y 70 27 o 7,8 ttd 71 39 - -
Duncan et al.2014 188 8,7 y 72 30,5 o 6,7 ttd 75,5 31,9% attendance with 
seizures
- - 22.8% of 114 patients in 
employment
Chen et al. 2012 47 6-9 m 71 - - - 62 38 - -
Duncan et al. 2011 47 6 m 87 30 o 1,7 ttd 82 36 13 51 - -
Jones et al. 2010 57 4,1 year 26 39 D 6,7 ttd 61 16 35 42 7
McKenzie et al. 2010 187 6- 12 m 72 38 B 7 ttd 76 62 38 Good 11,5%, 
intermediate 
47,5%, poor 36%
23,5% employed (10% at 
baseline)
An et al. 2010 52 15.7 81 21 o 0.5 ttd 50 - 46 54 - -
Arain et al. 2007 48 3 m 29 30 o 9 ttd 63 65 35 - 50% employed at f-u
Bodde et al. 2007 22 4-7y 96 30 D 7,2 ttd 86 - 36 32 32 - -
O’Sullivan et al. 2007 38 21 m 76 34 o 1,7-3,8 ttd 61 84 16 - -
Carton et al. 2003 78 0,5-7 y 93 23 o 10 ttd 77 11 13 48 28 - --
Reuber et al. 2003 164 4,1 y 50 27 o 7,7 ttd 79 71 29 56,4% dependent 40,5% employment or school, 
12,4% unemployed, 41.4% 
retired on health grounds, 
4,8% retired on age grounds
Selwa et al. 2000 57 19 - 4 y 67 40 - ? 74 4 56 40 - -
Silva et al. 2001 17 0,5 -3 y 100 25 o 9 ttd 70 77 23 - -
Ettinger et al. 1999 43 6-9 m 78 34 o - 91 9 16 56 19 - -




Kanner et al. 1999 45 14 m 100 30 b 1,7 b 69 - 71 29 - -
Riaz et al. 1998 15 14 m 60 16 o 17,2 ttd 80 13 7 53 27 - -
Ramani et al. 1996 21 4,7 y 62 - - 5 14 81 Improved in 24%
Lancman et al. 1993 63 60 m 86 32 o - 84 75 25 - -
Buchanan & Snars 1993 
acute/chronic group
50 2,5y / 
3,4 y
100 18 / 28 - 72 42 58 - -
Walczak et al. 1995 51 16 m 71 36 D - 84 0 0 65 35 Improved 20 %
Kristensen & Alving 1992 22 5,8 y 79 28 D 9 ttd 86 - (2 patients died) 45 - -
Meierkord et al. 1991 70 1-14 y 64 7 – 71 o 1-20 ttd 78 60 40 - -
Lempert & Schmidt 1990 40 24 m 80 38 B - 64 - 42,5 22,5 35 good 3 pts, fair 
15, poor 18, very 
poor 5
28% at work, 42 % out of 
work
Total nr of patients in f-u: 1058
Weighted mean complete remission rate: 33%
diagnosis’ (ttd). Percentage of females in the study, mainly from the baseline population (not 
at follow-up). Symptom outcome in percentage of patients with improved, same, worse or 
remitted symptoms at follow-up. Only studies that reported specifically on complete remission 
were used to calculate the mean weighted complete remission rate.
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The prognosis of dissociative (non-epileptic) seizures (DS) has also been subject to a 
systematic review (Durrant, Rickards and Cavanna, 2011). This review, of 15 studies, 
suggested the overall prognosis was poor. In eleven studies, 40% or less patients 
achieve seizure remission in the follow-up period ((Meierkord et al., 1991; Ettinger et 
al., 1999; Kanner et al., 1999; Selwa et al., 2000; Silva et al., 2001; Carton, Thompson 
and Duncan, 2003; Reuber et al., 2003; Arain et al., 2007; Bodde et al., 2007; O’Sullivan 
et al., 2007; McKenzie et al., 2010).
Our own search of the literature found an additional 10 studies both before and 
after the publication of the Durrant et al review giving a total of 25 studies(Table 2). 
Looking at these 25 studies (Table 2), 20 found <50% of the patients had completely 
recovered at follow-up. The total weighted remission rate in non-epileptic seizure 
studies was 33%. This number is not corrected for follow-up duration or follow-up 
rate. In the largest study of 260 patients, 19% of patients actually had an increase 
in the frequency of seizures at a follow-up duration of 6 to 12 months (McKenzie et 
al., 2010).
However, more promising outcomes have also been reported and it is perhaps useful 
to look at these studies in more detail to understand why. One study found relatively 
good outcome in DS (Buchanan and Snars, 1993). They divided patients in two groups: 
acute (n=18) and chronic (n=32). In the acute group, a very high number of 83% of 
patients completely recovered after a mean of 2.3 years of follow-up. In the chronic 
group 38% of eight patients in total remained the same.
Some studies (Walczak et al. 1995; Ramani et al. 1996; An et al. 2010; Duncan et al. 
2011) found that greater than 50% of patients improved at follow up. Although some 
of these can be explained by short duration (Duncan et al. 2011) or young age (An et 
al. 2010) in other studies this outcome is harder to understand.
Sensory symptoms
Functional sensory symptoms like numbness or paraesthesia are mostly reported in 
combination with motor symptoms or non-epileptic attacks. Only two studies report 
specifically on the prognosis of sensory symptoms (Table 3).
Stone et al. carried out 12 year follow up on 42 from 70 baseline patients with 
weakness, sensory disturbance or both (Stone et al., 2003). At baseline 57% of 
patients experienced numbness, 48% of patients still reported this symptom 12.5 
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years later. A high proportion of patients crossed-over from weakness to numbness 
and vice versa in this study. However, the 45% of patients with solely sensory 
symptoms at outset had a better outcome on pain, physical and social functioning 
than patients who complained of weakness.
Another study followed up 26 from 34 patients with unexplained hemisensory 
disturbance with numbness, tingling, but excluding patients with chronic pain 
(Toth, 2003). One third of these patients had motor symptoms with heaviness or 
clumsiness, and other symptoms including intermittent blurring of vision (28%) 
ipsilateral disturbance of hearing (16%) were also recorded. At 16 months of follow-
up in 30 patients, 17% of patients had the same severity of symptoms and 83% 
of patients’ symptoms were completely resolved. A cautious conclusion from this 
limited amount of data could be that isolated sensory symptoms seem to have a 
relatively good prognosis, while outcome of sensory symptoms within a broader 
spectrum of functional neurological symptoms remains undetermined.
Visual symptoms
The prognosis of functional visual symptoms also appears somewhat better than for 
motor symptoms. Five studies, in 132 patients, have found a frequency of 46-78 % 
of patients with improved or remitted symptoms at follow-up (Table 3) (Friesen and 
Mann, 1966; Behrman and Levy, 1970; Kathol et al., 1983; Sletteberg, Bertelsen and 
Høvding, 1989; Barris, Kaufman and Barberio, 1992) (see table 1c). Follow-up rate 
in these studies was low, ranging from 20% to 71%.
Hearing loss
Functional hearing loss is rare and literature on the topic is scarce. There are no 
studies that met our quality demands with respect to number of patients and follow-
up duration. Oishi et al. (2009) and Ban et al.(2006) found in 13 patients in total that 
patients who were diagnosed early and were treated with steroid injections and 
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Mixed studies
The largest prospective follow-up study in mixed functional neurological symptoms 
is a cohort study of 716 patients followed up over a 1 year period from 1144 seen by 
41 neurologists across Scotland. (Scottish Neurological Symptoms Study - SNSS) 
(Sharpe et al., 2010). Patients were included if the neurologist rated their symptoms 
as ‘not at all explained’ or ‘somewhat explained’ by disease. The symptoms included 
‘conversion disorder’ symptoms (sensory and motor symptoms) but also fatigue and 
pain disorders, and patients who had a neurological disease but the neurologist 
viewed the symptoms as unexplained by that disease. Poor outcome, defined as 
unchanged, worse or much worse symptoms, was reported by 67% of the 716 
patients at one year follow-up. This study confirmed findings of an earlier study in a 
comparable population (Carson et al., 2003), that found 54% of 66 patients were the 
same or worse at follow-up. Some older studies are still relevant. Carter et al (REF!) 
found relatively favourable results. Apart from the results in paresis and tremor 
(Table 1) it was reported that 20 out of 24 patients with amnesia recovered completely 
within one week after hypnosis or suggestion and stayed well in the following 4-6 
years. Only one patient relapsed and developed tremor additionally, the others were 
untraced. From 29 patients with aphonia, 19 remained well at follow-up, while 7 
kept losing their voice in stressful circumstances. Three patients with blindness 
completely recovered after hypnosis.
QUALITY OF LIFE AND FUNCTIONING AT FOLLOW-UP
Persistence of functional symptoms at follow-up is not the only relevant measure for 
prognosis. Arguably, quality of life (Jones, Reuber and Norman, 2015) and functioning 
at follow-up provide a better indication of long term outcome of patients suffering 
from functional neurological symptoms. As Kathol et al.(Kathol et al., 1983) pointed 
out in their study with visual impairment, the difficulty in interpreting these data is 
knowing how much of the impairment relates to the specific neurological symptom 
compared to other comorbidities commonly found in these patients such as pain, 
fatigue and emotional disorders.
Studies have reported on several different outcome measures but again outcome 
is generally unfavourable with high percentages of disabled and impaired patients. 
A study in weakness found 38% of patients were limited in moderate activities at 
follow up (Stone et al., 2003), another study in tremor reported daily activities were 
moderately (75%) or markedly (25%) impaired in the patients with same or worse 
7
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symptoms (Deuschl et al., 1998). Couprie et al. (Couprie et al., 1995) found 41% of 
the patients were disabled (grade 2-5 Modified Rankin) at follow-up and 26% still 
regularly visited a specialist. McKeon et al. (McKeon et al., 2009)found 40% of patients 
were severely impaired in at least one activity.
In non-epileptic seizures comparable numbers were reported. Lempert & Schmidt 
(Lempert and Schmidt, 1990) found the impact of psychogenic non-epileptic seizures 
at 8-39 months of follow-up on daily life was minor in 32% of patients, moderate in 
37% and serious in 29% within a sample of 41 patients. One study investigated the 
outcome on a epilepsy scale and found global measures to be lower than quality of 
life in a typical epilepsy cohort (Jones et al., 2010). It was found patients had poor 
physical function, physical symptoms (like energy/fatigue and pain), poor emotional 
wellbeing and negative health perception. Another study found 36% of patients rated 
their general quality of life as being poor(McKenzie et al., 2010).
WORKING STATUS
The frequency of patients in work at follow-up also provides a marker of the overall 
outcome. Several studies report a high rate of patients not working, ranging from 
43% to 89% (Binzer and Kullgren, 1998; Crimlisk et al., 1998) and 20% to 47% of 
patients taking medical retirement who had motor symptoms (Ljungberg, 1957; 
Crimlisk et al., 1998; Stone et al., 2003). One study in fixed dystonia even found all 
patients were on disability allowance at follow-up (Schrag et al., 2004). Similar 
numbers are seen in non-epileptic seizures (Reuber et al., 2003). Two studies in 
seizures found numbers of patients in work had increased after the follow-up period, 
but at baseline this number was already very low in both cases (10 % increased to 
24% at follow-up in McKenzie et al. (McKenzie et al., 2011), rates increased from 
15% at baseline to 23% at follow-up in Duncan et al. (Duncan et al., 2014)). All of 
these studies suffer from a lack of a control group to gain an understanding both 
of rates of working in disease controls and also in the general population of similar 
age and gender.
CROSS-OVER
As patients with functional neurological symptoms often have more than one 
symptom and having a functional symptom is a risk factor for developing other 
541743-L-bw-Gelauff
Processed on: 21-10-2020 PDF page: 151
151
Review prognosis of FMD
functional symptoms, it would be conceivable symptoms might interchange during 
the follow-up period. Especially in a therapeutic setting this can be cause for 
concern: if patients recover from the initial symptoms only to develop new functional 
symptoms, their functional disorder as a whole has not improved. There is not much 
evidence that symptoms are replaced in such a manner. In motor symptoms for 
example, many studies looked at comorbid functional symptoms, but non compared 
follow-up with baseline symptom count (Gelauff et al., 2014).
One study has specifically looked into symptom cross-over in a cohort of 187 patients 
with psychogenic non-epileptic attacks at an average follow-up duration of 6 to 12 
months (McKenzie et al., 2011). A high number of ‘unexplained’ (functional) symptoms 
was reported at baseline. At follow-up it was found that the total number of patients 
with other ‘unexplained’ (functional) symptoms had increased with 6.4%, but this 
was not statistically significant. New symptoms were recorded in 23.5% of patients. 
No correlation was found between recovery from the non-epileptic attacks and an 
increase in other functional symptoms. Those who continued to have attacks were 
just as likely to have new MUS as patients who were attack free. Feinstein et al. found 
38% of patients developed other physical symptoms at follow-up, in addition to their 
original abnormal movements (Feinstein et al., 2001). This was not correlated with 
good outcome of the initial movement disorder. Stone et al. (Stone et al., 2003) found 
58% of those who only had sensory symptoms initially went on to develop weakness. 
These findings generally oppose the idea that cross-over occurs when symptoms 
resolve, many studies do show a high rate of functional symptoms at follow-up and 
symptom replacement is undoubtedly a relatively common clinical experience.
PROGNOSTIC FACTORS
In clinical practice, prognostic factors can be useful to guide treatment in individuals. 
Studies report on several different factors that are correlated with good or bad 
outcome in prognostic studies. Table 4 summarises studies looking at prognostic 
factors (see end of this chapter).
Gender
Gender does not influence outcome of functional neurological disorders. In motor 
symptoms no correlation was found between gender and symptom outcome (Gelauff 
et al., 2014). In the SNSS cohort no effect of gender was found either (Sharpe et al., 
2010). The only two studies in non-epileptic attacks that found a predictive effect of 
7
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age were contradicting: one study found a positive predictive effect of male gender 
(McKenzie et al., 2010), while another found a positive predictive effect of female 
gender (Meierkord et al., 1991).
Age at onset
As will be discussed in more detail below, prognosis in children with functional 
symptoms seems to be better than prognosis in adults. Therefore Durrant et al.(2011) 
concluded that age has a strong effect on outcome. However, studies that only include 
adults with non-epileptic attacks, general unexplained neurological symptoms and 
motor symptoms show heterogeneous results.
In the SNSS cohort of unexplained symptoms (n=716) older age predicted poor 
outcome (Sharpe et al., 2010). Two studies in non-epileptic attacks (n=268) found 
older age predicted poor outcome (Reuber et al., 2003; An et al., 2010), as did four 
studies in motor symptoms (n=211) (Mace and Trimble, 1996; Deuschl et al., 1998; 
Stone et al., 2003; Thomas, Dat Vuong and Jankovic, 2006). Two studies in sensory 
symptoms found a correlation between age and outcome, but they included both 
adults and children (Sletteberg, Bertelsen and Høvding, 1989; Barris, Kaufman and 
Barberio, 1992). Eight studies in motor symptoms (n= 670) (Ljungberg, 1957; Couprie 
et al., 1995; Williams, Ford and Fahn, 1995; Binzer and Kullgren, 1998; Crimlisk et 
al., 1998; Feinstein et al., 2001; Ibrahim et al., 2009; Erro et al., 2014) and five studies 
in non-epileptic attacks (n=410) (Lempert and Schmidt, 1990; Lancman et al., 1993; 
Carton, Thompson and Duncan, 2003; Arain et al., 2007; Duncan et al., 2014) found 
no correlation between age and outcome. All in all the effect of age on outcome is 
not evident from these studies.
Health related benefits
The influence of receiving health related benefits on outcome of functional 
neurological disorders is subject of speculation. It has been suggested that personal 
gain from having a functional neurological disorder, like receiving health related 
benefits, would prevent recovery. It is a somewhat controversial point of view, 
as it implies personal gain could be an incentive to remain ill which in turn tends 
to suggest symptoms are under voluntary control. Alternative explanations of a 
correlation between litigation and/or receiving health related benefits and poor 
outcome are conceivable. It could be that disease severity leads to unemployment 
and is therefore indirectly responsible for the poor outcome. Or worry about their 
financial situation could prevent patients from improving.
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Not many prognostic studies have looked at health related benefits as a prognostic 
factor. Within the SNSS cohort is was found receiving health-related benefits at initial 
consultation had a negative effect on outcome (Sharpe et al., 2010). McKenzie at al. 
(McKenzie et al., 2010) (non-epileptic attacks) found that not receiving social payment 
predicted good outcome. In motor symptoms one study confirms this (Crimlisk et al., 
1998), while three other (partly overlapping) studies found no correlation between 
litigation and outcome (Feinstein et al., 2001; Jankovic, Vuong and Thomas, 2006; 
Thomas, Dat Vuong and Jankovic, 2006).
Employment and educational status
Other socio-economic factors that have been studied are employment, which was 
found to be correlated with good outcome in two studies in non-epileptic attacks 
n=125 (Carton, Thompson and Duncan, 2003; Duncan, Razvi and Mulhern, 2011) or 
higher educational status/IQ, which has been found to have a positive predictive 
effect in non-epileptic attacks (Reuber et al., 2003; Arain et al., 2007; McKenzie 
et al., 2010). However, a higher number of studies with more patients in total in 
non-epileptic attacks, motor symptoms and mixed symptoms found no correlation 
between employment or educational status and outcome (see table 3).
Co-morbidity
Comorbidity, both psychiatric and neurological, is high in functional neurological 
disorders, but the influence of comorbidity on outcome of the presenting symptoms 
remains unclear.
In one study in functional tremor it was found that any kind of comorbidity, either 
psychiatric, somatic or functional, was associated with poor outcome (Jankovic, 
Vuong and Thomas, 2006). In combination with another five studies it was found in 
a total of 633 patients with motor symptoms that psychiatric comorbidity (anxiety, 
depression or personality disorders) predicted worse outcome (Ljungberg, 1957; 
Mace and Trimble, 1996; Binzer and Kullgren, 1998; Feinstein et al., 2001; Ibrahim 
et al., 2009).
Two studies in non-epileptic attacks (Kanner et al., 1999; McKenzie et al., 2010) and 
two studies in visual symptoms (Sletteberg, Bertelsen and Høvding, 1989; Barris, 
Kaufman and Barberio, 1992) found the same relationship between depression and 
outcome. One study showed that inhibitedness as a personality trait predicted poor 
outcome (Reuber et al., 2003). Interestingly three studies, two partially overlapping 
studies in motor symptoms (Jankovic, Vuong and Thomas, 2006; Thomas, Dat Vuong 
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and Jankovic, 2006) and one study in non-epileptic attacks (Kanner et al., 1999) found 
depression or anxiety at baseline was correlated with better outcome. This is most 
probably due to synergistic effect of improvement of the functional disorder and the 
psychiatric disorder.
Only a few studies investigated the effect of comorbid functional symptoms or 
‘unexplained symptoms’ on outcome, one study found a low somatisation score 
predicted good outcome (Reuber et al., 2003). Another study found unexplained 
symptoms other than NES predicted poor outcome (McKenzie et al., 2010), but a 
study in motor symptoms and one in NES found it had no influence on outcome 
(Crimlisk et al., 1998; Duncan et al., 2014).
The influence of organic comorbidity on outcome is also indistinct. For example 
epilepsy alongside non-epileptic attacks was found to predict poor outcome in three 
studies (Meierkord et al., 1991; Reuber et al., 2003; Duncan et al., 2014), although 
Duncan et al. (2014) reported attendance with seizures as outcome variable, which 
could refer to epileptic seizures too. In another study this effect was not found 
(Lancman et al., 1993). In motor studies conflicting results were reported (Binzer 
and Kullgren, 1998; Thomas, Dat Vuong and Jankovic, 2006).
Duration of symptoms
Longer duration of symptoms was found to be correlated with negative outcome in 
many studies. In non-epileptic attacks this association was found in three studies 
(Lempert and Schmidt, 1990; Selwa et al., 2000; Reuber et al., 2003) and in motor 
symptoms in five studies (Knutsson and Martensson, 1985; Mace and Trimble, 
1996; Feinstein et al., 2001; Jankovic, Vuong and Thomas, 2006; Thomas, Dat Vuong 
and Jankovic, 2006). Two other studies in motor symptoms did not find an effect 
of duration of symptoms on outcome (Williams, Ford and Fahn, 1995; Ibrahim 
et al., 2009). All in all longer duration of symptoms seems to be one of the most 
consistent negative predictors of outcome in functional neurological disorders. Many 
explanations for this effect have been proposed, but irrespective of the mechanism 
it is important to prevent symptoms from becoming chronic.
Early diagnosis and confidence in the diagnosis
In motor symptoms the only predictor that is tested in more than two studies and 
also correlates consistently with poor outcome is a long duration between start of 
symptoms and patients receiving a diagnosis (n=307) (Couprie et al., 1995; S. a Factor, 
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Podskalny and Molho, 1995; Crimlisk et al., 1998; McKeon et al., 2009; Munhoz et al., 
2011; Erro et al., 2014).
In non-epileptic attacks only one study found an early diagnosis to be predictive of 
good outcome (Duncan, Razvi and Mulhern, 2011), while two others did not find any 
correlation (Meierkord et al., 1991; Lancman et al., 1993).
Also, two partially overlapping studies in motor symptoms (Jankovic, Vuong and 
Thomas, 2006; Thomas, Dat Vuong and Jankovic, 2006) and 2 studies in non-epileptic 
attacks (Silva et al., 2001; Carton, Thompson and Duncan, 2003) found confidence in 
the diagnosis to positively influence prognosis. SNSS found that beliefs about illness 
were of key importance in predicting outcome (Sharpe et al., 2010). Expectation of 
non-recovery and non-attribution of symptoms to psychological factors predicted 
poor outcome.
Crimlisk et al.(2000) showed in 64 patients with unexplained neurological symptoms 
that the referral pattern is often extensive. After consultation at the National Hospital 
for Neurology and Neurosurgery in London, 48% were seen by a neurologist, and 
27% by another specialist. A total of 42 (66%) had been admitted to hospital (number 
of admissions ranged from 0 to11). Furthermore 34% of patients had been referred 
to rheumatologists, general physicians and specialists in infectious diseases, 
orthopaedics and immunology for their functional symptoms. This referral behaviour 
can result in iatrogenic damage and undermines understanding and belief of the 
diagnosis of a functional neurological disorder. Patients who were not referred, had 
a better change of improvement in this study.
These findings are clinically highly relevant, because they support the idea that 
an early, tangible, positive diagnosis is essential in the approach of patients with 
functional neurological disorders. This has been argued in literature (Carton, 
Thompson and Duncan, 2003; Stone and Carson, 2011).
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Both patients and physicians can remain unconvinced of the diagnostic certainty of 
functional neurological disorders. They think symptoms that are diagnosed as being 
a functional neurological disorder often prove to be part of neurological disease 
eventually. In medical literature this concern has been strongly influenced by one 
paper on prognosis in which a misdiagnosis rate of more than 50% at 10 years follow-
up was found in patients with hysteria (Slater and Glithero, 1965). Based on these 
findings the author concluded that the concept of hysteria as a syndrome ‘was based 
entirely on tradition and lacked evidential support’ (Slater, 1965).
However, Stone et al. (Stone, 2005) have shown in their systematic review on 
misdiagnosis that included 27 studies and 1466 patients with motor and seizure 
conversion disorder that since the 1970s the rate of misdiagnosis of functional 
symptoms has only been 4%(Adler et al., 2014). This is similar to the rate of 
misdiagnosis for other neurological and psychiatric disorders (Figure 1) There was 
no difference between motor symptoms (4% ) and seizures (2.6%) overall. There was 
some suggestion that movement disorders and gait disorders specifically were more 
prone to error. the higher rate of misdiagnosis seen in earlier studies such as Slater 
appears to relate more to poorly defined cohorts and outcomes than clearly worse 
diagnosis. The data is compatible with a view that functional neurological disorders 
are a clinical bedside diagnosis that has been reliably made since before CT scans 
and videotelemetry.
Figure 1. Misdiagnosis of functional neurological disorders (mean %, 95% confidence inter-
vals, random effects) plotted at midpoint of five year intervals according to when patients 
were diagnosed. Size of each point is proportional to number of subjects at each time point 
(total n=1466, 27 studies). Reproduced with permission from BMJ publications (Stone, 2005)
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Within a prospective large sample of patients (N=1030 followed up from 1144) with 
unexplained neurological symptoms from the Scottish Neurological Symptom Study, 
it was found that after 1 year and 7 months of follow-up only four patients acquired 
a diagnosis of new organic disease that was unexpected at initial assessment and 
provided a better explanation for the symptoms(Stone et al., 2009). In movement 
disorders a comparable low rate of zero to three percent was found in 195 patients 
(Jankovic, Vuong and Thomas, 2006; Ibrahim et al., 2009; McKeon et al., 2009).
One of the reasons for discrepancy between these recent findings and early findings 
is the interpretation of the definition of misdiagnosis. A change of diagnosis at follow-
up does not necessarily explain the original symptoms better, it could simply mean 
narrowing of the differential diagnosis, a difference in opinion between the initial 
neurologist and the subsequent physician or a co-morbid neurological diagnosis that 
does not account for earlier symptoms, but might explain symptoms at follow-up. 
Earlier studies did not take these subtleties into account(Stone et al., 2009).
Misdiagnosis is a pitfall in many neurological disorders but undoubtedly physicians 
have traditionally been more worried to miss an organic diagnosis than a functional 
disorder, although the consequences for the patient are considerable in both 
situations.
Paediatric studies
On average, children with a functional neurological disorder seem to have a better 
prognosis than adults with the same symptoms.
Although numbers of patients are low, paediatric studies in non-epileptic attacks 
show relatively high percentages of completely remitted symptoms. Reilly et al.(Reilly 
et al., 2013) reviewed the available literature on NES in children and found remission 
rate ranges from 43 to 81 percent in studies with 15 to 50 patients in follow-up. 
The proportion of patients with improved or remitted symptoms, 71 to 100%, is 
impressive compared to the numbers in adults (Durrant, Rickards and Cavanna, 
2011; Reilly et al., 2013). It is hypothesized perhaps the shorter duration of symptoms 
at presentation or possibly more effective local treatment interventions could explain 
this difference, but no evidence is available.
In a one year follow-up study with motor symptoms, sensory symptoms and/or non-
epileptic attacks 75 to 100% of 147 children (median age 12,5 years) had improved 
symptoms (Ani et al., 2013). In this study motor symptoms and non- epileptic attacks 
7
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had a more favourable outcome (90-100% improved) than sensory symptoms like 
visual loss, hearing loss, speech problems and paraesthesia. Many of these children 
received some kind of psychotherapy. Despite the favourable outcome for the 
neurological symptom, a quarter of the children developed a new psychiatric disorder 
during follow-up, especially anxiety and depressive disorders. Another paediatric 
study of mixed functional neurological symptoms reported outcome of 30 children that 
were seen at the emergency department with relatively short duration of symptoms. 
Symptoms were resolved at follow-up of 3-6 months in 83% of cases (De Gusmão 
et al., 2014). Despite this, patients on average missed 22.3 days of school, parents 
missed 8 days of work and patients visited the emergency department twice during 
the follow-up period. In a study of 15 children with functional movement disorder 
followed up of 3.1 years, 12 had substantially improved or remitted symptoms. The 
three children that did not recover, remained highly disabled (Schwingenschuh et 
al., 2008). Another study summarized findings of outcome in visual symptoms in 
childhood. In their own series of 58 patients and in the existing literature, outcome 
was good, with almost all patients completely recovered (Toldo et al., 2010).
Prognostic factors in paediatric studies that correlated with bad outcome are 
longer duration of symptoms before diagnosis (Pehlivantürk and Unal, 2002; 
Schwingenschuh et al., 2008), and premorbid conduct problems (such as behaviour 
that expressed disrespectfulness, difficulty to get along, arrogance or aggression) 
(Pehlivantürk and Unal, 2002). Comorbid neurological disease (such as epilepsy) 
was found to be correlated with poor outcome in some but not all studies (Durrant, 
Rickards and Cavanna, 2011).
CONCLUSION
There are many methodological problems in studying the prognosis of functional 
neurological disorders but in general they appear to have a poor prognosis with low 
remission rates at follow-up. Patients with pure sensory symptoms and paediatric 
populations appear to have a better outcome, although numbers are low. In non-
epileptic attacks and motor symptoms differences between symptoms remain 
unclear.
High frequency of psychological and physical comorbidity is typically reported at 
baseline and follow-up. From the small number of studies that looked into cross-
over at follow-up there was no obvious indication that symptoms get replaced by 
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other symptoms after they have resolved but this is an unresolved epidemiological 
question. Perhaps unsurprisingly quality of life, general functioning and working 
status at follow-up is often found to be low in many cases.
The most consisent negative prognostic factor is long duration of symptoms. 
Psychiatric comorbidity was not looked at in many different studies, but was found 
to be an inconsistent predictor of poor outcome. The effect of other comorbidities on 
outcome remains uncertain. The effect of age is highly dependent on the population. 
Paediatric studies have shown better outcome than adult studies, so age is clearly 
predictive of outcome. But within the adult population varying results were found. 
Socio-economic factors including health related benefits were too variable to draw a 
conclusion but may be relevant. Gender does not influence outcome. A larger studies 
with multivariate regression suggest the relevance of illness beliefs in particular.
7
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Reliable data on the prognosis of functional motor disorder are scarce, as existing 
studies of the prognosis of functional motor disorder are nearly all retrospective, 
small and uncontrolled. In this study we used a prospectively recruited, controlled 
cohort design to assess misdiagnosis, mortality and symptomatic and health 
outcome in patients with functional limb weakness compared to neurological disease 
and healthy controls. We also performed an exploratory analysis for baseline factors 
predicting outcome.
107 patients with functional limb weakness, 46 neurological and 38 healthy controls 
from our previously studied prospective cohort were traced for follow-up after an 
average of 14 years. Misdiagnosis was determined in a consensus meeting using 
information from records, patients and their GPs. Numbers and causes of death were 
collected via death certificates. Outcome of limb weakness, physical and psychiatric 
symptoms, disability/quality of life and illness perception were recorded with self-
rated questionnaires. Outcome measures were compared within and between 
groups.
Seventy-six patients (71%) with functional limb weakness, 31 (67%) neurological and 
23 (61%) healthy controls were included in follow-up. Misdiagnosis was found in one 
patient in the functional limb weakness group (1%) and in one neurological control 
(2%). Eleven patients with functional limb weakness, 8 neurological controls and 1 
healthy control had died. Weakness had completely remitted in 20% of patients in the 
functional limb weakness group and in 18% of the neurological controls (p=0.785) 
and improved in a larger proportion of functional limb weakness patients (p=0.011). 
Patient outcome was comparable between patient groups, but worse than outcomes 
in healthy controls. No baseline factors were independent predictors of outcome, 
although somatisation disorder, general health, pain and total symptoms at baseline 
were univariably correlated to outcome.
This study is the largest and longest follow-up study of functional limb weakness. 
Misdiagnosis in functional limb weakness is rare after long-term follow-up. The 
disorder is associated with a higher mortality rate than expected, and symptoms 
are persistent and disabling. It appears difficult to predict outcome based on 
common baseline variables. These data should help inform clinicians to provide a 
more realistic outlook of the outcome and emphasises the importance of active and 
targeted therapy.
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INTRODUCTION
The prognosis of functional motor symptoms is unclear. Whilst there is growing 
recognition that the diagnosis is normally stable, there is a notable absence of data 
to guide clinicians in answering the key question patients ask- “will it get better?”
There is now scientific consensus, supported by systematic review, that poorly 
conducted but widely cited early reports of high rates of misdiagnosis were 
erroneous. Rates of diagnostic revision have been around 4% since 1970 [1]. But 
despite this, fears of misdiagnosis are still widely expressed, and some senior 
clinicians still extol the view that the diagnosis of functional symptoms should not 
be made for fear of clinical error. Our own large epidemiological study of patients 
presenting to neurologists with symptoms lacking a pathophysiological explanation, a 
wider phenotype than functional motor symptoms [2], found a much lower frequency 
of that diagnostic revision and highlighted that actual diagnostic error was rare (4 
out of 1040) [3]. However, follow-up was only 18 months and it could be argued that 
many alternate diagnoses may only become apparent after the passage of time.
The Scottish Neurological Symptoms Study also had an intriguing secondary finding 
that a subgroup of patients with dissociative seizures had an unexpectedly high 
mortality rate of 5% (4 out of 80). This was partially replicated by Duncan et al [4] 
who found the premature (<75 years of age) death rate in dissociative seizures was 
somewhat higher compared to the local national death rate (0.58% compared to 
0.41% per year). In functional motor symptoms the limited available data does not 
provide a meaningful answer [5–8].
Significantly, more attention has been paid to diagnostic accuracy than patients’ 
actual outcomes. We conducted a systematic review of the prognosis of functional 
motor symptoms consisting of 24 studies with a duration of follow-up between 1.5 
and 12.5 years, with only two longer than 10 years. We found that 39% were the same 
or worse at follow-up. However, most studies were small, retrospective, performed 
in tertiary centres, and without a control group. Studies were too heterogeneous for 
clear predictors to emerge but a long duration between the diagnosis and symptom 
onset were consistently associated with bad outcome [9].
In this study we describe the long term follow-up of a prospectively ascertained 
case-control cohort study of 107 patients with functional limb weakness [10,11]. 
We aimed: (1) to determine the rate and type of misdiagnosis in the functional limb 
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weakness group and the neurological control group; (2) to describe the frequency 
and cause of death in patients with functional limb weakness and compare it to 
neurological disease and healthy control groups from the same baseline study; (3) 
to determine the outcome of limb weakness in terms of change in the presenting 
symptom, physical and psychiatric symptoms, disability / quality of life and illness 
perceptions in patients with functional limb weakness compared to neurological 
controls (4) to conduct an exploratory analysis of baseline factors that predict poor 
outcome at follow-up in the functional limb weakness group.
METHODS
This study received ethical approval from the South Central – Oxford C research 
ethics committee, a body representing the UK Health Departments’ Research 
Ethics Service (Rec reference: 14/SC/0209). Consent was obtained according to the 
declaration of Helsinki.
Baseline
Between 2000 and 2003, 107 patients with functional limb weakness, 46 patients 
with neurological disorders causing limb weakness (the neurological controls) and 
38 healthy subjects (the healthy controls), were included. Patients with functional 
and neurological limb weakness were recruited consecutively by referral from 
all consultant neurologists working in South East Scotland (population about one 
million). Inclusion criteria for patients were: weakness/paralysis of one or more 
limb(s) diagnosed by a consultant neurologist as completely unexplained by organic 
disease for the functional weakness group, and completely explained by neurological 
disease in the neurological control group. Symptom onset had to be within the 
previous 2 years. Patients had to be over 16, able to consent and should not have an 
intellectual disability. Healthy control subjects, without neurological disease or limb 
weakness, were asked to take part when they visited their GP for a cervical smear, 
an oral anti-conceptive health check or a minor upper respiratory tract infection. 
Four studies have been published on the baseline data [10–13].
Follow-up
We located participants from the original study using the electronic record system of 
NHS Lothian (TRAK) and by contacting GPs (in some cases via Practitioners Services 
Scotland). Subjects who agreed to participate provided written informed consent and 
were then asked to fill out a questionnaire, either online or on paper.
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Misdiagnosis
The possibility of misdiagnosis was assessed from three overlapping sources: 
Patients were asked if ‘a new diagnosis which explains the weakness at the time of 
the baseline study’ had occurred during follow-up. The patients’ GPs were asked 
the same question by means of a short postal questionnaire. Third, the electronic 
records system of NHS Lothian was searched to find any indication of misdiagnosis 
during the follow-up period. Records were classed as ’reviewed’ if at least one 
medical record was available from 2012 onwards.
A consensus meeting (JS, AC and JG) was held to review this data and determine 
whether the initial symptoms of functional or neurological limb weakness could, with 
the benefit of hindsight, be explained better by another diagnosis. Not all diagnostic 
revision represents a ‘misdiagnosis’ and we categorised patients according to the 
classification of Stone et al. [3].
Deaths
We contacted the National Records of Scotland and England to determine if 
participants had deceased during the follow-up period. The primary and secondary 
cause of death was extracted from death certificates The UK uses WHO criteria in 
which the primary cause of death is the disease or event that started the chain of 
events that led to death, the secondary cause is either a consequence or complication 
of the primary cause, or another disease which might have contributed. These were 
then evaluated against the clinical data from the initial presentation.
OUTCOME
Outcome in patients and controls was measured by questionnaires. Change in 
severity of limb weakness in both patient groups was rated on a 6-point Likert 
scale ranging from ‘completely remitted, to ‘much worse’. Rates of depression and 
anxiety were measured using the Hospital Anxiety and Depression Scale (HADS). 
Overall symptom burden was measured using the current physical symptoms list 
on the adapted Illness Perceptions Questionnaire (IPQ). Disability/ quality of life 
was assessed using Medical Outcome Study Short form 36 items (SF36) and the 
Work and Social Adjustment Scale (WSAS) and questions on whether or not the 
subject was in work or studying, receiving social and/or health related benefits. 
Illness perceptions in patients were measured using selected items from the Illness 
Perception Questionnaire (IPQ) (‘My illness is likely to be permanent rather than 
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temporary’, ‘My illness is a mystery to me’, ‘stress or worry was a cause for your 
weakness’, ‘damage to the nervous system was a cause for your weakness’) scored 
on a 5-point Likert scale. Patients were asked if they received any treatment, and 
if so, if this was physiotherapy, psychotherapy and/or any other treatment during 
the follow-up period. Treatment was not explored further, because patient’s recall 
of details of treatment was considered biased and unreliable after 12-16 years of 
follow-up.
Prognostic factors
Several baseline variables were selected for a prognostic factor analysis to predict 
change in severity of limb weakness (as measured by the CGI), and for the post-hoc 
comparison of patients in follow-up, not in follow-up and deceased, in order to find 
potential selection bias and predictors of death.
The selection of prognostic baseline variables (see results, table 4) was based on our 
systematic review on the prognosis of functional motor disorders [9], complemented 
with variables that predicted functional vs neurological limb weakness at baseline 
[10]. Prognostic factors were only assessed in the functional weakness group.
Most of these factors were based on standardised questionnaires (as described in 
Stone et al. 2010), these are listed in the corresponding tables. Deprivation category 
was determined based on postcode data (which is a measure of socioeconomic 
deprivation), registration of appendectomies and hysterectomies was part of the 
baseline inventory, as a marker of vulnerability to functional disorders. Change 
in severity of limb weakness, as measured by the CGI was used as the outcome 
measure. The selection of prognostic baseline variables (see results, table 4) was 
based on our systematic review on the prognosis of functional motor disorders 
[9], complemented with variables that predicted functional vs neurological limb 
weakness at baseline [10]. Prognostic factors were only assessed in the functional 
weakness group.
Statistical analysis
All patients were analysed in their initial group, irrespective of possible misdiagnosis. 
Misdiagnosis was reported as a percentage in both patient groups. The standardised 
mortality ratio (expected deaths based on national reports / measured deaths) was 
calculated for both patient groups. The number of people that died in Scotland from 
2000 to 2015 was extracted from the National Records of Scotland. As patients 
were included in our study from 2000 untill 2003, standardised mortality ratios 
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for the cohorts from 2000, 2001 and 2002 up and until 2015 were compared to the 
corresponding cohorts in Scotland separately and a weighted mean standardised 
mortality ratio was calculated. Baseline characteristics of subjects in follow-up, 
not in follow-up and the deceased were compared between the three groups using 
non-parametric testing, in order to find potential selection bias and predictors of 
death (Chi Square, Kruskall-Wallis and Mann-Witney U testing). Baseline factors that 
were found to have a prognostic value, were selected post hoc for this comparison. 
No prognostic analyses were performed in patients who had deceased.
Patient outcomes were compared between (follow-up) and within group (follow-
up versus baseline). Group comparisons with normally distributed continuous data 
were tested with T-tests (normal or paired for repeated measures). Continuous and 
categorical data that was not normally distributed was tested using non-parametric 
methods: Mann-Witney U or Chi square tests (between group analysis), Wilcoxon 
Signed Rank tests (within group analysis).
Prognostic factors were determined in the functional weakness group using binary 
logistic regression analysis. Weakness severity, the dependent variable, was 
dichotomised into same/ worse (bad) or better/remitted (good). Univariate testing 
was performed for all baseline factors, all factors that reached a p-value of p<0.05 
were subsequently included in a multivariate analysis. The multivariate binary 
logistic regression was performed using backwards elimination.
Additionally, correlations using the non-parametric Spearman’s Rho, were made 
between outcomes and the change from baseline to outcome, to determine if bad 
outcome of limb weakness is correlated to bad outcome in other domains. Also, 
correlations were made between improvement of secondary outcome measures 
and weakness outcome, to determine factors that might be interesting for targeting 
treatment.
All missing data was reported, no imputation methods were used. To correct 
for multiple comparisons, we handled interpretation of p-values cautiously and 
considered p values larger than 0.01 to be insignificant.
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Figure 1. Flowchart follow-up. Misdiagnosis and patient outcome (including deaths) 
were studied parallel in the baseline population. Functional = Functional limb weakness, 
Neuro = neurological control subjects, Healthy = Healthy control subjects. *In 8 functional 
limb weakness patients, 1 neurological control and 8 healthy controls we did not have suffi-
cient information to determine if they had died during follow-up. In 3 out of 65 functional limb 
weakness patients, only main outcome (acquired by phone) was available.
The mean follow-up duration was 14 years for functional limb weakness patients 
and neurological controls, (range 12-16 and 13-15 years respectively) and 13 years 
for healthy controls (range 12-15 years). Figure 1 shows a flowchart of follow-up, 
including misdiagnosis, deaths and patient outcome. Neurological controls that took 
part in the follow-up study had the following baseline diagnoses: Multiple Sclerosis 
(n=12), Guillain-Barré (n=4), transverse myelitis (n=3), clinically isolated syndrome 
(n=1), ganglionopathy (n=1), ulnar neuropathy (n=1), myasthenia gravis (n=1). From 
those who were lost to follow-up 14 out of 19 functional limb weakness patients, 10 
out of 11 neurological controls and 6 out of 7 healthy patients had either definitely 
or probably moved out of South East Scotland. When patients in follow-up and not 
in follow-up were compared at baseline (see supplementary table 1), patients in 
the functional weakness group who were not in follow-up had a higher percentage 
of somatisation disorder (42% vs 20%, p=0.02). In the neurological control group, 
patients in follow-up had a significantly worse general health, compared to the group 
not in follow-up. The healthy control group did not show any differences.
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Misdiagnosis
Sufficient data was available to determine whether there had been a change in 
diagnosis in 85% of the baseline cohort, comprising 89 functional limb weakness 
patients and 41 neurological controls. The data came from electronic records alone 
(n=49), combination of the patient and/or the GP and/or electronic records (n=40) 
(Table 1).
In the functional limb weakness group, one patient had a diagnosis of multiple 
sclerosis (MS), which, with hindsight could have been diagnosed at baseline with 
the information available at that time. However, it should be noted that this patient 
still had functional neurological symptoms comorbid to MS symptoms at follow-up. 
In addition, six patients developed a neurological disorder during the follow-up period 
that could not explain the initial functional limb weakness. In three of those patients 
(Huntington’s disease, Parkinson’s disease and idiopathic cerebellar degeneration), 
the consensus view was that whilst the disorder would not have directly explained 
the symptom of functional limb weakness, the prodromal phase of the neurological 
condition may have contributed to the development of functional weakness. 
Prodromal phases of neurodegenerative diseases may promote functional disorders 
for many reasons, including altered somatosensory feeling in the limb, or because of 
alterations in cognition and emotions, especially in relation to attentional processing. 
In the three cases of ischaemic stroke there were strong reasons to argue the initial 
functional limb weakness was not related (onset, anatomical location or normal 
MRI at baseline) and was therefore not considered a TIA or stroke. Finally, for one 
patient there was uncertainty, at follow-up, whether this patient had a combination of 
a functional disorder and MS with very limited symptomatology, or only a functional 
disorder.
In the neurological control group one patient was categorised as misdiagnosis. The 
diagnosis of common peroneal palsy was with the benefit of hindsight an early sign 
of Spinal Muscle Atrophy (the stated cause of death in this patient) and therefore 
labelled as misdiagnosis. One patient developed functional symptoms during follow-
up on top of the neurological diagnosis and is therefore categorised as ‘de novo 
development of ‘functional disorder’. Two neurological controls with a single episode 
of demyelination at baseline, developed more episodes, therefore the diagnosis 
changed to MS. Table 1 summarises these findings.
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Functional limb weakness patients (n=89) Neurological controls (n=41)
Change of diagnosis 
category*
N Follow-up Diagnosis N Follow-up Diagnosis
Misdiagnosis 1 Multiple Sclerosis and 
Functional Disorder
1 Common peroneal nerve 
palsy changed to Spinal 
Muscle Atrophy
Diagnostic refinement - - 2 Clinically Isolated 
Syndrome evolving to MS
De novo development of 
new disease/disorder










1 Disagreement between “MS 
and functional disorder” vs 
only functional disorder
Table 1. Change in diagnosis during follow-up. * from Stone et al. [3].
Deaths
In 101 functional limb weakness patients (94%), 45 neurological controls (94%) and 
30 healthy controls (79%) we had sufficient information to determine if they had 
died during follow-up. Eleven functional limb weakness patients, eight neurological 
controls and one healthy control had died.
The cause of death is shown in table 2. Within the functional group, the deceased 
were older at symptom onset, had a worse general health and were in a lower 
deprivation category at baseline, compared to all other functional limb weakness 
patients. No such differences were found within the neurological control group. 
There was no difference in the number of smokers or opioid users between the 
deceased group and the other patients at baseline, (supplementary table 1), although 
the absolute values of the numbers of smokers were 25% in follow-up compared 
to 45% in the deceased group, raising the possibility of a type 2 error due to small 
numbers.
The primary cause of death in the functional limb weakness group were all non-
neurological. In three cases the secondary cause of death was a neurological 
disorder that patients developed after their initial episode of functional weakness; 
these cases (two with an ischaemic stroke unrelated to initial presentation and one 
suffering from idiopathic cerebellar degeneration) were discussed above. For two 
patients no death certificates were available in the UK and we were unable to trace 
location of death outside of the UK.
541743-L-bw-Gelauff
Processed on: 21-10-2020 PDF page: 183
183
Prognosis of functional limb weakness
In the neurological control group 6 out of 8 patients’ deaths were related to their initial 
known diagnoses, either as a primary or secondary cause of death (glioblastoma 
(n=2), multiple sclerosis (n=2), motor neuron disease /spinal muscular atrophy (n=2)).
The (weighted mean) standardised mortality ratio for the death rate under 75 years 












Deaths 11 (11%) 8 (18%) 1 (3%) P = 0.54
Mean age at onset 
of symptoms 
(years)
47 (SD 15) 41 (SD 12) NA P = 0.310
Mean age at death 
(years)
56 (SD 14.2) 48 (SD 13.6) 59 P = 0.079
Cause of death Primary Secondary Primary Secondary Primary




Infectious disease 2 1 3 1
Neurological 
disorder
3 4 2 NA -
Other 1* 1 NA -
Unknown 2 - -
Death related to 
initial presentation 
with limb weakness





Table 2. Deceased subjects. Based on data of 176 out of 191 baseline subjects (92%). 
Comparison of age: Mann Whitney U test, comparison of number of deaths: Chi square test. 
Causes of death (both primary as secondary) are given as stated on the death certificate. 
Secondary neurological disorders in the functional group were idiopathic cerebellar 
degeneration and ischaemic stroke(2). *Cause of death: Systemic sclerosis.
PATIENT OUTCOMES
Table 3 shows all outcome measures at baseline and follow-up for the three groups.
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Functional limb weakness symptom outcome
Functional limb weakness completely remitted in 20%, improved in 31% (14% much 
improved, 17% improved) and remained the same or worsened in 49% (23% same, 
14 % worse, 12 % much worse) of patients. In the neurological control group, limb 
weakness completely remitted in 18%, improved in 8% (4% much improved, 4 % 
improved) and remained the same or worsened in 74% (17% same, 35% worse, 22% 
much worse). A significantly larger percentage of patients improved in the functional 
limb weakness group (p = 0.011 on the Mann-Whitney U test across all categories) 
but complete remission was equally low in both groups (p=0.785) (Fig 2).
Figure 2. The severity of limb weakness at follow-up in the functional limb weakness group 
and the neurological control group. A Mann-Whitney U test comparing the whole scale in both 
groups, provided a p-value of 0.011.
Depression and Anxiety
Depression scores on the HADS were slightly better at follow-up than baseline 
in the functional limb weakness group, but this did not reach significance (52% at 
baseline versus 37% at follow-up, above the cut-off of 8, p=0,137). In the neurological 
control group, percentage of patients above the cut-off of 8, decreased from 41% 
to 27% (p=0.508), with no statistical difference. In the healthy controls, numbers 
changed from 32% to 11% (p=0.219). Follow-up depression scores in the functional 
limb weakness group were not statistically different from the neurological control 
group (p=0.616) and scores were worse than the healthy control group (p=0.037).
Mean anxiety levels on the HADS were comparable in the three groups at follow-
up, using a cut off score of 8 or above, 69% of functional weakness patients, 36% of 
neurological controls and 42% of healthy controls suffered from anxiety, which was 
not statistically different.
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Global symptom burden
Compared to baseline, we did not find a change in the number of co-morbid 
symptoms, measured on the IPQ symptom list, in patients with a functional disorder 
(baseline median 9, IQR4, follow-up median 8, IQR5, p=0.076) or neurological controls 
(baseline median 8, IQR3, follow-up median 7, IQR5, p=0.986), nor a difference 
between patient groups at follow-up (p=0.292). In healthy controls, only data at 
follow-up was available (median 3, IQR4). They scored significantly lower than the 
functional limb weakness group (p<0.001).
Disability / Quality of Life
At follow-up, 54% of the functional limb weakness patients reported fair or poor 
general health compared to 39% in the neurological control group (p=0.122) and 9% 
in the healthy control group (p<0.001). In none of the groups there was a significant 
change compared to baseline. Functional limb weakness patients and neurological 
controls scored similarly on all subdomains of the health-related quality of life 
and functioning SF-36 scale at follow-up, except for pain, which was worse in the 
functional limb weakness group (p=0.018). The functional limb weakness group 
scored significantly worse on almost all of these domains (physical functioning, 
physical role functioning, energy, pain) compared to the healthy control group, except 
for the emotional-role functioning domain and the social functioning domain.
At follow-up in the functional limb weakness group, 41% were not employed for 
health related reasons. In comparison, 39% versus 9% respectively were out of 
work for health-related reasons in the neurological and healthy control groups. 
The work and social adjustment scale showed similar outcomes in functional and 
neurological groups, while healthy controls were much less impaired. As at baseline, 
there was no statistical difference in the number of patients in receipt of state related 
financial benefits at follow-up between functional and neurological groups (43% vs 
65%, p=0.066).
Illness perception
At baseline, 89% of patients with functional limb weakness agreed or strongly agreed 
that the limb weakness they experienced was a mystery to them, while at follow-
up this was 51% (p<0.001). At baseline, 23% of patients agreed stress or worry was 
a causative factor for their limb weakness , versus 19% at follow-up (p=0.695) and 
for damage to the nervous system the percentages were 31% at baseline and 32% at 
follow-up (p=0.186), suggesting remarkable stability of illness beliefs.
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Treatment
52% of functional limb weakness patients versus 70% of neurological controls 
(p = 0.154) reported receiving some form of treatment for their limb weakness during 
the follow-up period. Of the functional weakness patients, 76% reported receiving 
physiotherapy at some stage during the follow-up period, and 36% reported received 
psychotherapy. In the neurological control group, 75% reported physiotherapy, and 
only one patient reported psychotherapy. Other therapies in the neurological control 
group included medication for the underlying condition.
Prognostic factors and correlations
Univariate analysis of prognostic factors in the functional limb weakness group, is 
shown in Table 4. Patients with baseline presence of somatisation disorder (0.22 
(0.05-0.89) p =0.034), pain (1.04 (1.01-1.06) p=0.007) and a high number of physical 
symptoms (0.84 (0.72-0.19=0) p=0.037) were less likely to improve. Patients with a 
better general health score on the SF36 at baseline (1.03 (1.00-1.05) p=0.017) were 
more likely to improve. The multivariate analysis showed none of the factors alone 
significantly predicted weakness outcome. This multivariate model provided a Cox 
and Snell R squared of 0.17, suggesting that these factors were only explaining a 
small amount of the variance.
In the functional weakness group, several follow-up outcome measures: general 
health, physical functioning, pain, energy, work and social adjustment and the total 
number of symptoms on the IPQ symptom list, showed significant correlations with 
weakness severity at follow-up, (supplementary table 2). Depression and anxiety did 
not correlate with weakness outcome. In the neurological group this was only the 
case for physical functioning. Change in energy correlated only weakly to a change 
in weakness severity in the functional group (rho -0.361 p=0.004). In the neurological 
group, a change in physical functioning correlated strongly to change in weakness 
severity (rho -0.712, p<.001), change in pain correlated moderately to a change in 
weakness severity (rho -0.610, p=0.003). Any treatment during the follow-up period 
did not influence weakness severity outcome in both groups.
8
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Limb Weakness Severity (CPS)
Univariate analysis Multivariate analysis
Baseline variables Odds ratio (CI 
95%)
p-value Odds ratio (CI 
95%)
p-value
Age at onset 1.01 (0.96-1.05) 0.829 - -
Gender 1.25 (0.30-5.15) 0.757 - -
Symptom duration 0.98 (0.92-1.04) 0.474 - -
Being in work 1.13 (0.81-1.57) 0.486 - -
Benefits 0.43 (0.16-1.18) 0.100 - -
Deprivation category 0.64 (0.41-1.00) 0.050
Appendectomy 0.70 (0.24-2.10) 0.528 - -
Hysterectomy 0.30 (0.08-1.10) 0.069 - -
Psychiatric co-morbidity and childhood trauma
Depression (HADS) 0.99 (0.90-1.08) 0.769 - -
Anxiety (HADS) 0.95 (0.86-1.04) 0.273 - -
Somatisation Disorder (SCID) 0.22 (0.05-0.89) 0.034 0.44 (0.09-2.14) 0.312
Total psychiatric diagnoses on SCID 0.81 (0.58-1.13) 0.210 - -
Physical abuse (CTQ) 1.00 (0.89-1.13) 1.000 - -
Sexual abuse (CTQ) 1.02 (0.93-1.12) 0.723 - -
Health related quality of life and functioning (SF36)
General health 1.03 (1.00-1.05) 0.017 1.02 (1.00-1.04) 0.085
Physical functioning 1.02 (1.00-1.03) 0.065 - -
Pain 1.04 (1.01-1.06) 0.007 1.03 (1.00-1.06) 0.030
Energy 1.01 (0.99-1.04) 0.268 - -
Illness Perception (IPQ)
‘my weakness is a mystery to me’ 1.08 (0.57-2.05) 0.808 - -
‘my weakness is permanent rather 
than temporary’
0.82 (0.55-1.22) 0.330 - -
‘what I do can determine if my 
illness gets better or worse’
1.23 (0.77-1.96) 0.392 - -
‘damage to nervous system caused 
my symptoms’
1.12 (0.70-1.80) 0.628 - -
‘stress or worry caused my 
symptoms’
1.14 (0.78-1.67) 0.487 - -
‘I wish the doctor had listened 
more’
0.83 (0.54-1.24) 0.353 - -
‘I have lost faith generally in 
doctors’
0.96 (0.67-1.36) 0.804 - -
IPQ number of symptoms 0.84 (0.72-0.99) 0.037 0.93 (0.78-1.10) 0.375
Table 4. Prognostic factors. Univariate and multivariate binary logistic regression analysis of 
baseline factors on two dichotomised outcome measures. For both outcome measures, the 
relationship of baseline factors with good outcome is displayed. R squared (Cox and Snell) 0,17.
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DISCUSSION
This study is the largest and longest prospectively recruited follow-up study of 
functional limb weakness, and it also includes a neurological and healthy control 
group. It is also the longest follow-up study ever for any functional neurological 
disorder [14].
Misdiagnosis
In this study, we found only one example of clear-cut misdiagnosis of functional 
limb weakness (1/89=1%), which was half the misdiagnosis rate of the neurological 
control group (1/41=2%). In three additional patients the development of functional 
limb weakness may have been part of a non-specific prodrome to the development 
of a neurodegenerative condition not associated with limb weakness. This in line 
with observations that functional neurological disorders often occur in the context 
of recognised neurological disease [15–17].
Even accounting for these possible prodromal cases, the misdiagnosis rate was 
low, and in keeping with other recent studies of functional neurological disorders, 
as discussed in the introduction. Our prospectively ascertained follow-up data 
was acquired over a much longer time period than any other study and provide 
important evidence of the stability and persistence of the symptoms in patients with 
functional limb weakness. These findings should encourage physicians to consider 
misdiagnosis in this patient population no more of an issue than in other neurological 
conditions . Reluctance to make a positive diagnoses of a functional motor disorder, 
or diagnostic uncertainty can powerfully impair treatment. We recommend that 
physicians should continue to reconsider any neurological diagnosis and remain 
vigilant of comorbid neurological disease, which is a powerful risk factor for all 
functional disorders. Our findings create an argument for neurologists to stay 
involved with the long term management of at least some patients with functional 
limb weakness, to guide treatment and detect neurological disease, sometimes 
occurring years after start of the functional symptoms.
Deaths
In our cohort, we found a standardised mortality ratio for the death rate under 75 
years of age for the functional weakness group of 1.48 and of 2.4 for the neurological 
control group. Duncan et al. [18] found a death rate of 0,58% per year in a group of 
patients with psychogenic non-epileptic attacks (n=260). This was somewhat lower 
than our findings (our data converted to death rates: 0.77% per year in functional limb 
8
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weakness and 1.27% in neurological controls). In that study, as in ours, none of the 
causes of death were directly related to the initial symptoms. Cardiovascular cause of 
death was most frequent. There is very limited data on death rates from other follow-
up studies in functional motor symptoms. From two studies in functional weakness, 
1 patient out of 56 died after 12 years follow-up [5], and 5 out of 64 after 5-7 years of 
follow-up [6]. In the latter one patient died of pneumonia due to immobilisation (in a 
tetraplegic patient), one died of possible overdose, the others in these two studies 
died of cardiovascular disease or malignancy. These findings correspond generally 
to our findings. In two retrospective studies in movement disorders, 1 out of 25 [19] 
and 3 out of 88 [8] died, of whom one from suicide and the others of unrelated causes. 
The increased death rate in our cohort compared to the general population may 
have several causes: i) three patients died of neurodegenerative diseases, and their 
functional limb weakness may have been part of a prodromal state ; ii) secondary 
effects of having chronic illness including depression, anxiety or stress where 
present. iii) among patients with functional weakness patients, those that died had 
a poorer general health status at baseline compared to the patients that survived iv) 
it is possible that patients with functional weakness had a more sedentary lifestyle, 
because cause of death was often cardiovascular and a lower deprivation category 
was associated with death. However other cardiovascular factors were not found 
to be increased in the deceased group, although numbers were small, so caution is 
due for type two error.
Patient outcomes
In 80% of the functional limb weakness group, patients still had symptoms of 
weakness in one or more limb(s) after an average of 14 years follow-up, compared to 
83% of patients in the neurological control group. There was a similar remission rate 
but overall better prognosis in the functional group compared to the neurological 
controls. The results are in line with our earlier retrospective follow-up study in 
which 83% of 42 patients still had weakness after 12,5 years [5]. Other smaller 
studies of outcome of patients with functional weakness, with 10 to 30 patients over 
0.5-6 years, found a large range of outcomes with10 to 56% being the same or worse 
weakness at follow-up [20–23].
From a scientific perspective, it would be useful to investigate the natural history of 
untreated patients with functional limb weakness. Inevitably a large percentage of 
patients received some form of treatment (52% in the functional weakness group, 
70% of neurological controls) during follow-up. Treatment did not correlate to 
outcome. However, the nature of these treatments remained unclear, as our study 
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was not focused on treatment, which were not standardised and randomised,. Also, 
we could not reliably collect data on types of treatment using self-report over a period 
of 14 years. One of the authors (JS) saw all the patients for research assessments at 
baseline between 2000 and 2003, not for specific treatment. Patients were told they 
were in a study of ‘unexplained motor symptoms’ only and didn’t receive the detailed 
explanations, supported by written materials, that they would in 2019 in Edinburgh. 
The impression from review was that it was often not delivered by practitioners 
experienced in functional disorders.
Mirroring the persistent nature of the symptom of functional limb weakness, patients 
also failed to improve on most secondary health outcome measures. Total symptom 
burden and measures of disability/ quality of life were all correlated moderately 
to weakness severity, which (with the exception of physical functioning) were not 
found in the neurological control group. This could be due to quality of life being 
more greatly determined by functional symptoms in the functional weakness group 
compared to neurological controls.
More patients with functional limb weakness were out of work at follow-up than 
had been at baseline. Other studies of patients with functional motor disorders have 
found a low frequency of being in work ranging from 11% to 57% [20,24]. In our data, 
patients with functional weakness were less likely to receive benefits at follow-up 
(43%) than neurological controls (65%), although this did not reach significance 
(p=0.066), while disability at follow-up was equal. In contrast to findings from the 
Scottish Neurological Symptoms Study of 3781 outpatients [2], in which patients with 
functional disorders in general were slightly more likely to be on disability benefits, 
receipt of benefits did not predict outcome in patients with functional limb weakness.
Over time, financial benefits for functional limb weakness patients did not increase 
and receiving benefits did not predict outcome, which contradicts the notion that 
patients would perpetuate their symptoms in order to gain benefits.
Prognostic factors
Several factors were found to influence weakness severity at follow-up in the 
univariate analysis.
General health at baseline was, perhaps unsurprisingly, found to be associated 
with limb weakness outcome. Pain was also found to influence symptom outcome. 
From clinical practice we know pain is an important impairing symptom for many 
8
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functional limb weakness patients. However it has only been studied in fixed dystonia, 
where it found to be a negative predictor [25]. In our limb weakness study, many 
patients had worse pain scores at baseline (median score 33 out of 100, (IQR 35), 
lower score equates to more pain), and even worse (median 20, IQR 20, p<0.001) 
at follow-up, which was significantly worse again than the control groups. Also, a 
change in pain between baseline and follow-up was correlated to general health 
outcome. This highlights the importance of assessing pain at baseline and possibly 
targeting it as a stratifying factor in treatment trials.
Somatisation disorder at baseline, an indicator of individuals with functional 
symptoms in several domains, was also found to influence limb weakness at 
follow-up negatively in univariate analysis. In total 13 patients met the criteria for 
somatisation disorder at baseline, of those, 12 (92%) had poor or fair general health 
and 10 (77%) had same or worse weakness at follow-up. The two studies that have 
investigated this have found no correlation between somatoform disorders and 
outcome [24,25]. From our data, patients with a longstanding vulnerability to various 
symptoms throughout their life, do seem to have a worse prognosis. Total number of 
physical symptoms at baseline, which was found to be a univariate prognostic factor 
as well, could be seen in the same light.
The factors we included in the prognostic analysis were determined based on 
previous findings in the literature and in our baseline study, but many factors were 
not found to have a prognostic value. For age and gender, this was expected based 
on the literature. It was however striking that factors found to be predictive in other 
studies like benefits, working status, frequency of physical and sexual abuse and 
certain illness perceptions, were not prognostic [9]. Notwithstanding the risk of a 
false negative result, as our numbers are relatively low for a multivariate analysis, 
these are important observations, as many of these factors are often suggested to 
play an important role in the prognosis of functional neurological disorders.
Factors that have most consistently correlated with positive outcome in the literature 
included an early diagnosis and short duration of symptoms at baseline [8,21,24,26–
33]. Symptom duration before diagnosis was not found to be a prognostic factor in 
our study. However, the original study set a maximum 2 years of symptom duration 
as an inclusion criterion at baseline which means this study could not easily look 
at that issue.
541743-L-bw-Gelauff
Processed on: 21-10-2020 PDF page: 193
193
Prognosis of functional limb weakness
Generally, we found it difficult to predict outcome in our cohort, let alone at a 
patient level. Apart from the low yield of prognostic factors, part of the problem 
may be heterogeneity between patients. Moreover, our model only explained 17% 
of the variance of the functional weakness outcome, and 38% of the general health 
outcome, which means other unknown factors influence outcome substantially. In 
practice, this means that clinicians should be wary about judging the likely outcome 
in individuals with functional limb weakness and keep an open mind, regardless of 
apparently poor prognostic features.
LIMITATIONS
Inclusion to the original study was consecutively by all neurologists working in a 
regional clinical neurosciences centre covering the South east of Scotland region, 
population about one million. This is likely to be representative of the population in 
this region, as there is limited private medical care and in particular no inpatient 
private neurological beds. Incomplete ascertainment at follow-up is clearly a 
potential issue. However, our follow-up rate of 71% in the functional weakness group 
after 14 years (including the deceased patients) is respectable given the duration 
of time, and baseline variables appeared similar between responders and non-
responders There was a higher percentage of patients with functional weakness 
in the group not in follow-up with somatisation disorder (42%) compared to the 
group in follow-up (20%). As we found somatisation disorder to be a (univariable) 
predictor of bad outcome, the higher drop-out of these patients could have caused 
bias towards more favourable outcome. Patients who could not be contacted had 
most commonly moved out of the area, so is arguably less likely to be a confounding 
factor. Patients declining to participate most likely introduced confounding, however 
whether that would be in favour of good or bad outcome is speculative. Our results 
on misdiagnosis may have been biased by the fact that these patients were all part 
of a study. Patients in whom there was doubt about the diagnosis may have been 
less likely to be referred to the study. Our data on cause of death is partly limited by 
accuracy of death certification. The patient outcome data was based on self-report. 
However, in previous studies comparing subjective and objective outcome measures 
there has been little difference between the two. Patients with very short duration 
of symptoms were not included in this study (ie if they had recovered by the time of 
the baseline assessment). As duration of symptoms has been found to be a negative 








Functional limb weakness can be diagnosed accurately and misdiagnosis is rare even 
after long term follow-up. Functional limb weakness is persistent, disabling, and 
associated with higher mortality than expected. It is very difficult to predict outcome 
based on common baseline variables, although pain and propensity to longstanding 
multiple functional disorders, may be important stratifying variables for clinical 
trials and treatment decision-making. These data should help clinicians to provide 
a more realistic prognosis for functional weakness patients and also stress the 
importance of active and targeted treatment.
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(n in follow-up = 63)
Neurological 
controls (n in follow-
up = 23)






General health (SF36) at FU  0.55 p<0.001  0.41 0.053
Change in general health -0.24 p=0.058 -0.26 p=0.244
Physical functioning (SF36) at FU -0.58 p<0.001 -0.83 p<0.001
Change in physical functioning -0.32 p=0.011 -0.71 p<0.001
Pain (SF36) at FU -0.57 p<0.001 -0.40 p=0.062
Change in pain -0.01 p=0.929 -0.61 p=0.003
Energy (SF36) at FU -0.50 p<0.001 -0.41 p=0.050
Change in energy -0.36 p=0.004  0.25 p=0.262
Work and social adjustment (WSAS) at FU -0.47 p<0.001  0.59 p=0.003
Depression (HADS) at FU  0.32 p=0.009  0.36 p=0.096
Change in depression  0.25 p=0.051 -0.09 p=0.683
Anxiety (HADS) at FU  0.12 p=0.352  0.33 p=0.126
Change in anxiety  0.00 p=0.982  0.18 p=0.416
IPQ total symptoms  0.52 p<0.001  0.34 p=0.112
Change in response to ‘my weakness is a 
mystery to me’
 0.23 p=0.082 -0.03 p=0.898
Change in response to ‘stress or worry 
caused my symptoms’
-0.13 p=0.304  0.09 p=0.702
Change in response to ‘damage to 
nervous system caused my symptoms’
 0.26 p=0.043 -0.02 p=0.944
Change in IPQ total symptoms  0.25 p=0.048  0.25 p=0.262
Any treatment  0.15 p=0.237  0.27 p=0.209
Supplementary table 2. Correlations at follow-up. Correlations between weakness outcome 
in the functional and neurological group and factors at follow-up (at FU) or differences 
between baseline and outcome (change).
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For the treatment of functional motor disorder, we recommend a three-stage 
approach. Firstly patients must be assessed, and given an unambiguous diagnosis 
with an explanation that helps them see they have a genuine disorder which has the 
potential for reversibility. Key ingredients are allowing the patient to describe all their 
symptoms and to explain their ideas about what may be wrong. It should be made 
clear that the diagnosis is a positive one based on the presence of typical signs (eg 
Hoover’s sign for paralysis, entrainment test for tremor) which in themselves indicate 
the potential for reversibility. We suggest an approach leaving out the assumption 
there are psychological stressors in the patient’s life that have caused the symptom. 
Often the symptoms themselves are the main stressor. Insisting that there must be 
others simply leads to a frustrated doctor and angry patient. Instead, at this first 
stage we encourage exploration of mechanism, e.g. triggering of symptoms by pain, 
injury or dissociation and a discussion about how symptoms arise as “abnormal 
motor programs” in the nervous system.
Secondly, further time spent exploring this diagnosis, treating comorbidity and, in 
the context of a multidisciplinary team, trying out altered movements and behaviors 
may benefit some patients without the need for more complex intervention.
Thirdly, some patients do require more complex treatment, often with a combination 
of physical rehabilitation and psychological treatments. Hypnosis, sedation and 
transcranial magnetic stimulation may have a role in selected patients.
Finally many patients do not respond to treatment, even when they have confidence 
in the diagnosis. Ultimately however, patients with functional motor disorder may 
have much greater potential for recovery than health professionals often consider.
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INTRODUCTION
Functional (also known as psychogenic) motor disorders encompass weakness or 
movement disorders (such as tremor, gait disorder or dystonia), that are genuine 
but do not relate to recognised neurological disease. Symptoms are involuntary and 
should not be confused with feigning or malingering. The diagnosis should not be one 
of exclusion but rather based upon positive clinical signs of internal inconsistency. 
In some cases incongruity with recognised neurological disorder is also important 
but this is a lesser issue [1;2].
Functional motor disorders (FMD) have a signfiicant impact on both the individual 
patients and the health care system as a whole. They are the second most common 
functional neurological disorder seen in outpatient practice [3;4] and account for 
a substantial number of inpatient admission days [5]. Patients with symptoms 
unexplained by a recognized neurological disease have similar levels of disability, 
and more distress than patients with symptoms explained by disease [6]. Case 
control studies have shown levels of disability and health status comparable to 
Parkinson’s disease [7] and multiple sclerosis [8]. The prognosis of FMD is variable 
but generally unfavorable [9].
From a historical perspective, the range of treatments in FMD (described as hysteria 
or conversion disorder at the time), has reflected the many differing hypotheses 
regarding their origin. These include hysterectomy, hypnosis, suggestion, abreaction, 
electrical stimulation (of the affected limb), various forms of constrained and other 
physical rehabilitation, and psychotherapy including psychoanalysis [10-12]. We have 
largely restricted ourselves to studies since 1965 whilst remaining aware that there 
are many important lessons to be learnt from older treatments.
In this review we summarize current evidence for treatment of FMD focusing 
on physiotherapy and psychological treatments [13], but also discussing other 
treatments such as hypnosis, transcranial magnetic stimulation, sedation and 
pharmacologic treatment.
Throughout, we would like to emphasize our clinical experience that there is little 
benefit attempting to embark on treatment before a good initial consultation [1;14]. A 
patient who has no confidence or understanding of the nature of its diagnosis rarely 
benefits from the treatments described below. It is our view that the neurologist 
or diagnosing physician is in a position to deliver the first phase of treatment and 
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not just the diagnosis. Figure 1 shows a proposal of a ‘stepped care’ approach in 
FMD where the neurologist provides ‘Step 1’ of the treatment, brief therapy [most 
commonly delivered by a physiotherapist for FMD] can be seen as ‘Step 2’ and more 
complex multidisciplinary care involving the full rehabilitation team and psychiatry/




Patients are often referred for physiotherapy after consulting a neurologist. The 
emerging evidence supports the idea that, regardless of psychiatric comorbidity, 
patients with FMD often benefit from an approach in which they are taught about 
the nature of their abnormal movements and how to move in a more normal way. 
The most successful programs appear to do this by conceptualizing the FMD as 
a problem with abnormally learnt ‘motor programs’ in the brain which have to be 
‘unlearnt’ [13;16]. More data is certainly required, and in particular, there is much 
work to be done on refining and describing techniques that may be specifically helpful 
for individual symptoms. Physiotherapists are surprisingly positive about treating 
this group of patients but feel lacking in knowledge and support from medical 
colleagues in doing so [17].
The first randomized controlled study of physiotherapy in 60 patients with functional 
gait disorder (mean duration of symptoms of 9 months), was reported recently by 
Jordbru et al[16]. The authors compared immediate or delayed inpatient physical 
rehabilitation without any psychotherapy. The intervention led to a mean 7 point 
change in a 15 point measure of functional mobility compared to controls waiting for 
the treatment and a return to normal functional independency in the active treatment 
group.
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A retrospective study of physiotherapy compared 60 patients (mean duration of 
symptoms 17 months) with 60 patients who had received historical usual care 
[18]. The one week intervention, like that of Jordbru et al. focused on physical 
function, with gradual progression from elementary to more complex movements, 
in combination with only a little psychotherapeutic element [16]. Directly after 
treatment, 74% were improved according to both physician- and self-rating. At 
follow-up (median 25 months) 60% had self-rated improved symptoms and 62% mild 
or no disability level, compared to 22% and 44% respectively in the control group. The 
main methodological limitation of the comparison is that the control group consisted 
of those patients who refused to have treatment and so were intrinsically less likely 
to do well. Nonetheless, even as a retrospective uncontrolled series these data 
suggest a possible better outcome in chronic FMD than might be expected based 
on existing literature.
Another study investigated the effect of a thrice-weekly, 12-week mild walking 
program on mild to moderate functional movement disorders (mean symptom 
duration 15 months) on 16 patients [19]. Results showed an average of 70% 
improvement of symptoms in 10 of 16 patients. As no control group was used and 
symptom duration was short, the intervention effect could be attributed to several 
factors: there is a social element to group walking therapy since it has been shown 
that walking improves general wellbeing, improvement could also be attributed to 
natural history of the disorder, although again the improvement after a long duration 
is encouraging.
A systematic review of physiotherapy for FMD found a further 25 case series and 
reports of physiotherapy for FMD with low levels of evidence but nonetheless a 
trend towards positive outcome [13]. In most studies a behavioral motor learning 
program was used: positive reinforcement with praise or rewards and privileges, 
while ignoring abnormal movement and maladaptive behaviors.
Inpatient rehabilitation with combined multidisciplinary treatment
A recent study [20] (n=33, mean duration of symptoms 48 months) used a 
combination of occupational therapy, focusing on motivation and reinforcement, 
physiotherapy with posture exercises and massage and psycho-education. 85% of 
patients received CBT, techniques included ‘fostering insight and assertiveness’. 
Significant improvement was found in MRS scores (p<0.001), mobility (p<0.001) and 
ADL (p=0.002). No control group was studied.
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A retrospective study [21] (n=26, 63% symptom duration > 3 years, all previously 
received failed treatment) investigated an inpatient intervention consisting of 
physiotherapy, occupational therapy, cognitive behavioral therapy, neuropsychiatry 
assessment and neurology input as required. 58% of patients reported benefit from 
the program on discharge and the same percentage at a mean follow-up of 7 years, 
but no improvement on employment rate was found. Patients were excluded if they 
did not accept the rationale for CBT. Thus even in a treatment resistant population, 
treatment is still possible, although is not suitable for those who do not accept the 
premise of treatment in the first place.
Contraindications, complications: Patients typically report that exercising 
exacerbates pain and fatigue which needs to be anticipated as part of therapy.
Cost/Cost effectiveness: No literature is available concerning the cost-effectiveness. 
Costs depend on treatment duration, which vary highly between studies.
Psychotherapy
The level of available evidence for psychotherapy of FMD is low [22] and much of the 
suggested emphasis on psychotherapy is based on historical practice or inferred 
from studies of similar patient populations such as patients with non-epileptic 
attacks or other functional somatic symptoms.
Psycho-education and explanation
To our knowledge there are no studies specifically focusing on the effectiveness 
of explanation and education of symptoms in this population. It is however widely 
believed by many specialists that education is important and can often be an effective 
treatment strategy [23]. Studies of non-epileptic attacks have shown that around one 
third of patients will improve with a single consultation [24;25] and prognostic studies 
of both FMD and non-epileptic attacks suggest that anger with the diagnosis predicts 
poor outcome [14;26]. Qualitative studies have also reinforced the importance of 
giving patients tangible diagnoses [27-29]. A combined consultation and written 
information can be carried out with a high level of patient satisfaction [28].
Most articles on the process of giving the diagnosis of FMD and other functional 
neurological disorders emphasize the importance of some of the items in Table 1. 
In fact these are no different to important ingredients of giving a diagnosis for any 
medical condition.
541743-L-bw-Gelauff
Processed on: 21-10-2020 PDF page: 209
209
Review treatment of FMD
Where authors diverge is in the name given to the condition and by default the 
associated explanation. Some deliberately avoid making a diagnosis [30] others 
emphasize re-learning normal movement [18] as part of a functional explanation. 
Others may use a more clear cut ‘psychogenic’ explanation [31]. We know something 
of which terms patients prefer but this is an area that would benefit from further 
study [33].The pros and cons of different terms and models of these disorders is 
discussed elsewhere [32].
Explanations that rely on normal imaging or normal examination are generally 
not appreciated by patients who want to know what they have got, not what they 
don’t have. For the same reason terms such as ‘medically unexplained’ tend to be 
regarded especially negatively.
Combined psychiatric and neurological consultation
One study investigated the effect of a combined consultation of a psychiatrist and 
a neurologist and a number of subsequent consultations, depending on individual 
demand (mean 2.8 visits) in 12 patients and 11 control subjects (usual care) [34]. The 
aim was to explain the functional nature of the symptoms, offer coping strategies 
and address the potential role of psychological factors. Of the patients from the joint 
consultation group 83% reported good outcome, compared to 36% of the control 
group, furthermore this group scored better on SF-12 scale, reported significantly 
lower symptom severity and sought less medical help.
Element Example
Give the patient a diagnosis. “You have a functional movement disorder.”
Emphasize that symptoms are 
genuine (and common).
“Your symptoms are not ‘imagined’ or ‘crazy.’”
Explain on what basis the 
diagnosis has been made.
e.g., showing patient positive features of the 
diagnosis such as Hoover’s sign or tremor 
entrainment test
Emphasize potential for 
reversibility.
“Your Hoover’s sign shows us that your leg has the 
potential to improve.”
Emphasize the role of self-help/
education. “
I’d like you to read this information (e.g., www.
neurosymptoms.org]. It’s not your fault that you have 
this, but you will need to work at it to get better.”
Table 1. Some commonly agreed initial ingredients of a successful explanation of functional 
neurological symptoms
Cognitive behavioural therapy (CBT)
Cognitive behavioural therapy broadly describes a psychotherapy in which the patient 
is encouraged to challenge patterns of thinking and behaviour that are creating 
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obstacles to symptom improvement. It focuses more on perpetuating factors than 
on predisposing factors. There are no trials of CBT in functional motor disorder, 
[22;35] although individual case studies report success [36], as do above mentioned 
studies combining CBT with physical therapy [20;21]. A RCT of a brief guided self-
help intervention based on CBT for patients with a variety of functional neurological 
disorders including FMD demonstrated benefit at 3 months and 6 months in the 
treatment group [37] with a number needed to treat of 7.
Most studies of CBT for functional disorders show benefit. Even a study of CBT in 
‘somatisation disorder’ was effective [38]. Patients with FMD typically do have many 
other functional somatic symptoms but we should be cautious about assuming that 
CBT is necessarily beneficial without more evidence.
Psychodynamic therapy
Psychodynamic therapy generally involves helping the patient to see their symptoms 
in the context of interpersonal relationships and life narrative. In a randomised trial 
by Kompoliti et al. (n=15) with early psychodynamic therapy versus three months 
of monitoring from a neurologist and after that psychodynamic therapy [39], found 
the same improvement in both groups. This study evolved from a case series of 10 
patients of whom 8 improved [40]. Both studies are too small to draw conclusions 
from although did highlight a high refusal rate for this kind of therapy in a trial setting 
(60% eligible patients refused).
Reuber et al. also described tailored psychodynamic therapy for 91 patients with 
functional neurological symptoms including at least 15 with FMD [41]. 49% improved 
by at least one standard deviation on measures of health status.
Contraindications, complications: It is recognized that psychotherapy can 
sometimes temporarily worsen FMD, especially when adverse experiences are 
discussed for the first time.
Costs/ Cost effectiveness: Reuber et al. studied CBT in several functional 
neurological symptoms, amongst which 15% movement disorders and 12% problems 
with gait [41]. They estimated a cost per “quality adjusted life year” at £5.328 based 
on the total study population.
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Pharmacologic treatment
Antidepressants
Little has been published on pharmacological treatment of motor symptoms in FMD. 
No randomized or controlled studies have been conducted. Voon et al. published 
a series of 15 patients with functional hyperkinetic movement disorders who 
underwent treatment with different kinds of SSRI’s (Selective Serotonin Reuptake 
Inhibitors) [42]. The study was confounded by concurrent psychotherapy and does 
not meaningfully contribute to the evidence regarding antidepressant use.
Contra-indications and side effects, other than those that are known, of the use of 
an SSRI in this specific patient group are not known. Based on present literature 
there is no evidence to support efficacy of any pharmacological treatment for the 
motor symptoms of FMD. However it is reasonable to consider antidepressants for 
other common symptoms in FMD such as pain, insomnia, anxiety and depression.
Interventional procedures
Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) is a non-invasive method by which 
electromagnetic induction is used to explore cortical excitability and connectivity. 
Repetitive TMS (rTMS) can generate long-term potentiation or depression. TMS 
has been widely used in neurological and psychiatric disorders as a tool to gain 
insight into pathophysiology as well as a possible therapeutic treatment [43;44]. 
Abnormalities in cortical excitability have been found in functional limb weakness 
[45;46] although it may be that these changes are similar to those found in volunteers 
feigning [47].
A systematic review has been conducted on the effectiveness of TMS and rTMS in 
FMD which explored the quality and limitations of seven studies [48]. Combining this 
with one subsequent study means there are uncontrolled data on 119 patients who 
have received TMS treatment (78 weakness, 41 movement disorder) [49].
The publications are dominated by two French studies both reporting successful 
outcomes. Chastan and Parain’s retrospectively studied the use of rTMS delivered 
over a single 2-3 minute period in the hemisphere contralateral to the weakness 
to 70 patients with functional limb weakness [50]. In this highly acute and young 
group (44 of whom were under 20 years of age with a median duration of 5 days) 
there was a 89% recovery either immediately or within days. It recurred in some but 
repeated treatment was reported as effective. The study by Garcin et al. was from 
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a different centre and also reported single session TMS treatment in a group of 24 
with movement disorder of much longer duration (2.8 years) [49]. 75% of the patients 
improved by more than 50% immediately after TMS with 6 patients experiencing 
complete resolution. The patients then received physiotherapy, psychology and 
neurology follow up and were assessed at a median duration of 20 months later. 
At that point 71% of patients were much improved. Both studies used a stimulus 
sufficient to induce movement in the limb. Only one study had negative findings [51].
From a methodological perspective these studies do suggest that TMS may be a 
useful treatment for FMD but we should be careful to jump into too many conclusions. 
Patients with acute FMD may improve anyway, especially if acute, and the results 
in the patients from the Garcin study may have been influenced by subsequent 
therapy from an interested team [49]. The only study with negative results was not 
published so far and included patients with chronic symptoms [51]. Authors have 
argued that TMS can induce changes in cortical excitability [50], whereas others 
have pointed out that the duration of the TMS stimulus is not sufficient to induce a 
long lasting physiological change in the brain [48;49]. Alternative possibilities are a 
placebo effect, ‘relearning’, regaining function with a treatment that is acceptable 
to the patient and/or facilitating insight in the disorder. Garcin et al. described it as 
a “cognitive-behavioral effect when patients see an unexpected alteration of their 
movement disorder. This, combined with suggestion, could be a powerful stimulus 
inducing change in belief about symptoms and could trigger or help recovery”[49]. 
It certainly warrants further evaluation in controlled studies.
Contraindications, complications: TMS is considered a safe therapy, although 
seizures have been reported sporadically, the risk is considered very low [52].
Cost/Cost effectiveness: No literature is available on the costs or cost-effectiveness.
Transcutaneous Electrical Nerve Stimulation / Peripheral Stimulation.
Transcutaneous Electrical Nerve Stimulation (TENS) refers to a treatment concerning 
low-voltage electrical currents applied to the skin. Although there is no consensus 
on the optimal paradigm nor the mechanism of action, it is a widely used treatment 
in acute and chronic pain. Studies have been published with positive results using 
TENS in other movement disorders [53-55], little is known of its efficacy in FMD.
Literature on TENS in FMD consists of case reports or small case series [56-61]; 
and one larger study [62] in which 19 patients with various functional movement 
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disorders underwent a trial of TENS therapy. Electrodes were placed on the muscles 
most affected. All patients who considered the trial effective were offered daily 
TENS treatment during 30 minutes. Results showed that 15 patients (79%) chose to 
continue TENS after 4 months, although only 5 demonstrated a clear (>50%) effect 
on blindly assessed standardized videotapes, or phone assessment (42%). Shorter 
duration of symptoms was associated with better outcome. Because of the small 
population, study design, lack of a control or use of placebo no firm conclusions can 
be drawn on efficacy of this treatment strategy, but like TMS it may have a place in 
the context of rehabilitation.
Electrical stimulation of muscles using functional electrical stimulation (which 
produces more of a muscle jerk than TENS) has been reported in a case report [63]. 
Varieties of electrical stimulation were common practice as a treatment for FMD in 
the late 19th and early 20th century and were frequently reported to be successful. 
EMG feedback has also been reported successfully in four patients which may involve 
similar mechanism when successful [64].
Contraindications, complications: in the study by Ferrara et al. two patients 
temporarily got worse. TENS is generally considered a safe therapy, contra-
indications include patients with an Implantable Cardioverter-defibrillator (ICD) [65].
Cost/Cost effectiveness: no literature is available on the costs or cost-effectiveness.
Abreaction and Sedation
Abreaction describes a psychiatric interview carried out while the patient is 
deliberately sedated. The original purpose of this was, in psychoanalytic terms, to 
access hidden memories, induce catharsis and thus resolve the hypothesized conflict 
underlying the symptom. A review summarized studies of abreaction for functional 
neurological disorders (33% FMD) [12]. The effect was often positive, but none of 
the 55 included studies (mainly older case reports or case series) had a (placebo) 
control group.
Stone et al described the effects of sedation with the anaesthetic propofol on 11 
patients with severe FMD median duration 14 months who had already accessed 
multidisciplinary treatment and explanation [66]. The rationale here was to use 
sedation to demonstrate reversibility of symptoms to the patient in situations where 
this was not possible using the normal consultation (ie fixed dystonia, mutism). A 
case report of a woman with chronic bilateral upper limb functional dystonia showed 
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the same effect, with complete (temporary) disappearance of dystonia during short 
propofol induced narcosis [67]. Five patients experienced rapid resolution or major 
improvement of their symptoms. These studies are subject to the same criticism as 
other case series but the effect was not confounded by other new treatments and 
the patients largely had chronic symptoms.
Acupuncture
Although acupuncture is widely studied in other functional disorders only one case 
report was found in English literature [68] on a patient with longstanding functional 
myoclonus, who responded to acupuncture. The authors contemplate a placebo 
effect to explain the results. In the Chinese literature there are other reports of 
acupuncture for FMD including one paper describing a 99% success rate in 1316 
patients with functional paralysis [69].
Other therapies
Suggestion / Placebo
Placebo and suggestion cover a wide variety of potential treatments, ranging from 
an inert pill or infusion, to simply suggesting to the patient they may get better. 
The latter could be said to be a very simple form of cognitive therapy and as such 
is not really placebo. This may explain why placebo performs so differently among 
different studies.
One study with saline infusion and one case report with a placebo pill in FMD found 
respectively improvement in 7 of 12 patients at follow-up (duration not stated), and 
complete recovery [70;71].
Edwards et al report immediate resolution of symptoms of botulinum in three 
patients with fixed dystonia [72]. As the authors discussed, had to be consistent with 
a placebo effect since botulinum only becomes active after 72 hours. The authors 
sound a note of caution about the use of this treatment but it nonetheless deserves 
consideration in patients where improvement by other means is not possible.
Neurologists who value transparency and honesty in diagnosis and treatment of 
FMD naturally object to the idea of deceptive placebo. There is a counter argument 
however. Placebo could be especially beneficial in functional disorders, since they 
may share similar pathways [73] and may be associated with similar activity of 
brain regions found in fMRI-studies [74]. Furthermore deception is not necessary to 
achieve a placebo effect [75] and patients might not reject placebo use [76]. Placebo 
541743-L-bw-Gelauff
Processed on: 21-10-2020 PDF page: 215
215
Review treatment of FMD
response is of course an issue for many disorders in medicine and the topic is 
certainly an important one to consider in the design of trials.
Deliberate restriction of activity or deception by the doctor.
Several earlier studies report on strategies to motivate patients recovery by 
restricting their activity or use of facilities [77;78]. In a series of papers Shapiro and 
Teasell described a paradoxical rehabilitation technique in which patients were told 
that their symptoms would be purely psychiatric if they did not improve [79;80]. The 
authors report improvement (71% of 23 patients improved or remitted at discharge) 
but we cannot endorse an approach which deliberately sets out to deceive patients 
and are doubtful that it would lead to long lasting improvements. Likewise deliberate 
restriction of facilities or enforced disability is not compatible with modern clinical 
practice.
Hypnosis
Hypnosis has been used widely for FMD since the 19th century. Studies of hypnotic 
models of FMD have highlighted similarities to patients with clinical FMD [81;82]. 
Hypnosis was studied in a randomized controlled trial (RCT) as an addition to 
standard inpatient treatment with multidisciplinary physical and psychological 
therapy in 92 patients with FMD [83]. There was impressive symptom reduction in 
both groups suggesting benefit from multidisciplinary treatment but no additional 
benefit from hypnosis.
In another RCT the effect of ten sessions of hypnosis on 44 outpatients with 
long duration FMD was studied (median 3.7 years) [84]. Patients improved highly 
significantly compared with a waiting list control group after with before treatment.
Separating out the specific effects of hypnosis from other elements of the 
consultation is probably impossible but the technique almost certainly has a useful 
role in some patients.
Complications and contraindications: Hypnosis and placebo, in common with all 
treatments for FMD, run the risk of nocebo, that is the possibility that the patient 
responds negatively to the suggestions and develops worsening symptoms.
Cost / cost effectiveness; No literature is available on the costs, nor the cost-
effectiveness of above mentioned therapies.
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This review of existing studies highlights the relatively low quality of most studies 
and lack of randomized designs. There are particular challenges in designing 
treatment trials for patients with FMD. These range from how to deal with a 
‘placebo’ arm when placebo may be an effective and desirable treatment to the 
difficulty of finding outcome measures that capture improvement in patients who 
are often polysymptomatic. Building an evidence base for a multimodal and stepped 
approach to treatment of FMD does remain possible. Trial registers indicate ongoing 
interest in TMS, psychotherapy in functional movement disorders and YD and MT 
are currently conducting a trial investigating botulinum-toxin injections in functional 
jerky movements.
Treatment of Pediatric FMD
The course of functional motor disorder in children is often thought to be benign, 
but data is limited and in some studies school absence, disability and morbidity is 
high [85]. It seems likely that many of the same factors that are associated with 
adult FMD can be translated in to the pediatric disorder. Several small uncontrolled 
studies have examined the effect of a multidisciplinary approach involving neurology, 
psychiatry, and social work/psychology [86], with good results . All studies underline 
the importance of family involvement in the treatment.
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Background: Explanation of the diagnosis has been suggested as the first step in 
the approach to motor Functional Neurological Disorder (FND). In this randomised 
trial we investigated if an online education and self-help intervention, added to usual 
care, would improve self-rated health in motor FND.
Methods:  Patients were 1:1 allocated to an unguided education and self-help website 
in addition to usual care, or usual care only. Patients over 17 years of age with 
a functional motor symptom which caused distress or disability were included. 
The primary outcome was self-rated health on the Clinical Global Improvement 
(CGI) scale, at three and six months. Secondary outcomes were severity of motor 
symptoms, other physical and psychiatric symptoms, physical functioning, quality 
of life, work and social adjustment, illness beliefs and satisfaction with care. 
Results: 186 patients were randomised, with a follow-up rate of 87% at 6 months. 
There was no difference in improvement of self-rated health at three months (44% 
vs 40%, p=0.899) or six months (42% vs 43%, p=0.435). Secondary outcomes did not 
differ between groups with a threshold of p<0.01. Satisfaction was high, with 86% of 
patients recommending the website to other patients.
Conclusion: We found no significant effect of the intervention added to usual care on 
self-rated health or secondary outcome measures, despite high patient satisfaction 
with the intervention. These results suggest online education and non-guided self-
help could be valuable additions to stepped care for motor FND, but are not effective 
treatments as interventions in their own right. 
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INTRODUCTION 
Expert opinion often suggests that a stepped care approach may be optimal for the 
treatment of motor Functional Neurological Disorders (FND) as it has the potential 
to optimise use of health care resources for these common, disabling and persistent 
disorders. In this context the first important treatment step is the neurologist not 
just making the diagnosis but explaining the disorder [1, 2]. Good practice statements 
suggest this should be supported by written information including suitable advice 
for initial self-management. However, despite enthusiastic advocates, evidence 
for this approach is lacking. Supporters point to prognostic studies in motor FND 
[3], dissociative non-epileptic attacks [4, 5] and the broader group of functional 
neurological symptoms [6], that suggest patient confidence in the diagnosis and the 
potential to recover is correlated with good outcome. In addition, there are studies 
that have found improvement in symptoms [7, 8] and high satisfaction with care [9, 
10] after explanation of the diagnosis. By contrast, some clinicians express concerns 
that giving too much information may make symptoms worse and talk about the 
problem of ‘over-medicalisation’. Patient groups have expressed the concern that 
neurologists might consider self-help as the only required treatment, instead of 
considering further face-to-face treatment. 
We argue that communicating the diagnosis as clearly as possible to patients is 
a legitimate expectation of any healthcare interaction and it would be unethical 
not to do so. However, the extent to which supplementing that with online self-
help material is beneficial or potentially harmful, is an important but unanswered 
scientific question.
Within the field of self-help a distinction is generally drawn between ‘guided’ and 
‘non-guided’ self-help. In guided self-help the patient returns to see a healthcare 
professional, who monitors progress with the provided information, guides self-help 
exercises and gives advice. A study that tested such an approach in a more general 
group of  FND patients found modest improvements in the intervention group and 
no harmful effects [11]. However, although much more widely used, there is far 
less evidence about unguided self-help, apart from a small number of non-guided 
interventions in whiplash injury, fibromyalgia and irritable bowel syndrome with 
mixed results in meta-analysis [12]. No such studies have been performed in FND. 
For this study we developed a non-guided web-based programme for use by patients 
with motor FND. Our model of motor FND was of involuntary motor symptoms 
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arising from disordered nervous system functioning. This includes changed 
predictive processing [13], occurring in the context of predisposing, precipitating and 
perpetuating factors that vary considerably between patients and may be biological, 
psychological and/or social in nature [14]. Our underlying premise was that the 
intervention would improve patients’ understanding of the disorder and encourage 
patients to take an active role in their treatment, leading to improvement on clinical 
meaningful outcomes.
We aimed to test the hypothesis that provision of this website added to usual care, 
improved the self-rated health status in patients with motor FND compared to usual 
care only. Our primary outcome was self–rated clinical global improvement with 
secondary measures of severity of motor symptoms, other physical and psychiatric 
symptoms, physical functioning, quality of life, and work and social adjustment, 
illness beliefs and satisfaction with treatment and with the website intervention at 
three and six months. 
METHODS
Study design and procedures
This was a two-group parallel superiority non-blinded randomised controlled trial 
with patient-rated outcomes at 3 and 6 months. Between October 2015 and July 
2017, neurologists from 31 neurology centres across the Netherlands referred 
eligible patients to the study. These patients were informed about the study by email 
or post. After giving consent and completing the online baseline questionnaires, 
patients were randomised into two arms. The intervention group received access 
to the password-protected unguided education and self-help website as an addition 
to usual care. They were instructed to read the website at their own pace and 
preference. The control group received usual care only. ‘Usual care’ in both groups 
was not standardised and included any treatment patients received during the trial. 
Patients were not allowed to discuss medical problems with the investigator after 
randomisation. This was not violated. All outcome measures were self-report, using 
online questionnaires at three and six months. 
The SHIFT study was performed in accordance with the ethical and legal guidelines 
of the University Medical Center Groningen (METc 2015/141, M14.150920). All 
participants gave written consent. The trial was registered at clinicaltrials.gov 
(NCT02589886). 
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Participants 
Inclusion criteria were (1) 18 years of age or older; (2) functional motor symptom (limb 
weakness or movement disorder) diagnosed by a neurologist; (3) symptoms causing 
distress or impairment in social, occupational or other important areas of functioning 
or warrant medical evaluation (definition according to DMS 5); (4) able to read the 
Dutch language; and (5) access to a computer with an internet connection on a 
regular basis. We excluded (1) patients who were unable to provide informed consent; 
(2) patients with other (functional) complaints, in whom the motor symptom was an 
accidental finding; and (3) who were known visitors of the (previously available, but 
during the study offline) translated version of a website by JS (see below). Patients 
with co-morbid (neurological) disease were not excluded from the study. 
Intervention
The tested intervention was a newly developed educational website in Dutch, 
which included self-help elements. The content was in line with the explanatory 
biopsychosocial model described by Stone et al [15]. It combined elements of a 
website developed by JS, www.neurosymptoms.org, a self-help workbook developed 
for functional neurological symptoms [6] and expert opinion of JS, MT, JR, AC and GN. 
Fig 1. Overview of the non-guided self-help website. Left panel shows examples of pages 
and descriptions of the content of the four blocks on general FND (1), specific motor symptoms 
(2) that patients could choose (2), rehabilitation advice, exercises and information on treatment 
possibilities (3) and on the influence of FND on daily life (4). The right panel shows the different 
media that were used to provide information, that were mostly newly developed for this study. 
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The website consisted of four blocks focusing on different domains, and included 
several different sources of information (figure 1). The website also included 
exercises adapted from physiotherapy recommendations from Nielsen et al [16]. 
It was piloted and altered based on the feedback of 12 patients and their family 
members for intelligibility, clearness, relevance and applicability. Readability scored 
level B1, with a moderate Douma readability score of 64 out of 100 (based on the 
English Flesh-Kincaid test), corresponding with a reading age of 13/14 (adjusted for 
‘functional’ and ‘disorder’).
Outcome Measures
The main outcome was self-rated health, measured on the Clinical Global 
Improvement (CGI) scale, a seven-point Likert scale (high scores correspond to 
poor health) at three and six months. 
Secondary outcome measures were: severity of all individual motor symptoms (self-
rated change in presenting symptom scale (CPS) (range 0-7), fatigue (Checklist 
Individual Strength (CIS), fatigue severity subscale (range 7-56)), pain (RAND36, 
the Dutch equivalent of the SF36, subscale (range 0-100)), depressive symptoms 
(Patient Health Questionnaire-9 (PHQ-9) (range 0-27), anxiety (Generalized Anxiety 
Disorder Questionnaire (GAD-7; scores 0-14)), health anxiety (Whitely Index (WI-7 
range 0-7), health related quality of life and functioning (RAND36) and quality of life 
(using a single question from the WHO Quality of Life scale “How would you rate your 
quality of life” (five-point Likert scale, 5 representing good quality of life) (Group, 
1998), work and social adjustment (Work and Social Adjustment Scale (WSAS range 
0-40)). Illness perception, satisfaction with care and confidence in physiotherapy 
and psychotherapy were assessed by the level of agreement on a five-point scale on 
several statements, partly derived from the Illness Perception Questionnaire (IPQ) 
(see table 1 and 2) and the patient satisfaction questionnaire (PSQ). Additionally, 
hospitalizations, visits to other websites on FNS and other treatments were 
recorded. Open fields were available for additional comments, including comments 
on improvement if that occurred. 
A combination of patients’ self-report and the number of times they logged on to the 
website was used to record use of the website. Evaluation of the intervention website 
was carried out by agreement on a series of statements on a five-point scale (Not 
at all – strongly agree) (table 3).  If patients did not fill out the online questionnaires, 
they were contacted by phone at 6 months to assess the main outcome, change in 
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presenting symptoms, quality of life and agreement with the statements ‘I would 
recommend this website to other patients’ and ‘the website helped me a lot’. 
Baseline data from this study was used in another publication on fatigue severity [17]. 
Sample size
Sample size calculation, using Fisher’s exact proportions for independent groups test 
in G-power version 3.1.7 software, was based on the expected percentage of patients 
showing any improvement on the CGI self-rated health scale (all scores below 4 ‘no 
change’).  Based on a previous RCT on self-help [18], our prognosis review [19] and a 
pilot study of 10 patients in which 40% of patients improved, we estimated that 20% 
of patients would improve in both groups and an additional 20% in the intervention 
group. With an alpha of 0.05 and a power of 0.80, a two-tailed calculation resulted 
in a sample size of 90 patients per group. To anticipate drop out, we aimed for 100 
patients per group. No interim analyses were performed. 
Randomisation and blinding
Block randomisation with stratification, with a ratio of 1:1 into the intervention and 
control group, was performed by an online randomisation tool, ALEA, programmed 
by the Clinical Research Desk of the University Medical Center Groningen. 
Stratification factors were having limb weakness as a main motor symptom and 
duration of symptoms > 1 year. 
Patients were not blinded to the intervention allocation, because of the obvious 
difference between the two groups (with and without access to the website). 
Investigators were not blinded: outcome measures were collected remotely via 
an online form (with equal procedures in both groups), without interference of the 
investigator. All research data was anonymised before analysis. 
Statistical analysis 
An intention to treat analysis was performed at three and six months post 
randomisation. A between x within design was used, by subtracting outcome and 
baseline values and comparing the differences between groups. Mann-Whitney-U 
tests (using the whole scale) and Chi-squared tests were used for non-parametric 
and t-tests for normally distributed variables. 
For the main outcome, missing data were imputed, by means of multiple imputation 
methods using linear regression in SPSS (version23). We imputed missing data 
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based on all baseline and follow-up variables, generating 5 new datasets. These 
were used for a sensitivity analysis (to explore the effect of dropout). In the data 
displayed in tables and outcomes below, data without imputation is provided.
An additional per protocol analysis was planned, excluding patients who never logged 
on to the website from the intervention group, to investigate if the website itself has 
a beneficial effect, but would need promotion. 
Post-hoc we analysed the effect of change between baseline and follow-up on 
agreement with the statements  ‘I am confident that the diagnosis functional disorder 
is correct’, ‘My disorder is a mystery to me’ and ‘What I do determines the outcome 
of my disorder’ on the main outcome. Furthermore, we investigated a limited number 
of possible prognostic factors (baseline factors that influence outcome):duration of 
symptoms, type of referring center (academic vs non-academic), age, gender, and 
the same illness perception statements as listed above. For these correlations, we 
used univariable ordinal regression models. First in the entire cohort, and secondly 
with randomisation group to the model, to investigate if these associations between 
groups.
Due to multiple comparisons, secondary outcome measures were interpreted 
conservatively with p values of greater than 0.01 treated with caution. 
Data availability statement
Data is available on request from the authors 
RESULTS
Participants
355 patients were screened for eligibility, of whom 186 participated in the study. 
Randomisation resulted in 93 patients for each group at baseline. The flowchart 
(figure 2) summarizes reasons for exclusion and loss to follow-up. 
Reasons for not visiting the website varied. At three months, some patients reported 
forgetting about it (n=4), believing (n=2) or being concerned (n=2) about undesirable 
content, alleviated symptoms (n=1), scepticism regarding diagnosis (n=1), and various 
additional reasons. Between three and six months most patients (n=44) ceased 
further website visits, primarily due to improved symptoms (n=7), having fully 
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read the website (n=8), being focused on a different treatment (n=5,); and severe 
symptoms and/or impaired concentration (n=5). Two patients disagreed with the 
content citing: dislike of the term ‘disorder’ and uninformative content; another two 
‘did not feel like’ visiting the site.
Fig 2. Flow diagram (adapted from CONSORT). *Data was missing at three months, but 
present at six months (and therefore these participants were not lost to follow-up). 
Baseline
The majority of patients were female (72%) and many were out of work (74%), 
mainly for medical reasons. Mean duration of symptoms was 5.7 years. Self-rated 
severity of motor symptoms was moderately severe to very severe in 82% of cases. A 
majority of patients reported confidence that the diagnosis of a functional movement 
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disorder was correct (62%), however 54% felt the disorder was a mystery to them. 
Patients reported poor quality of life (only 30% had good or very good quality of life), 
physical functioning was impaired (median 40 out of a 100 (100 corresponding to 
unimpaired functioning) and 26 out of 40 on the work and social adjustment scale 








Age in years, mean (SD) 48 (15) 49 (15)
Sex, % female 73% 70%
Not in work
For non-medical reasons
On health-related benefits < 2 years









Referring center (% academic hospital) 55% 55%
Symptoms
Duration of motor symptoms in months, mean (SD) 70 (108) 66 (105)
Severity all presenting motor symptoms (CPS) (% moderately 
severe/severe/very severe)
81% 82%



















Pain (RAND36) median (IQR) 45 (55) 57 (47)
Fatigue (CIS severity), median (IQR) 44 (16) 46 (17)
Depression (PHQ9), median (IQR) 9 (9) 7 (7)
Anxiety (GAD7), median (IQR) 6 (10) 5 (9)
Health Anxiety (WI), median (IQR) 3 (2) 3 (2)
Self-rated health, quality of life and functioning
Self-rated health (CGI),% moderately bad and bad and very bad 43% 39%
Quality of life (WHO-QoL), % good and very good 32% 29%
Physical functioning (RAND36) median (IQR) 40 (45) 40 (50)
Work and social adjustment (WSAS), median (IQR) 26 (18) 26 (15)
Illness beliefs and satisfaction with care (% agree and strongly agree)
I am confident that the diagnosis functional disorder is correct. 63% 61%
I am afraid that something (e.g a possible serious diagnosis) has 
been missed when making the diagnosis.
15% 17%
My symptoms are caused by stress/worry or psychiatric 
problems in the past
19% 25%
Functional movement disorders are disorders of the nervous 
system
56% 51%
My disorder is a mystery to me (IPQ) 56% 48%
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What I do determines the outcome of my disorder (IPQ) 54% 63%
My disorder is rather permanent then temporary (IPQ) 51% 48%
I think physiotherapy will improve my symptoms 37% 33%
I think psychotherapy will improve my symptoms 19% 17%
I have confidence in my neurologist 65% 58%
My neurologist and I agree on the nature of my symptoms 61% 52%
I would recommend the care I received to other patients 27% 31%
Communication with doctors (PSQ) 3 (1) 3 (1)
Interpersonal relation doctors (PSQ) 4 (1) 4 (1)
Technical quality of doctors (PSQ) 3 (1) 3 (1)
Table 1. Baseline data by treatment arm. Higher scores represent bad outcome in: CGI, CPS, 
CIS, PHQ, GAD, WI, WSAS, higher scores represent good outcome in: RAND36. CPS= change in 
presenting symptoms scale, RAND36 = Dutch equivalent of SF36 Health Related quality of life, 
PHQ-9=Patient Health questionnaire, GAD-7 = Generalized Anxiety Disorder Questionnaire 
health anxiety WI=Whitely Index, WHO-QOL = a single question from the WHO Quality of 
Life (Group, 1998), WSAS = Work and Social Adjustment Scale, IPQ = Illness Perception 
Questionnaire (IPQ) (see table 1 and 2) and the PSQ = patient satisfaction questionnaire. 
All statements on illness and satisfaction agreement were measured on 5-point Likert 
scale (1=totally disagree, 2 =disagree, 3 = agree nor disagree, 4 = agree, 5 = totally agree), 
percentages are displayed for readability, statistics were performed on the whole scale.
OUTCOME 
Main outcome
At three months, 44% (n=31) of patients in the intervention group reported 
improvement of their general health (‘minimally’, ‘much’ or ‘very much’ improved), 
compared to 40% (n=26) of the controls on the CGI, the Mann-Whitney U test on the 
whole scale provided U=2247, p=0.899. At six months, 42% (n=35) of patients in the 
intervention group reported to have improved, compared to 43% (n=34) in the control 
group (U=3087, p=.435). Figure 2 shows the CGI scale for both groups.  
The sensitivity analysis with imputed data did not result in a different main outcome. 
To investigate potential harm, the number of patients with worse general health on 
the CGI was compared between groups. At three months 20 (29%) patients in the 
intervention group reported worse general health, compared to 18 controls (28%) 
(U=2255, p=0.910). At six months 30 patients in the intervention group (36%) had 
worse outcome, compared to 21 controls (27%) (U=3015, p=0.210). 
The per protocol analysis (where patients that never logged on to the website were 
excluded from the intervention group) did not show a significant difference between 
groups either (see supplementary table 1). 
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Figure 3. Main outcome, change in self-rated general health at three and six months compared 
to baseline in both groups. 
Secondary outcomes
There were no differences between groups on any of the outcome measures at three 
and six months follow-up, using a cut off for statistical significance of p<0.01.
Symptom severity of all functional motor symptoms improved in less than half of 
the patients (between 40 and 44%) at 3 and 6 months in both groups compared to 
baseline. Depression scores were significantly higher in the intervention group than 
in the control group at baseline, while at three and six months this equalized. Anxiety 
and health anxiety remained stable over time in both groups, as well as pain, fatigue, 
physical functioning, quality of life and work and social adjustment.  
There were no significant differences between groups on the illness perception 
questions. Agreement with the statement ‘I am confident that the diagnosis of a 
functional disorder is correct’ was higher in the intervention group (62%) than in the 
control group (47%) at three months, but this did not reach significance (p=0.014). 
Less than half of the patients (36% of controls vs 41% of patients in the intervention 
group at 3 months, p=0.089 and 26% vs 41% at 6 months, p=0.052) believed 
physiotherapy would improve their symptoms, and an even smaller number believed 
psychotherapy would improve their symptoms (20% of controls, 27% of patients 
in the intervention group, p=0.101 at 3 months, 19% vs 20%,p=0.963 at 6 months), 
neither changed significantly over time. Overall satisfaction with their clinical care 
(i.e. care other than the website) increased slightly over time (at baseline 29% of 
patients would recommend their clinical care to others, at  3 months follow-up 36% 
of controls vs 54% of patients in the intervention group, at 6 months 38% vs 47%). 
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There were no statistically different outcomes from the per protocol analysis 
(supplementary table 1).
Other websites and other treatments
During the study, four patients in the intervention group and three patients in 
the control group reported to have read information on the English website 
neurosymptoms.org. 12% of patients in the intervention group and 20% in the control 
group (Chi squared 2.5, p=0.111) visited one or more other related websites.  
In the first three months, 69% of the patients in the intervention group received 
physiotherapy and 68% in the control group. Respectively 33% and 37% received some 
form of psychotherapy. 19% of the intervention group and 15% of controls reported to 
have received no therapy at all. Between three and six months, 49% of the intervention 
group and 50% of controls received physiotherapy, 23% and 26% respectively received 
psychotherapy and 17% / 18% respectively reported to have received no therapy. 
Hospital admissions
Twelve patients in the intervention group (14%) were admitted to the hospital during 
the six months follow-up period; related to motor FND (n=6) unrelated (n=4) missing 
information (n=2). Twelve controls (15%) were admitted to the hospital during the 6 months 
follow-up period; related to motor FND (n=7), unrelated (n=4), missing information (n=1).
Post-hoc correlations
Correlation between baseline variables and outcom
Duration of symptoms of more than 6 months at baseline (mean duration at baseline 
was 5.7 years) was associated with bad general health outcome at six months in a 
univariable logistic regression model, odds ratio (OR): 2.80 (1.45-5.42) p=0.002. 59% of 
patients with short duration improved, compared to 37% with long (>6 months) duration 
of symptoms. This relationship was stronger in the intervention group (interaction group 
x duration of symptoms, OR 1.84 (1.05-3.20), p=0.033), although not significantly. Outcome 
was worse in men (28% of patients were man), OR 2.94 (1.58-5.48) p=0.001, which was 
not significantly different between groups. A number of variables were not significantly 
associated with outcome in the entire cohort, nor in the groups separately: The referring 
centre (55% of patients were referred from an academic center) (OR: 1.49 (0.86– 2.60), 
p=0.158), older age at onset (OR 1.02 (1.00 – 1.04), p=.026), ‘I am confident that the 
diagnosis functional disorder is correct’ (62% agreed), OR 1.14 (0.84-1.55), p=0.405. 
‘My disorder is a mystery to me’ (52% agreed) OR 1.07 (0.86-1.33), p=0.533. ‘What I do 
determines the outcome of my disorder’ (58% agreed) OR 0.98 (0.77-1.24), p=0.877. 
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Correlation between change in illness perceptions and outcome
The effect of change in understanding the diagnosis (measured on a change on 
three illness perception questions) on the main outcome at six months (general 
health on the CGI) was investigated by univariable ordinal regression. An increase 
in agreement from baseline to six months with ‘I am confident that the diagnosis 
functional disorder is correct’, provided an odds ratio of 1.43 (1.12-1.83), p=0.004 with 
good general health (CGI) at six months in the entire cohort. When the randomisation 
group was added as an interaction term, the odds ratio was 1.42 (1.01-2.00), p=0.044, 
indicating there was a trend towards a bigger effect in the intervention group. A 
decrease in agreement with ‘My disorder is a mystery to me’ (odds ratio 1.30 (1.02 
– 1.63), p=0.033), and an increase in agreement with ‘What I do determines the 
outcome of my disorder’ (odds ratio: 1.13 (0.93– 1.36), p=0.234), were not significantly 
associated with outcome.
Evaluation of the education and self-help website
63 patients in the intervention group (74% of the 85 that viewed the website at least 
once), filled out the evaluation. 86% of patients reported they would recommend 
the website to other patients, 68% of patients found the website very useful, and 
67% performed the exercises provided on the website at some point during the 6 
months follow-up. 
A smaller number of patients answered more detailed questions evaluating the 
website (n=55). 78% agreed with the explanation of their symptoms that was provided 
on the website, 89% found the information on the website was easy to understand, 
22% perceived difficulty in taking in the information, 49% agreed the information on 
the website matched the explanation given by the neurologist they had seen for their 
symptoms, and 75% reported they would want to keep on using the website in the 
future. Of them, 9% reported they felt angry or misunderstood (for divergent and 
sometimes multiple) reasons: the website was patronising (n=2), too negative (n=1), 
a specific symptom the patient suffered from was not mentioned (n=1), the website 
created a stronger focus on the symptoms, which was unhelpful (n=1), physical 
exercises made the symptoms worse (n=1), there was a discrepancy between the 
opinion of health care providers in reality and the information on the website (n=1). 
In additional comments, patients mentioned they experienced health care providers 
seemed to lack knowledge on functional neurological disorders (n=10), which either 
impeded treatment generally, or it made the website less helpful because of the 
lack of connection with their experience of healthcare (some felt this was highly 
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frustrating). Others remarked the website was actually helpful to educate their health 
care providers and/or explain the disorder to relatives and friends.  Several patients 
(n=10) mentioned they felt heard after reading the website and felt it validated their 
experiences, or they were relieved to see other patients had very similar symptoms 
and impairments.   Three patients asked for an overview of health care providers 
with experience in this field or a patient-forum (n=3). 
DISCUSSION
In this randomised controlled trial there was no difference in self-rated general 
health on the clinical global improvement scale at three or six months between 
motor FND patients who were directed towards an education and self-help website 
in addition to usual care and patients who received only usual care. Nor were there 
significant differences on the secondary outcomes (severity of motor symptoms, 
other physical and psychiatric symptoms, physical functioning, quality of life, 
work and social adjustment, or illness beliefs (including beliefs of the effect of 
physiotherapy/psychotherapy and satisfaction with care)). Patient satisfaction with 
the website was high. The per protocol analysis results were similar to the primary 
intention to treat analysis. 
Our results suggest non-guided online self-help is not effective as a sole addition to 
usual care for motor FND. There are no studies of unguided self-help and education 
for motor FND to compare our data with. A meta-analysis of self-help in the broader 
group of functional syndromes (chronic pain, chronic fatigue and irritable bowel 
syndrome), showed improvement of quality of life and/or symptom reduction of both 
guided and unguided self-help, although outcome measures were heterogeneous 
and there were only five unguided studies [12]. A recent meta-analysis of treatment 
modalities in depression, also showed unguided self-help therapy was not more 
effective than care as usual, while guided self-help was [20]. Our findings support 
patient group concerns, for example expressed by individual patients and patient 
organisations [28] that an unguided self-help website should not be regarded as 
all that is needed to manage motor FND. Motor symptoms improved in roughly two 
out of five patients spontaneously after diagnosis. This suggests that neurologists 
should follow FND patients up after diagnosis to monitor early improvement and to 
direct the remaining three out of five patients to further treatment, and not rely on 
the provision of information alone as treatment. 
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Providing patients with reliable and accessible information does not need to resolve 
or even improve symptoms in order to be justifiable. We showed no additional harm 
was done by the intervention (bad outcome and hospitalisations were as frequent 
in both arms). It is notable that the intervention was well received. 78% agreed with 
the explanation of the disorder on the study website, and 86% of patients reported 
they would recommend the website to other patients. Although it did not lead to 
demonstrable improvements in health status, 68% of patients reported they found 
the website very helpful. The website appeared to provide a sense of ‘acceptance’ 
and a feeling of being ‘heard’, which is a worthwhile goal in its own right. 
Explanation and education remain, in our view, an essential element of stepped 
care for motor FND. Improved confidence that the diagnosis was correct correlated 
with improvement in health across the whole cohort, and to a greater extent in the 
intervention group, although the latter did not reach the predetermined threshold 
(p<0.01) for significance. Nonetheless this suggests the right direction of travel 
in terms of improving understanding. Treatment studies of motor FND using a 
comparable educational model, either as a guided self-help intervention [11], or 
combined with physical and cognitive behavioural interventions in inpatient [21–23] 
or outpatient [24, 25] settings, have shown favourable outcomes. In practice though, 
patients often experience  lack of availability of expert knowledge, as reflected in 
patients’ written comments and the finding that only half (49%) of the patients agreed 
that the information from the website matched with the explanation of the neurologist. 
This is a problem recognised by physicians in the field [26] and emphasises the need 
for consistency between health professionals caring for the same patient. 
The study had several limitations. Patients in our study had a long duration of 
symptoms (mean of 5.6 years), which may have negatively influenced outcomes, as 
we found that symptom duration correlated to worse outcome. Prognostic studies 
[3] in general have found that a longer duration of symptoms correlates with poorer 
prognosis. Early intervention seems beneficial in some conditions commonly 
comorbid with motor FND [27, 28]. 
The fact that we employed liberal inclusion criteria and advertised the study broadly 
(with good result: 31 centers, both academic and non-specialised, referred patients), 
improved generalizability. This is to date the largest RCT in any FND. Also, the 
overall improvement of motor symptoms in 40-44% of patients is comparable to 
other cohorts [29, 30]. However, selection bias most likely occurred at patient level 
(patients who did not believe the diagnosis were less likely to enrol), and physician 
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level (neurologists with an interest in FND would be more likely to refer into the 
study). A large number of patients (n=128) refused to take part, In addition, 17 patients 
never completed the baseline questionnaires and many patients only viewed the 
website a few times. Follow-up rates were 70 % vs 75% in the control vs intervention 
group at three months and 85% vs 90% at six months. 
Outcomes might have been influenced because the study was not blinded, a nocebo 
effect in the control group could have occurred. However, this effect is likely to be 
small in this low-intensity study. Use of alternative websites like neurosymptoms.
org was low and equal between groups. Furthermore, the study website was 
different to the neurosymptoms.org, in that it provided a programme of information 
to work through, and numerous videos and examples not available elsewhere. Our 
patient cohort might have been too small to capture subtle differences in secondary 
outcomes. The follow-up period was relatively short and therefore long-term effects, 
for example on compliance with or effect of further treatments might have been 
missed. The fact that the study was internet-based, compared to on paper, did not 
appear to cause problems in inclusion or follow-up in the large majority of patients. 
CONCLUSION 
In this first randomised controlled trial of an online education and self-help 
programme for motor FND, we found it was well received but it did not lead to 
improvements in self-rated general health on the clinical global improvement scale 
at three or six months. Nor did it lead to any harmful effects. Furthermore, there 
were no differences between groups on any secondary outcome measures.
Overall, our findings support neurologists offering supplementary self-help 
materials at time of diagnosis, but we caution that such materials should not be 
regarded as efficacious treatment in their own right. 10
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Summary and general discussion
In the introduction we drafted how developments within the field of FMD in the last 
decade were the basis for the outline of this thesis. From these developments, we 
postulated new questions concerning the topics of the pathophysiology, prognosis 
and treatment of FMD. Below, we summarize the most important findings from each 
chapter within these three themes. This is followed by a more in depth discussion 
on a number of topics originating from our results: lumping and splitting, sense of 
agency and the measurement of outcome in FMD. Furthermore, we will discuss the 
implications of these findings for future studies and for clinical practice. We will 
finish with a number of personal reflections that arose during the work on this thesis.
RESULTS OF THE THESIS
Part 1. Pathophysiology
To better understand FMD, both clinical observation and experimental studies are 
needed. Clinical observational studies give insights in underlying mechanisms and 
provide us with new hypotheses. Experiments can challenge these hypotheses and 
unravel the specific mechanisms underlying FMD.
Clinical aspects
The clinical picture of FMD is heterogenous in terms of symptoms, risk factors, 
triggers and co-morbidity. Even within the same patient the type, severity 
and localization of FMD symptoms can change over time. Although not often 
systematically investigated, many studies have shown large numbers of additional 
functional and psychiatric symptoms in patients with FMD. There is a growing 
realization of the importance of non-motor symptoms in FMD.
Chapter 1 described a comparison between patients with different functional motor 
symptoms. The main motor symptom was categorised by the neurologist, resulting 
in the following groups: tremor, myoclonus, dystonia, paresis and gait disorder. We 
investigated demographics, mode of onset, non-motor symptoms, quality of life and 
functioning and self-rated additional motor symptoms. There were no differences 
between groups, except that impairment of physical functioning was worse in 
patients with functional paresis or gait disorder as the dominant motor symptom.
In chapter 2 we compared fatigue between the patients included in the SHIFT trial 
(chapter 10) and a group of patients with neuromuscular disorders [1]. We used 
the checklist individual strength (CIS) fatigue questionnaire, which contains four 
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subdomains of fatigue. Patients with FMD had higher scores compared to the group 
of neuromuscular disorders on all these subdomains (fatigue severity, motivation, 
concentration, physical activity). Severe fatigue (>34 on the fatigue severity 
subdomain) was present in 78% of patients with FMD, compared to 53% of patients 
with neuromuscular disorders (p < 0.001). We found fatigue, but not symptom 
severity, influenced self-rated general health and quality of life in FMD. We found 
correlations between fatigue and motor symptom severity, depression and anxiety. 
Therefore fatigue is most likely both a co-morbid symptom as a consequence of 
(chronic) multimorbidity.
In chapter 3 we found that fatigue, depression and anxiety were as high in 
functional myoclonus as in (‘organic’) cortical myoclonus. Pain was the only non-
motor symptom that was worse in functional myoclonus. Additionally, we found 
that functional myoclonus severity was correlated to anxiety and depression, while 
this was not the case in the cortical myoclonus group. Despite the limitations of a 
small sample size (functional myoclonus n=16, cortical myoclonus n=23) in a tertiary 
clinic, we concluded that both functional and cortical myoclonus patients suffer from 
comorbid psychiatry to the same extent. This contradicts often held beliefs that 
functional movement disorders would be more strongly associated with psychiatric 
comorbidity. We found that the relationship between anxiety and depression and 
functional myoclonus is most likely bidirectional.
Experimental aspects
In the experimental studies that we performed, the concepts of sense of agency, 
attention to the self and perception of body scheme were central.
In chapter 4 we describe an experiment in which we aimed to elicit a decrease in the 
sense of agency when performing a motor task (pressing a button), by manipulating 
the feedback patients received. This manipulation consisted of a variable delay in time 
between button press and the sound resulting from that. Subjects were asked if they 
felt they were the cause of the sound that followed a button press, or not. This was 
performed in the same patients and healthy controls that underwent fMRI scanning 
in chapter 5 and 6. We did not find differences between groups. We concluded that 
the chosen paradigm most likely does not resemble the exact element of sense of 
agency that is disturbed in FMD. Explicit sense of agency, which is considered to be 
conceptually different from implicit sense of agency [2], might be less affected than 
implicit sense of agency in FMD.
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In chapter 5 and 6 we performed two different fMRI paradigms, in a group of 17 
patients with functional tremor and/or jerky movements, compared to 17 healthy 
controls.
In chapter 5 we performed an action selection task fMRI study to investigate the 
neural correlates of perception of body scheme and sense of agency in FMD. In 
this action selection task, subjects were alternatingly choosing or instructed to use 
either a finger of a button, resulting in two axes of comparison: free versus fixed 
and button versus finger selection. We confirmed findings in healthy controls of 
predominantly prefrontal and parietal activations in free versus fixed conditions; 
the opposite contrast showed the extra striate visual cortex and activation along the 
dorsal intraparietal sulcus. In finger versus button selection, we found activations 
of the occipital and anterior parietal cortices, including the postcentral sulcus. This 
reaffirmed the notion that voluntary action resides in both prefrontal areas and 
the parietal cortex [4, 5]. In FMD compared to healthy controls, we found reduced 
activation of the left primary motor cortex in the conjunction of all motor conditions, 
attributed to disrupted explicit motor control in FMD. This finding fits with the notion 
that patients are experiencing difficulties ‘accessing’ normal initiation of movement, 
as often vocalized in clinical practice. The left insula showed reduced activity in 
free finger selection and activity of the insula in this contrast was also correlated to 
symptom severity in patients. This confirmed our hypothesis of alterations in sense 
of agency and perception of body scheme in FMD, and confirmed earlier studies 
showing involvement of the insula [6–8].
In chapter 6 we performed an exploratory resting state study, investigating brain 
networks using a data-driven approach: independent component analysis. We found 
altered regional brain activity in the component consisting of the (pre)cuneus and 
posterior cingulate cortex (PCC), consisting of decreased power of lower-range 
frequency fluctuations and increased power of upper-range frequency fluctuations. 
Both the (pre)cuneus and PCC network, as well as the cuneus and inferior parietal 
lobe are known to be involved in attention shifting and sense of agency. Although 
the time course fluctuations have been found to correlate with altered brain activity 
and with other measures of functional connectivity[3], they are relatively unexplored. 
This impedes too strong conclusions concerning these time course fluctuations. Our 
findings confirm the role of brain regions implicated in sense of agency and altered 
attentional processes in FMD.
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The most noticeable aspect of the combined findings of chapter 5 and 6 is the scarcity 
of differences between FMD and healthy controls within the resting state whole 
brain approach in chapter 6, while more outspoken differences were found when 
testing the specific hypothesis in chapter 5. This indicates differences in brain activity 
between groups might be subtle and specific.
Part 1 Implications
Based on our studies and the literature, we concluded that similar to patients with 
non-functional movement disorders, non-motor symptoms like pain and fatigue 
and psychiatric co-morbidity, should not be underestimated in FMD and need more 
attention in history taking, treatment studies and treatment strategies.
The findings from our fMRI studies confirm the theories of altered direct motor 
control, abnormal sense of agency and perception of body scheme. Amongst others, 
this underpins the role of focusing on relearning normal, automatic movements to 
‘retrain the brain’ in the treatment of FMD.
Part 2. Prognosis
In order to determine the prognosis of FMD, we performed a systematic review 
(chapter 7) and the largest and longest follow-up study in FMD (limb weakness) 
(chapter 8).
The systematic review of 24 mostly retrospective studies that were heterogeneous 
in terms of size, follow-up duration and clinical setting showed a rough mean 
percentage of patients that were the same or worse at follow-up for all studies of 
39%, (range 10% - 90%). We also found that poor symptom outcome goes hand-
in-hand with a loss of quality of life and impairment. That indicates a generally 
unfavorable prognosis of FMD.
Chapter 8 is a follow-up study of a large cohort of patients with functional weakness, 
a control group of patients with neurological disease causing limb weakness, and 
a healthy control group [9]. Symptom outcome in our study was largely the same 
as in the systematic review: 20% of patients had totally remitted functional motor 
symptoms at follow-up. Compared to the control group of neurological disease, 
functional weakness did improve more often over the 14 year follow-up period. 
However, most secondary measures (like general health, physical functioning 
and work) showed FMD patients and neurological controls had comparably bad 
outcomes, which were significantly worse than in the healthy control group.
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Misdiagnosis was very rare (1 patient in the FMD group and 1 neurological control 
were misdiagnosed), which confirms a literature overview [10], and a large prognostic 
study in FND [11].
Death rate in the functional weakness group was higher than in the healthy 
population, but no deaths were linked to the initial functional symptoms. Explanations 
of this increased death rate should be interpreted cautiously, because of the small 
group (n=11 deaths in the FMD group). Still we found the higher death rate in FMD 
is most likely due to the negative biopsychosocial side effects of having a chronic 
illness.
Prognostic factors were difficult to determine in both studies. From the systematic 
review, short duration of symptoms, early diagnosis and high satisfaction with care 
predicted positive outcome. Sex had no effect. Delayed diagnosis and personality 
disorder were negatively correlated with outcome. Prognostic factors that varied 
between studies included age, comorbid anxiety and depression, intelligence, 
educational status, marital status and pending litigation. In our follow-up study 
there were only univariable baseline predictors for weakness outcome: somatization 
disorder, general health, pain, and total symptoms.
The most important limitation from both studies is that the majority of patients had 
a long duration of symptoms prior to inclusion, while this is correlated with worse 
outcome. The data might therefore not be representative of acute functional motor 
symptoms. For chronic FMD prognosis seems unfavourable, especially in a tertiary 
setting, while misdiagnosis is rare and prognosis remains difficult to predict on an 
individual level.
Part 2. Implications
The follow-up data from the systematic review and prognostic study can add to a 
realistic explanation of the natural history of FMD to patients. It endorses FMD is a 
potentially reversible disorder. However, it is important to realize that FMD does not 
have a benign course when left untreated in a large number of patients. Our data 
urge physicians to take FMD seriously. It also seems advisable to start treatment 
early (long duration of symptoms was the strongest predictor of poor prognosis). 
Also, the data lend urgency for treatment studies.
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Part 3. Treatment
Well conducted treatment studies in FMD are rare. In chapter 9 we reviewed the 
literature on treatment for FMD. Studies with the aim to explain the diagnosis and 
retrain normal movement, sometimes combined with psychological treatments 
in a multidisciplinary setting, have been found to improve symptoms and general 
health outcomes. However, evidence on psychological treatments is lacking and 
only a small number of studies investigated multidisciplinary treatments. Although 
a stepped care approach is highly recommended, this is merely a utopia in clinical 
practice, where treatment options are very scarce. Fortunately, since the beginning 
of this thesis, promising results have been published. After the publication of our 
review, a feasibility trial into physiotherapy for FMD was published, with good results, 
confirming the theory that retraining automatic movements using education and 
distraction techniques can be beneficial [12].
In our own randomized controlled trial, in chapter 10, we studied the effect of an 
online education and self-help website added to usual care, and compared it to 
usual care only. The content of the website matched the theoretical framework 
we describe in the introduction. We randomized 186 patients to usual care with or 
without website access, and found no difference on the main outcome, self-rated 
health on the Clinical Global Improvement scale at three and six months follow-
up between groups. There were no significant differences on secondary outcome 
measures either. However, patient satisfaction with the online intervention was 
high. In the entire cohort, we found a significant association between a change in 
confidence in the disorder and FMD outcome, which underlines the importance of 
education as part of treatment. Selection bias most likely occurred, because a large 
number of patients refused to take part and the majority of patients had long duration 
of symptoms. Still this is to date the largest randomized cohort study within the field 
of FMD, which adds important findings to the literature.
Part 3 Implications
Within FMD, evidence based treatments are scarce, but an increasing number of 
studies provide promising new insights. Our findings caution that self-help materials 
should not be regarded as the sole treatment approach.
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FURTHER CONSIDERATIONS
Lumping or splitting
In part 1, we have studied the role of non-motor features in FMD. We aimed to 
determine their importance, but we also compared patients with different main 
motor symptoms, studying a possible link between certain motor and non-motor 
symptoms. This touches upon the long-lasting discussion on lumping or splitting 
the different FND syndromes [13–15]. Whether FND syndromes should be lumped 
together and considered one disorder, or should be considered separate disease 
entities is a matter of debate. As they are often defined based on the symptoms and 
linked to their ‘organic’ counterpart (‘non-epileptic attacks’ for example), they end up 
in different health services. At the same time the underlying mechanisms of these 
syndromes share many similarities and they are all considered to be ‘functional’ 
in nature.
The argumentation to consider all functional syndromes as a single entity was 
best articulated by Wessely et al in 1999 [15]. The authors noted a large overlap 
between different functional syndromes making discrimination between phenotypes 
difficult. Secondly, they argue that patients share many characteristics like sex 
ratios, comorbid emotional disorders and etiological factors. Thirdly, they observed a 
comparable response to similar treatments across studies. In neurological functional 
disorders, a review paper comparing non-epileptic attacks and FMD concluded that 
similarities exceed the differences [13], while another review concluded the opposite, 
based on differences in non-symptom characteristics and mode of onset [14]. A 
recent paper also detected differences in personality traits and psychopathology 
between non-epileptic attacks and FMDs [16]. Patients with non-epileptic attacks 
had higher levels of neuroticism and depressive and anxiety symptoms, overall 
psychopathology, a greater history of sexual abuse and alexithymia and more 
dissociative symptoms. FMD patients had higher scores of conscientiousness.
Our results showed indications of large overlap in motor symptoms between groups: 
The majority of patients reported to have more than one motor symptom, and there 
was a significant number of patients (12%) that could not be classified into one 
main motor group by the neurologist because these patients had several equally 
impairing motor symptoms. Also, similarities in signs and symptoms between 
groups contributed to the hypothesis of a shared underlying mechanism of functional 
motor disorders. Our study does not resolve the lumping versus splitting debate. 
However, we did not find evidence for large differences in non-motor features or 
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in level of impairment between the different motor symptom groups. This means 
that stratifying FMD is not specifically helpful when measuring outcome or when 
randomizing patients in treatment studies (as we did in chapter 10).
In fact, the value of studying co-morbidity in FMD is debatable. One could argue, 
like we did with regard to the symptom of fatigue, that the different symptoms partly 
share a pathophysiological mechanism, and are therefore considered part of FND 
itself. However, since many of the non-motor co-morbidities that we studied are 
highly prevalent in other (non-functional) movement disorders as well, they could 
be non-specific consequences of having a neurological disorder. Also, the symptoms 
themselves might have limited discriminating value: almost all patients with FND 
report a large number of varying symptoms. That could implicate they are more 
likely to perceive physical symptoms in general, without an underlying reason for 
each symptom individually.
Naturally, it remains important to take note of all symptoms a patient experiences. 
Whether the treatment should be focused on shared factors between patients 
(for example in the underlying pathophysiology) or tailored to the symptoms is 
not clarified yet and was not the focus of the studies in this thesis. However, it 
seems reasonable that there will remain the need for symptom-based treatments, 
like in other movement disorders. Because of the large overlap, it is desirable to 
adapt a holistic view and aim (multidisciplinary) treatment at all symptoms patients 
experience, while health services are often not equipped to offer that.
Sense of agency
In the leading explanatory theory on FMD, abnormal sense of agency and 
dysfunctional attentional processes play a key role. We performed two fMRI studies, 
the findings of both studies were compatible. The identified brain regions together 
form a network that is associated with sense of agency. This network has previously 
been described as consisting of: the lateral temporo-parietal cortex, medial frontal 
cortex, the dorsolateral prefrontal area, frontal operculum/insula regions and 
posterior midline structures, mainly the precuneus and posterior cingulate cortex 
[17]. Our key findings of involvement of the insula, parietal operculum and premotor 
cortex from the action selection paradigm (chapter 5) and the posterior midline 
structures (pre)cuneus and PCC, from the resting state data (chapter 6), match that 
network exactly. The data was derived from the same population, which makes this 
link stronger. Although studies have shown the involvement of many different brain 
areas in FMD, there is a growing body of evidence towards areas associated with 
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willed motor action and sense of agency. Imaging studies associated a number of 
brain regions with FMD, mainly comprising the insula, prefrontal regions and the 
parietal cortex, including the temporoparietal junction, as summarized in a recent 
meta-analysis and found in recent task-paradigms and resting state fMRI [6, 8]. 
These regions are strongly associated with willed action and sense of agency. Our 
data confirm that.
Additionally, our studies provided a link between the concepts of sense of agency 
and attentional processes, partly due to altered self-attribution to externally cued 
movements. This link can be explained by the phenomenon that enhanced attention to 
a motor task has a seemingly contradictory effect of reducing the feeling of being in 
control over that movement, thus reducing sense of agency. Attention and enhanced 
perceived effort (when movements are less automatic) could be partly overlapping 
concepts in that respect. This is shown in physiological studies in which movement 
control is impeded by enhanced attention [18].
Resting state findings of Maurer et al [7] showed decreased functional connectivity 
between the right TPJ and the right sensorimotor cortex, cerebellar vermis, bilateral 
supplementary motor area (SMA), and right insula in FMD compared to healthy 
controls. They suggest reduced sense of agency could result from the combination 
of distorted sensory perception and disturbed feed-forward motor control. The 
latter might be attributed to altered attention to movement, especially given the 
involvement of the SMA and insula. Thereby their data indirectly provides the same 
link between attentional processes and sense of agency.
fMRI studies have drawbacks impeding strong conclusions. Many different brain 
areas have been found to be associated with FMD in the different fMRI studies, 
mirroring clinical heterogeneity and revealing the influence of the large variety 
in study set-up [8, 19]. The study set-up is crucial in fMRI studies, and therefore 
conclusions should be confined to the experiment. On the one hand this is very 
helpful, as the experimental setting enables the opportunity to test very specific 
hypotheses. On the other hand there is a risk that results are interpreted within 
a set framework, while brain regions are known to have different functions, 
especially within networks. Like in our results, brain regions that we attribute to 
sense of agency, are not only involved in sense of agency, but also in many other 
functions. Within our experiment and in combination with the overall findings, it is 
very reasonable to interpret them as such, but it has to be noted that this is not the 
only possible explanation. Also, as most studies in the field are cross-sectional, it 
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is impossible to determine if the found abnormalities are cause or consequence 
of FMD and if they represent a state or a trait. Having said that, it is of interest 
that there is large overlap in fMRI findings between patients with dissociative 
non-epileptic attacks and FMD. Kruijs et al [20] performed a resting state fMRI 
analysis in dissociative non-epileptic attacks, and proposed a circuit based on their 
findings that has many resemblances with the findings from our studies. This circuit 
includes altered activity in the insula, cingulate gyrus, superior parietal lobe, pre- 
and postcentral gyri, supplementary motor cortex and the precuneus, within their 
network analysis. A comparative study confirms that there is overlap, when reviewing 
imaging studies into emotional dysregulation, dissociation and psychological trauma 
in the context of motor control in dissociative non-epileptic attacks and FMD [21]. 
Naturally, this is of interest to the above mentioned discussion on lumping or splitting 
functional syndromes.
Measuring treatment outcome
It is notoriously difficult to measure outcome in functional motor symptoms. Not 
only because their severity, symptom type and localization vary in time [22], but also 
because it is difficult to classify symptoms and to capture outcome that is meaningful 
for the patients. Here we discuss a number of considerations on measuring outcome 
in FMD, originating from our experiences in part 3.
The main topic of discussion is measurement by self-report, used in all studies in 
this thesis. In several chapters in this thesis we used patients’ self-report of the 
motor symptoms as outcome measure. This was on the one hand a drawback to the 
design, but on the other hand self-report can be regarded as the most meaningful 
way of capturing outcome, because patients’ own experience is more important than 
a doctors’ snapshot appraisal, especially given the variable nature of the disorder. 
When attempting to systematically investigate (other) treatments and functional 
co-morbidity during follow-up in both chapter 8 and 10, we met the limitations of 
self-report. Because of the limited standardized treatment options available for 
patients, patients have difficulty verbalizing what their treatments consisted of. 
There is no reliable registry of this either. As for functional co-morbidity, a study 
investigating a questionnaire designed for this purpose concluded that it remains 
difficult to distinguish if symptoms were functional or not based on self-report, even 
if the questions asked are based on discriminating features that are widely used by 
physicians [23].
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All studies in this thesis are limited by selection bias, which is very difficult to 
overcome in clinical research. Patients need to be informed and to provide consent, 
requiring them to at least acknowledge the diagnosis of a functional disorder, which 
can be a problem in FMD. Also, selection bias occurs at the level of symptom severity: 
patients at both sides of the spectrum (being very severely impaired or perceiving 
almost no impairment) are less likely to participate. In the SHIFT study, selection 
bias related to the referring neurologists might also apply: those with an interest in 
FMD were more likely to have heard of the study and could have been more eager 
to participate.
There are many difficult aspects of using (self-report) outcome measures in FMD. 
Imagine a patient with FMD who suffers from attack of myoclonus, fatigue and 
difficulty concentrating and who is worried about having all these symptoms, with 
increasingly a low mood. Should her symptoms of concentration problems and 
fatigue be considered part of a possible depressive disorder (considering her mood 
changes) or are they symptoms of the FMD? To what extent are mood changes a 
normal response to chronic illness or the lack of treatments available for FMD? And 
how can we study these different symptoms, when most questionnaires on these 
topics have overlapping questions? How should this patient fill out a questionnaire 
on physical impairment, when she only has impairing symptoms part of the time?
Scales that measure physical functioning are often more objective, but meant to be 
generic and therefore miss specific incapacitating symptoms (they measure walking 
distance, but do not include items for speaking or swallowing for example). Scales 
that measure subjective wellbeing, like the scales we used for general health and 
quality of life in most chapters, have the advantage of measuring outcomes that 
are meaningful to patients, but most likely represent different things to different 
patients. Also, within chronic and/or severe illness, interesting paradoxes have 
been described that limit their value. One example is the ‘response shift theory’, a 
phenomenon in which patients report better quality of life when they are ill, because 
they appreciate other thing in their lives more than when they were healthy [24]. 
It is difficult to capture actual outcomes, while preventing circular reasoning in 
analyzing data. When interpreting results of trials and cohort studies in FMD these 
are important considerations.
Finally, using self-report is influenced by participant reaction bias, which means 
patients adjust their answers based on expectations they have concerning the aim 
of questionnaires. One form, which seems likely to be present in FMD, is called 
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evaluation apprehension and refers to the concern of being judged based on certain 
answers [25]. In this thesis, it is likely that underreport of psychiatric symptoms has 
taken place. Patients that filled out questionnaires (as part of the fMRI studies) in 
the presence of the investigator, or patients who were questioned over the phone 
(in the prognosis study (chapter 8) or SHIFT study (chapter 10)), remarked they’d 
rather not admit to have depressive or anxious symptoms, because they feared 
this would be linked to the cause of their symptoms. Some indicated that these 
questions made them suspicious of the purpose of the study and the conviction of 
the research team on the nature of functional disorders. This in turn might have 
influenced their appreciation of the studied intervention. Stigma was also assumed 
be a factor in the explanation as to why FMD patients were less likely to agree that 
stress or worry was a cause for their symptoms (24% agreed) compared to patients 
with other neurological conditions (56% agreed, p<0.001) in the study by Stone et al 
that served as a baseline for the follow-up study in chapter 8 [9].
For most studies in this thesis we used the subjective clinical global improvement 
scale to overcome the difficulty in measuring symptom severity of FMD. Although 
not fine-grained, this clear 7-point Likert scale covers the average severity 
over a certain timeframe and thereby overcomes the problem of a snapshot 
measurement. It is used increasingly in FMD. Our studies would have benefitted 
from patient interviews and physical examinations alongside questionnaires, as this 
overcomes both the problem of rating functional co-morbidity and underreport. A 
recent recommendations paper by the EURONET-SOMA committee on outcome 
measurement in functional syndromes (comprising somatic symptom disorder, 
bodily distress disorder and functional somatic syndromes) underlines the value of 
interviews [26]. However interviews are less objective and cost more time and effort. 
The recommendations paper furthermore stressed the importance of testing patient 
satisfaction as an outcome measure, using the question ‘Would you recommend this 
treatment to another person/a friend with similar problems?’ In the SHIFT trial, we 
found patients were highly satisfied with an intervention that did not improve any 
other predefined outcomes. The intervention met meaningful needs of patients: being 
justly informed, getting recognition and feeling heard. It is important to realize these 
are in themselves important endpoints.
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FUTURE DIRECTIONS
Like we stated in the introduction, new findings provide new angles for research. 
Some of these future directions are discussed here.
Mechanism
To extend knowledge on sense of agency within FMD, using augmented/virtual 
reality is a logical next step. It is a promising way to manipulate sensory input and 
the experience of motor output, body scheme and attention. Nahab et al were the 
first to perform such a study in FMD [6]. Several ways to manipulate bottom up 
experiences of the outside world and the body itself, using either first person or 
third person perspective, could be studied. The use of virtual reality when studying 
the pathophysiology of FMD might have the additional benefit of a potential use for 
treatment interventions. Virtual reality is sometimes used within neurorehabilitation 
[27], and has been studied sporadically. For motor symptoms in for example stroke 
and PD, it does not always exceed the effect of real-life exercises [28, 29], although 
it seems helpful to improve the symptom of neglect after stroke [30]. It is reasonable 
to suggest virtual reality might be more helpful for motor symptoms in FMD than 
Parkinson’s disease or stroke, because motor expectations, sense of agency and 
attention play a larger role in FND, and these are presumably more susceptible to 
the effect of manipulation.
The notion that beliefs, or expectations, are crucial in the pathophysiology of FMD, is 
one of the reasons why education and cognitive therapy are thought to be effective. 
They are used to manage and alter beliefs. Within that framework, the role of 
suggestion in the treatment of FMD is often debated. The role of suggestion within 
FMD can be studied by looking at hypnosis. FMD patients were found to have higher 
hypnotic sensitivity [31] and hypnosis is sometimes used in treatment, although this is 
rarely studied. It has been argued hypnosis can be a model for functional symptoms, 
in the sense that alterations in mental representation and brain function occur 
through comparable mechanisms. A statement backed up by finding from imaging 
studies showing activity in overlapping networks in FND and hypnosis [32, 33]. In a 
comparable way, suggestion through placebo and nocebo effects have been linked 
to the mechanism and treatment of FMD. A strong placebo response is often found 
in treatment studies in FMD and the parallel with nocebo effects and the mechanism 
of FND has been made [34]. It needs to be noted that the placebo effect is high in 
all patients, functional and non-functional, and the mechanism behind that might 
not be any different in other neurological disorders. Also, ethical considerations 
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need to be taken into account when considering the direct use of suggestion in the 
approach to a patient with FMD [35]. However, it would be highly valuable to gain more 
clarity on the exact content of patients’ beliefs towards symptoms and treatment 
and to study the role of suggestion within education. Also, if patients with FMD are 
indeed more susceptible to suggestion, it is even more important to test treatments 
for FMD in randomized trials. This is especially relevant for the many treatment 
strategies that are currently promoted in practice (for example even in alternative 
medicine), in which the attributed effects are likely largely due to suggestion. All 
in all, disentangling beliefs, expectations, suggestion and the way education from 
the neurologist affects these components, will provide us with potentially valuable 
gateways for treatment of FMD.
Prognosis
No consecutive follow-up studies have been performed in patients with short 
duration of symptoms, for example presenting at the emergency department, or at 
the GP. The overall picture of the prognosis of FMD, and generalizability to clinical 
practice, would benefit greatly from such studies.
The role of education in treatment
As we concluded from the SHIFT study, educating patients on FMD remains an 
important pillar of treatment. However, although patients were satisfied with our 
intervention, we found it did not improve outcome on its own.
Anecdotally, we came across several interesting viewpoints from patients, that were 
not captured by the standardized questionnaires. Some of them were derived from 
open questions in the SHIFT study, which are shortly summarized in chapter 10. One 
important observation for example was that patients mentioned that contractionary 
explanations provided by health care professionals that lacked experience with FMD, 
hampered the effect the website could have had. Other patients provided reasons 
for improvement that were not in the standard questionnaire (like a newly born 
grandchild or changing physiotherapists). Generally, questionnaires are limited by 
their predefined set of questions, not leaving much room for new insights. Patient 
interviews could deepen our understanding of FMD. A recent qualitative study 
by Nielsen et al (2019) did exactly that, and found amongst others that a lack of 
understanding of their disorder left patients feeling unable to help themselves. The 
role of education within treatment in particular would be an interesting avenue to 
explore, for example by interviewing patients that have seen the website from the 
SHIFT trial. It would be valuable to advance from earlier studies into patients’ beliefs, 
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and to discern health related beliefs into meaningful categories that could be used 
to tailor (psychological) treatment. For example, in some patients, specific beliefs 
might need to be challenged before self-help education can be retained, such as a 
lack confidence in the diagnosis, or strong beliefs in the need for certain tests. These 
beliefs are most likely heterogenous.
This touches upon the popular theme of personalized medicine or ‘patient centered 
care’, which is just as relevant for FMD as for other disorders. Similarities between 
patients could be targets for treatment, but it might be more helpful to define 
subgroups that respond to specific interventions that can be used to triage treatment. 
Defining which factors should be specific targets for therapy would be the first step. 
There are no studies comparing and triaging subgroups of FMD patients, although 
many studies apply exclusion criteria, indicating a presumed association between 
these patient-specific factors and outcome. From our RCT (chapter 10), we found 
duration of symptoms had a negative effect on outcome. Long symptom duration 
is generally a poor prognostic sign, but it is potentially even more relevant when 
providing an education and self-help intervention, which might be more beneficial 
for patients with a recent diagnosis. Also, our prognostic study (chapter 8) showed 
somatization disorder at baseline negatively predicted outcome, which might indicate 
patients with numerous different functional symptoms throughout life are a distinct 
group. Many factors are conceivably important when designing and assigning 
therapy, like if symptoms come in attacks or are continuous and if psychopathology 
is prominent. More research into this area is duly needed.
PERSONAL REFLECTIONS
When working on this thesis, I have had the opportunity to talk to many FMD patients, 
witness expert physicians in clinic and discuss FND with fellow researchers from 
several countries. These encounters provided food for thought, not always directly 
related to the chapters of this thesis. Some of them I would like to share with you.
Firstly, we found neurologists often don’t explicitly record their diagnosis of FMD 
in their clinic letters. As an additional part of the prognostic study in chapter 8 
we tried - unfortunately fruitlessly - to collect numbers of hospital visits and the 
frequency of additional functional symptoms within the follow-up period. However, 
it was often not clear enough from the medical records if symptoms were diagnosed 
to be functional or not. When the described type and course of symptoms was 
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indicative of a functional cause, terminology used in the records was often vague 
or only the excluded diagnoses were listed. It is very likely these physicians did not 
discuss, let alone explain, the diagnosis to their patients either. This is not only a 
clear disadvantage when aiming for transparency between health care professionals. 
It also shows that many neurologists still feel insecure on how to determine the 
diagnosis, or how to explain it.
Secondly, from personal experience when talking to patients involved in the studies 
in this thesis and when presenting data on functional symptoms for neurologists or 
psychiatrists, it became clear that dualistic thinking is still very much ingrained in 
the thinking of both lay-people and physicians. It is very difficult to overcome as long 
as psychiatry and neurology are considered separate specialties and disorders are 
categorized as either psychiatric or neurological. Dualistic thinking triggers clear 
problems in the approach to the patient. Having a psychiatric disorder is considered 
taboo to begin with and therefore an explanation of FMD including psychological 
factors is often considered problematic. However, that could be overcome like in 
other psychiatric disorders. The main problem is the (wrong) assumption that is often 
made, that psychiatric disorders as opposed to neurological disorders, would be 
willed. Or in other words, when it is discussed with patients that psychological factors 
(often oversimplified called ‘stress’) might play a role in the origin of their symptoms, 
they feel accused of putting it on. This in turn inhibits an open conversation about 
the cause of FMD and the influencing factors that could be important in treatment. 
Paradoxically, the majority of patients do accept that there are many factors 
influencing health and wellbeing, including emotional states, stressful events and 
past experiences. As long as it is not implied their symptoms are feigned, I have 
found they are very willing to investigate the role of psychological factors as one of 
the factors that contributed to the disorder or as a potential focus for treatment. It 
would be very helpful if health care professionals would be more aware of this pitfall. 
By explaining to patients that their symptoms are genuine, that body and mind are 
one, and that many different factors can cause, trigger or sustain the symptoms, this 
problem is usually easily overcome. Perhaps needless to say, the same holds true 
for all other disorders (dualistically framed as ‘organic’). Perhaps the Dutch idiom 
‘tussen de oren’ (‘between the ears, an expression used figuratively to indicate a 
psychological cause) should be taken more literally: it’s all coming from the brain.
Thirdly, our review highlights there is now some evidence of effective treatments 
for FMD. The most promising approach is specialized physiotherapy, which includes 
education and movement retraining aimed to restore normal movement [12, 36]. 
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Furthermore, multidisciplinary rehabilitation was proven to be effective [37, 38]. 
Unfortunately, there is a large gap between needs and availability of treatment, 
internationally [39] as well as in the Netherlands, as noted by several patients that 
participated in the SHIFT study (chapter 10). Despite the potential reversibility 
and the growing load of effective rehabilitation studies, rehabilitation services in 
the Netherlands mostly reject patients with FMD. Involvement of rehabilitation 
physicians in the research field and in clinical practice is much desired. Also, 
there remains a great need for specialized therapists (physiotherapy, occupational 
therapy, psychology), who figuratively speak the same language. A Dutch network of 
specialists in which ideally physiotherapists, neurologists, occupational therapists, 
rehabilitation physicians, psychologists and patients share their knowledge and 
experience, would be an important step forward.
Finally, I came to realize that physicians and patients often have very different 
priorities and/or perspectives, sometimes causing misunderstandings or even harm. 
This is most prominent in the acute setting: when a patient presents with acute onset 
neurological symptoms, doctors want to rule out serious and/or life-threatening 
conditions first and fast. For a patient the testing and investigations that happen 
quickly without much explanation are often perceived out of their control, or even 
scary, and at the very least they suggest something serious must be going on. Once 
the doctor has ruled out these serious conditions, their immediate attention is no 
longer required and they often need to attend another acute patient. Leaving the 
patient without a clear explanation of what is going on, while they still experience the 
symptoms that were taken so seriously earlier. The uncertainty or anxiety resulting 
from such an experience can become a perpetuating factor. Furthermore, I have 
learned that patients often reason that severe symptoms (like tremor with a big 
amplitude or a severe headache), are most likely caused by serious disorders 
(potentially life-threatening or neurodegenerative disorders). Physicians do not 
recognize this. They have learned to look for specific red flags that can be subtle 
and usually not recognized by the patient as being alarming. Because of this clear 
difference in priorities, patients are often not reassured by the explanation provided. 
Also, partly to my surprise, belief systems about causes for the disorder (like Lyme 
disease or specific foods), or possible solutions (like alternative medicine), can co-
exist with a clear understanding of the explanation given by the physician on FND. 
Beliefs are often irrational. Physicians, trained to think in a very rational manner, 
should be aware of these belief systems and question their patients about them, as 
it is often important to counter them in order to start any treatment.
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‘After all, clinical medicine is above all the study of the difficult aspects and 
complexities of diseases. When a patient calls on you, he is under no obligation to 
have a simple disease just to please you.’
Charcot 1888 [40]
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Functionele motorische stoornissen (FMS) bestaan uit onwillekeurige bewegingen, 
houdingsveranderingen, loopstoornissen en parese. Ze worden gekenmerkt door 
specifieke afwijkingen in het neurologisch onderzoek en aanknopingspunten in de 
anamnese, die passen bij de functionele aard van de klachten, zoals variabiliteit, 
invloed van aandacht en afleiding en incongruentie met anatomische grenzen. FMS 
komen vrij veel voor; geschat wordt dat rond de 15-30% van de patiënten op de 
poli neurologie een functionele stoornis heeft. De stoornissen geven vaak ernstige 
beperkingen en een verminderde kwaliteit van leven, vergelijkbaar met de ziekte 
van Parkinson en Multipele Sclerose.
Het onderzoeksveld was aan het begin van dit proefschrift in hoog tempo aan 
het veranderen. Nieuwe inzichten veranderden de leidende theorieën over het 
mechanisme, de diagnose en de aanpak van patiënten met FMS. Deze ontwikkelingen 
waren cruciaal voor de opzet van dit onderzoek, dat zicht heeft gericht op het 
mechanisme, de prognose en de behandeling van FMS.
DEEL 1. PATHOFYSIOLOGIE
Om FMS beter te begrijpen zijn zowel klinische observatiestudies als experimentele 
studies nodig. Klinische observatie geeft inzicht in mogelijke onderliggende 
mechanismen en genereert nieuwe hypothesen. Experimentele studies kunnen die 
specifieke hypothesen toetsen. Dit proefschrift beschrijft een aantal studies die de 
pathofysiologie van beide kanten belichten.
Klinische observatiestudies
Het klinische beeld van FMS is heterogeen wat betreft risicofactoren, triggers en 
co-morbiditeit. Daarnaast zijn de symptomen veranderlijk: binnen dezelfde patiënt 
veranderen het type symptoom, de ernst en lokalisatie van de klachten regelmatig. 
Ondanks dat er niet veel systematische studies zijn gedaan, wordt wel beschreven 
dat veel patiënten met FMS ook andere functionele en psychiatrische symptomen 
hebben. Daarbij is er een groeiend besef dat niet-motorische symptomen een 
belangrijk aandeel hebben in de beperkte kwaliteit van leven van patiënten met 
FMS. Hoofdstuk 1 en 2 zijn gebaseerd op baseline data van patiënten met FMS die 
deelnamen aan de SHIFT trial, beschreven in hoofdstuk 10.
Hoofdstuk 1 beschrijft een vergelijking tussen 160 patiënten met verschillende 
functionele motor symptomen. Deze werden ingedeeld in groepen op basis van 
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hun dominante motor symptoom, bepaald door de verwijzend neuroloog. Dit 
resulteerde in groepen patiënten met als dominant symptoom tremor, myoclonus, 
dystonie, parese of loopstoornis. Verschillen in demografie, de manier waarop de 
symptomen begonnen, niet-motore symptomen, kwaliteit van leven en functioneren, 
en de aanwezigheid van andere functionele motor symptomen werden onderzocht 
tussen de groepen. Het merendeel van deze uitkomstmaten was niet verschillend 
tussen de groepen. Fysiek functioneren was sterker beperkt in patiënten met een 
loopstoornis en parese dan in alle andere groepen. Beperkingen in werk en sociaal 
functioneren werden meer gerapporteerd door patiënten met loopstoornissen en 
parese dan door patiënten met myoclonus. Veel patiënten rapporteerden naast het 
hoofdsymptoom ook andere motore symptomen. Deze bevindingen suggereren dat er 
veel overlap is tussen verschillende functionele motor symptomen, wat mogelijk ook 
geldt voor het onderliggende mechanisme en de manier waarop ze zouden moeten 
worden behandeld.
In de spreekkamer blijkt vaak dat patiënten met FMS veel last hebben van 
vermoeidheid. In hoofdstuk 2 is onderzocht hoe ernstig die vermoeidheid is in een 
groep van 181 patiënten met functionele motor stoornissen vergeleken met een 
groep van 217 patiënten met een neuromusculaire ziekte uit een bestaand cohort. 
Hierbij is gebruik gemaakt van de Checklist Individual Strength (CIS) vragenlijst, 
die vier subdomeinen van vermoeidheid onderzoekt; ernst van de vermoeidheid, 
motivatie, concentratie, fysieke activiteit. Patiënten met FMS hadden een hogere 
score dan patiënten met neuromusculaire ziekten op alle subdomeinen. Er was 
sprake van ernstige vermoeidheid, gedefinieerd als een CIS-score van 35 of 
hoger, in 78% van de patiënten met FMS, vergeleken met 53% van de patiënten 
met neuromusculaire ziekten. Daarnaast had vermoeidheid een significant effect 
had op de algehele gezondheid die patiënten zelf hadden gerapporteerd, terwijl 
de ernst van de functionele motor symptomen daar geen significant effect op had. 
Vermoeidheid bleek gecorreleerd aan ernst van de functionele motor symptomen, 
depressie en angst. Op basis van die bevindingen lijkt vermoeidheid zowel een co-
morbide symptoom van FMS als een gevolg van (chronische) multi-morbiditeit.
In hoofdstuk 3 zijn de niet-motore symptomen onderzocht in twee groepen patiënten, 
namelijk 16 patiënten met functionele myoclonus en 23 patiënten met corticale 
(organische) myoclonus. Symptomen van vermoeidheid, depressie en angst kwam 
net zo veel voor bij functionele als corticale myoclonus. Het enige verschil tussen de 
groepen was dat er meer pijn werd gerapporteerd in de functionele groep. Daarnaast 
bleek de ernst van de motore symptomen in de functionele groep gecorreleerd 
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te zijn aan angst en depressie, terwijl dat in de corticale myoclonus groep niet 
zo was. Ondanks de kleine groep die voornamelijk uit de derde lijn kwam, wat de 
nodige beperkingen met zich meebrengt, was de conclusie dat psychiatrische co-
morbiditeit veel voorkomt in beide groepen. Dat spreekt veelgehoorde ideeën over 
hogere prevalentie van psychiatrische symptomen in FMS tegen. De hoge prevalentie 
in beide groepen betekent echter wel dat er aandacht moet zijn voor niet-motore 
verschijnselen bij FMS in de klinische praktijk.
Experimentele studies
De experimentele studies in dit proefschrift waren gericht op de beleving van controle 
over beweging (‘sense of agency’), aandacht voor het lichaam en afwijkingen in het 
lichaamsschema.
In hoofdstuk 4 beschrijven we een experiment gericht op controle over beweging. 
Negentien patiënten met FMS en evenveel gezonde controle personen voerden een 
motorische taak uit, waarin de feedback die deelnemers ontvingen na het bewust 
drukken op een knop werd gemanipuleerd. De manipulatie bestond uit een variabele 
vertraging tussen actie en reactie (geluidssignaal na indrukken van de knop). 
Deelnemers werd vervolgens gevraagd of zij het geluid hadden veroorzaakt of niet. 
De hypothese was dat patiënten met FMS minder gevoel van controle zouden hebben 
over de beweging, maar dat kwam niet uit het experiment. Na analyse van alle 
reacties bleken er geen verschillen tussen de groepen te zijn. We concludeerden dat 
er nog steeds sprake zou kunnen zijn van een verstoring van het gevoel controle te 
hebben over beweging (sense of agency), maar dat ons experiment gericht was op een 
expliciet gevoel van controle, terwijl bij FMS mogelijk impliciete controle verstoord is.
In zowel hoofdstuk 5 en 6 worden fMRI studies beschreven, uitgevoerd in een groep 
patiënten met functionele myoclonus of tremor, vergeleken met gezonde controles 
van dezelfde leeftijd en geslacht.
Hoofdstuk 5 beschrijft de uitkomsten van een taak-gebonden fMRI experiment. In 
de actie-selectie taak moesten de deelnemers wisselend zelf kiezen, of er werd 
hen opgelegd, met welke vinger ze een knop moesten indrukken, of op welke knop 
ze moesten drukken. Hierdoor konden we het verschil tussen opgelegde motor 
actie en vrije keus aan de ene kant, en lichaamsschema (keuze voor een vinger) 
ten opzichte van doelgerichte actie (keuze van een knop) vergelijken. Eerdere 
bevindingen in gezonde deelnemers werden bevestigd: prefrontale en pariëtale 
activatie is geassocieerd met vrije ten opzichte van vastgelegde selectie. In de vinger 
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ten opzichte van knop selectie vonden we activatie van de occipitaal en anterieure 
pariëtaal cortex, inclusief de postcentrale sulcus. In FMS vonden we ten opzichte van 
gezonde controles een verminderde activatie van de linker primaire motor cortex in 
alle motorische taken. In de praktijk hebben patiënten vaak moeite met het uitvoeren 
van eenvoudige motorische taken, daarom zou deze bevinding kunnen passen bij 
verstoorde expliciete controle over beweging. De linker insula toonde verminderde 
activiteit in vrije vinger selectie in FMS en dit was ook gecorreleerd met ernst van 
de symptomen. Deze resultaten bevestigen de hypothese dat verstoringen in het 
gevoel controle te hebben over beweging (sense of agency) en in de perceptie van 
lichaamsschema optreden in patiënten met FMS.
In hoofdstuk 6 worden de resultaten beschreven van een data-gedreven exploratieve 
‘resting state’ studie. In een dergelijke studie voeren patiënten geen taak uit tijdens 
de fMRI scan, maar worden patronen van activatie in de hersenen bekeken die met 
elkaar samenhangen op basis van connectiviteit. De studie vergelijkt patronen 
tussen 17 patiënten met functionele tremor of schokken en 17 gezonde controles. De 
analyse-methode ‘independent component analysis’ is hierbij toegepast. Na selectie 
van componenten passend bij een vooropgestelde hypothese, werden de groepen 
vergeleken met een aantal statistische testen. We vonden veranderde activatie in een 
component bestaande uit de (pre)cuneus en gyrus cinguli (posterior) in de fluctuaties 
van lagere range frequenties. De betekenis van die frequentie fluctuaties is nog niet 
geheel opgehelderd; wel is bewezen dat ze correleren met hersenactiviteit en met 
andere maten van connectiviteit. De (pre)cuneus en andere midline structuren zijn 
geassocieerd met een verstoring van het gevoel controle te hebben over beweging 
(sense of agency), wat eerdere theorieën over functionele stoornissen zou bevestigen. 
Er waren geen andere verschillen tussen de groepen.
DEEL 2. PROGNOSE
Deel 2 van dit proefschrift beschrijft het natuurlijk beloop van FMS, door middel van 
een systematische review van de literatuur (hoofdstuk 7) en een grote lange-termijn 
follow-up studie in FMS (hoofdstuk 8).
In de systematische review van de literatuur werden 24 studies geïncludeerd die 
voornamelijk retrospectieve gegevens over het natuurlijk beloop van FMS bevatten. 
De studies waren erg heterogeen in aantal patiënten, duur van de follow-up (0.5 tot 
19 jaar) en klinische setting. Gemiddeld over alle studies was 39% van de patiënten 
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(10-90%) na de follow-up periode slechter of hetzelfde voor wat betreft de motorische 
symptomen; 20% van de patiënten was geheel hersteld. Daarbij gingen verminderde 
kwaliteit van leven en beperkingen van het dagelijks leven hand in hand met een 
slechte prognose van de motorische symptomen.
De follow-up studie was een case-control studie met drie groepen: patiënten met 
functionele parese, een controlegroep met andere neurologische aandoeningen die 
parese veroorzaken en een gezonde controlegroep. De follow-up duur was 14 jaar. 
Net als in de systematische review was ook in onze studie 20% van de patiënten 
in de functionele groep compleet hersteld. Vergeleken met de controle groep van 
neurologische aandoeningen verbeterden meer patiënten met functionele parese. 
Echter, de meeste secundaire uitkomstmaten (zoals algehele gezondheid, fysiek 
functioneren en werk) waren gelijk in beide groepen, en duidelijk slechter dan de 
gezonde controlegroep.
Misdiagnose was zeldzaam: bij één patiënt met FMS en één patiënt uit de groep 
met een andere neurologische aandoening bleek gedurende de follow-up de initiële 
diagnose onjuist te zijn geweest.
Het aantal patiënten dat tijdens de follow-up periode overleed was hoger in 
de functionele parese groep dan in de gezonde populatie in diezelfde periode in 
hetzelfde demografische gebied (Lothian, Schotland). De doodsoorzaak had in geen 
van deze gevallen direct te maken met de functionele parese. Gezien de kleine groep 
in totaal (11 patiënten) moeten de resultaten van deze bevinding voorzichtig worden 
geïnterpreteerd. Een mogelijke verklaring van dit verschil met de normale populatie is 
dat het hebben van een chronische aandoening waarschijnlijk negatieve gevolgen heeft 
voor de algehele gezondheid, werk en daarmee economische situatie van patiënten.
In beide studies was het moeilijk om prognostische factoren te bepalen. In de 
systematische review werden een aantal positief voorspellende factoren in meerdere 
studies gevonden: korte duur van de symptomen, vroege diagnose en tevredenheid met 
de zorg. Geslacht had geen invloed op de uitkomst. Een late diagnose en de aanwezigheid 
van een persoonlijkheidsstoornis waren gecorreleerd met een slechte uitkomst.
In onze follow-up studie vonden we alleen univariabele voorspellers voor slechte 
uitkomst: somatisatiestoornis, slechte algehele gezondheid, pijn en het totaal aantal 
symptomen bij inclusie hadden een negatief voorspellende waarde voor de uitkomst 
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van de parese. Deze bleven niet bestaan als ze voor elkaar werden gecorrigeerd in 
een multivariabel model.
De belangrijkste beperking van beide studies was dat het merendeel van de patiënten 
al lang symptomen had voor ze geïncludeerd werden, terwijl dat uit diezelfde 
studies naar voren komt als negatieve voorspeller van het beloop. Daarom zijn de 
bevindingen mogelijk niet te generaliseren naar een populatie met acute symptomen.
DEEL 3 BEHANDELING
Er is weinig wetenschappelijk onderzoek gedaan naar de behandeling van FMS. 
In hoofdstuk 9 hebben we de literatuur hierover samengevat. Hieruit blijkt dat 
een aanpak waarin patiënten uitleg krijgen over de diagnose en waarin normale 
bewegingen opnieuw worden getraind, soms in combinatie met psychologische 
behandeling, effectief kan zijn. Voor de effectiviteit van psychologische behandeling 
alleen is weinig wetenschappelijk bewijs. Ondanks dat een aanpak bestaande uit 
verschillende stappen (uitleg, eerstelijnstherapie, multidisciplinaire therapie) wordt 
aanbevolen, is dit in de praktijk nog niet altijd haalbaar, aangezien gespecialiseerde 
zorgaanbieders schaars zijn.
In de gerandomiseerde onderzoek met controlegroep (RCT) in hoofdstuk 10 is het 
effect van online educatie en zelfhulp als toevoeging op de normale zorg onderzocht, 
vergeleken met alleen normale zorg. 186 patiënten met FMS werden gerandomiseerd 
in twee groepen: met en zonder toegang tot de speciaal samengestelde website. 
Er waren geen verschil tussen de groepen op de hoofduitkomstmaat, algehele 
gezondheid (zelf-gerapporteerd) op de Clinical Global Improvement schaal op 
3 en 6 maanden na aanvang van de studie. Ook waren er geen verschillen op de 
secundaire uitkomsten, zoals ernst van de functionele symptomen, co-morbiditeit, 
of begrip van de diagnose. Patiënten waren wel erg tevreden over de informatie op 
de website. In het gehele cohort (de twee groepen bij elkaar) was een significante 
correlatie tussen vertrouwen in de diagnose en algehele gezondheid, wat het belang 
van educatie in het algemeen benadrukt en onze hypothese bevestigt dat educatie 
een relevant onderdeel is van de behandeling. De belangrijkste limitatie was selectie 
bias, die zowel op het niveau van de verwijzend neuroloog als van de patiënten heeft 
plaatsgevonden. Omdat er geen verschillen tussen de groepen werden gevonden, 
werd geconcludeerd dat educatie en zelfhulp zonder begeleiding van een therapeut 
als losstaande interventie niet effectief is in FMS.
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Mijn PhD-traject heb ik als een hele waardevolle periode ervaren en daar hebben 
heel veel mensen aan bijgedragen.
Allereerst wil ik graag alle patiënten met een functionele stoornis en gezonde 
vrijwilligers bedanken die hebben willen deelnemen aan de verschillende studies 
in deze thesis. Bedankt voor jullie hulp en geduld, en voor alle nieuwe inzichten die 
we hebben gekregen. Uiteraard ook grote dank voor de fondsen die het onderzoek 
mogelijk gemaakt hebben: de GSMS graduate school van de RUG voor financiering 
van mijn PhD-project, de de Cock-stichting, voor subsidie van het MRI-project, 
de UMCG Pilot Doelmatigheid HAP subsidie, voor financiering van de pilotstudie 
voorafgaand aan de SHIFT studie en stichting MIND (voorheen Fonds Psychische 
Gezondheid), voor de subsidie van de SHIFT studie.
Marina, Jon, Judith and Alan. What you all share is curiosity, passion and above all 
a good sense of humor, which has made this trajectory above all a lot of fun.
Marina, je persoonlijke aandacht en (Haagse) humor maken dat het vanaf het begin 
ontzettend vertrouwd is geweest om bij je binnen te lopen, en om samen van alles te 
organiseren. Je gunt het ons (je PhDs) om te delen in jouw netwerk, om onze eigen 
fouten te durven maken en stimuleert ons om ervoor te gaan. Jouw pragmatische 
insteek heeft me altijd op het goede moment ingeperkt waar ik de neiging kon hebben 
‘oeverloos’ te worden. Ik kan me geen betere begeleider bedenken.
Jon, you have inspired me to start this PhD. It’s admirable how you’ve put the topic 
of FND on the map and are now (one of?!) the world expert(s) in the field. I think our 
field is the most intriguing part of medicine. So thanks for paving the way! Also, I’ve 
found you to be a supportive, understanding, openminded and funny supervisor. You 
can be kind and critical at the same time, which is admirable. Thank you so much 
for all that.
Judith, jij hebt altijd weer een verrassende invalshoek, geeft de meest opbouwende 
kritiek en je hebt pijnlijk vaak gelijk, wat mijn proefschrift heel veel heeft verbeterd.
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Alan, your humor, experience, and your skill to give feedback in such a way that 
I never felt I’d done anything wrong, has been a great help in the process, many 
thanks.
Members of the examining committee, professor Mark Edwards, professor Teus 
van Laar, professor Odile van den Heuvel, professor Theo Bouwman, professor 
Joke Spikma, professor Peter van Harten and dr. Lineke Tak thank you for your 
critical appraisal of this thesis, I am looking forward to the defence.
Lenny, Julia, Martijn, Jona, Romy: bedankt voor het vele werk dat jullie gedaan 
hebben en voor de kritische vragen: ik heb me regelmatig gerealiseerd dat ik de 
beste (en leukste) studenten van de afdeling had!
Co-auteurs, bedankt voor de prettige samenwerking. In het bijzonder: Bauke, heel 
erg bedankt voor je optimistische en gedegen manier van begeleiden. Ondanks de 
vele keren dat alles toch weer anders was, was jij altijd in de stemming om het er nog 
maar weer eens over te hebben. Ik heb daar veel van geleerd! Jan-Bernard, ook jij 
bent altijd wel weer beschikbaar, en hebt me regelmatig op het laatste moment nog 
uit de brand geholpen. Bedankt daarvoor! Hans bedankt voor al je hulp met de MRI 
analyses en matlab-scriptjes!! Anita en Judith. Bedankt voor jullie geduld iedere 
keer te wachten tot het ‘alleen luisteren’-blok voorbij was om te zien of mensen 
überhaupt wel iets konden horen. En voor jullie hulp natuurlijk. Martijn: bedankt 
voor het kritische meedenken op velerlei gebied. Ruben Maalman, veel dank voor het 
maken van de getekende filmpjes voor de websites en de getekende samenvattingen 
in dit boekje. Sam Hoevenaar, bedankt voor het maken van de videos voor de website.
Rien Vermeulen en Gerty Casteelen bedankt dat jullie (los van elkaar) de interesse 
voor functionele stoornissen in mij gewekt en gestimuleerd hebben.
Kamer V4.105. Het zou een variant van het Stockholm-syndroom kunnen zijn, 
maar als je jarenlang in dezelfde kamer onderzoek zit te doen, blijkt dat je hoe dan 
ook vrienden wordt. Ik zal het poep-buisje van Jeffrey (‘dit buisje is de nieuwste 
ontwikkeling op poep-sampling gebied!’), de liefde voor excell (‘weet je waar ik echt 
van kan genieten? een nette tabel!’) van Hans, de eeuwige tegenspraak van Gerrit 
(‘Niet zo nuanceren, Jeannette, daar houd ik niet van’), de vaak verrassende humor 
van Jonathan (‘Ha meneer, ik wilde u gisteren bellen, maar uh, ik bel vandaag’), het 
enthousiasme voor zowel de ziekte van Parkinson als het Nederlandse levenslied 
(Wij zijn het derde..) van Robbert, de passie voor het zwabberbeen (wat extra goed 
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klinkt met een Canadees accent) van Beorn en de persoonlijke analyses met Sterre 
(‘tja, met je ogen dicht, zie je het niet aankomen’) missen!
Lieve Wieke en Anouk: wij hebben door de jaren heen zoveel meegemaakt dat ik 
niet weet waar te beginnen, alle gesprekken in V4.105, de vele bewegingsstoornissen 
projecten, (werk)weekendjes, gedeelde hotelkamers en daarmee gepaard gaande 
nachtelijke gesprekken. Ik hoop dat we dat gewoon voortzetten, ook al zien we elkaar 
niet meer elke dag. Heel veel dank.
Lieve Arthur, we hebben samen gestudeerd, maanden samen in een kamertje op de 
KNF in het AMC gezeten en het talent ontwikkeld om allebei tegelijk zowel te praten 
als te luisteren. Ik denk dat jij mij het meest hebt gevormd als dokter en onderzoeker 
(of misschien leken we altijd al op elkaar?), en dat bevalt me wel.
Lieve Myrthe, wat hebben wij veel gedeeld aan de Paramaribostraat en de 
Archimedesweg! Ondanks onverstandige keuzes en ingewikkelde overwegingen heb 
jij er toch altijd wel iets zinnigs en liefs over te zeggen, heel erg bedankt daarvoor.
Anne-Marthe, Anne, Gerrit en Yasmine: jullie als mede-onderzoekers naar 
functionele stoornissen bedankt voor jullie enthousiasme en interessante 
bespiegelingen Anne: voor onze fijne tijd samen in Edinburgh en gezellige 
samenwerking op de poli! Gerrit: heel erg leuk dat we nu samen op één dag 
promoveren en er een functionele dag van maken.
FRG (Functional Research Group) Edinburgh: Lea, Ingrid, Paula, Laura: It is great 
to share our enthusiasm for clearly the most interesting topic in the world. What a 
lovely, supportive group of people you are. I’m so thankful to have been part of that. I 
am missing the Thursday FRG meetings in the room with the horrible carpet. Glenn: 
definitely a support to know that you’ve struggled with the same things, but kept your 
enthusiasm! Trish, as a proud member of ‘your functional lot’ (as you tend to call us 
these days) I’ve had such a lovely time at North Park Terrace with you. Thank you 
for your patience with my late and ever changing planning.
De andere neuro-PhDs, Arnoud, Dan, Danique, Sygrid, Madelein, Marja, Myrthe d 
K, Sanne, Rodi, Martje, Marenka, Marieke, Marouska het staat al in elk dankwoord 
van onze inmiddels indrukwekkende reeks: alle (noodstroom/submit/reject/etc) 
borrels, retraites naar Londen, Utrecht, Haarlem en Edinburgh en onze gezamenlijke 
congressen zorgden voor een onvergetelijke tijd. Sanne ook dank voor het feit 
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dat jij mij vroeg of ik met jou op tennisles wilde (we kennen beiden het briljante 
eindresultaat van onze inspanningen). Arnoud voor de nodige rechtse tegenspraak 
en relativering. Marja en Madelein juist voor alles wat ik met jullie eens ben. Sygrid 
voor je voorbeeld in doorzettingsvermogen. Myrthe (de K.) voor het aanvoeren van 
het geheel. Dan voor je droge humor. Danique voor je enthousiasme. Rodi en Martje 
voor jullie voorbeeld hoe vanalles te combineren én leuk te blijven.
Massimo, Cécile, Michele, Gerd and Wieke: thanks for the amazing days and mostly 
nights at several movement disorders events. I hope we’ll see a lot more of each 
other when we grow old and wise (or just old).
Lieve vrienden. Carmen. Ondanks onze moeizame start (als kleuter vond jij mij suf 
en ik jou raar), ben ik nu bij jou het meest mezelf. Bedankt voor jouw positieve inslag 
en humoristische kijk op het leven, daarmee help je me vaak enorm en wordt er 
in ieder geval genoeg gelachen. Sanne. Dank voor jouw nooit aflatende steun, het 
eeuwige logeeradres en je altijd verfrissende blik. Ik heb mooie herinneringen aan 
je bezoek aan Edinburgh. Floor, ik heb veel bewondering voor jouw nuchtere houding 
en doorzettingsvermogen. Ester, Mauro, Anna, super bedankt voor het tweede thuis 
in Amsterdam en interesse, Mauro voor je hulp met de introductie! Joëtta. Wat 
hebben wij een ontzettend lange geschiedenis samen. Bedankt voor je lieve interesse 
en je voorbeeld om keuzes te durven maken voor waar je passie ligt. Jort. Dat jij 
vrij regelmatig op de plek uitkomt waar ik toevallig ook ben, en dat wij steeds onze 
ervaringen kunnen delen, geeft mij veel vertrouwen. Reinier, bijzonder hoe vaak 
jij zegt wat ik bedoel en prettig dat je me stimuleert om het hoe dan ook maar 
gewoon te gaan doen allemaal. Sebastiaan en Jill, veel dank onze lange vriendschap 
en vele mooie momenten. Peter en Nicolette en met jullie de hele gemeenschap 
Watergraafsmeer, bedankt voor de inspiratie die ik uit jullie ervaar. Arthur, Jessie, 
Roel, Astrid en Jeroen. Jullie altijd scherpe analyses en humor hebben gezorgd voor 
de nodige relativering en steun. Ik hoop dat we als we 80 zijn nog steeds elk jaar in 
Berlijn Edelweiss zullen zingen. Btissemme. Bedankt voor alle etentjes en zinvolle 
gesprekken over ons werk en leven. Nienke, Iris, Maayke, Lisa, er is veel gebeurd 
;) sinds wij in (minder) strakke formatie over de Amstel roeiden! Ik ben heel erg blij 
met onze lange vriendschap. Ruud, Illy, Sebastiaan, Marjolein, Iris: een verademing 
dat het tijdens onze etentjes altijd over politiek gaat en over wat er echt belangrijk is 
in het leven. Jullie inspireren mij om breder te kijken. Sebastiaan. Bedankt voor je 
steun in mijn keuze om naar Groningen te gaan. Les Oiseaux Bleus – vrijwilligers, en 
dan in het bijzonder Brian, Ans en Hamza, over inspiratie gesproken. Jullie hebben 
vele bruggen geslagen en dat is voor mij een prachtig voorbeeld.
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Ward, ik ben heel dankbaar dat jij er bent.
Maarten en Sam, ik kan me geen lievere broer en schoonzus bedenken, Bernard en 
Jenneke, Selma, Charlotte, Jurriaan, Jonathan, Rogier en Ting: bedankt voor de 
onvoorwaardelijke liefde die ik zo vaak uit jullie heb ervaren. George en Carolien: 
Jullie hebben mij voorgeleefd hoe je liefde en dankbaarheid de boventoon laat voeren 
in het leven. Heel erg bedankt dat jullie mij vrijheid geven, maar er tegelijkertijd altijd 
zijn als het nodig is.
Hoe, na een geweldig PhD-traject in Groningen en Edinburgh, toepasselijker te 
eindigen dan door te refereren aan Oma Hanzon: ‘Immers…thuisblijvers hebben 
altijd ongelijk.’
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